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SCOPE OF THIS THESIS
This thesis focuses on the generation of MHC ligands and their use in analyzing T cell 
immunity, both in mouse and man. It is roughly split into two sections: the first part deals 
specifically with the rules governing the generation of MHC ligands, while the second part 
describes technological advances in the use of these MHC ligands to analyze T cell immunity. 
The first part of this thesis starts with an introduction on antigen presentation, covering 
both the different mechanisms through which epitopes are generated and the process by 
which epitopes are presented to T cells. Emphasis lies on the discoveries in this field of the 
last decade. This introduction is followed by two chapters on the generation of antigenic 
epitopes. Chapter two describes the analysis of protease activity in the endocytic pathway, 
while chapter three investigates the antigenic source of epitopes generated during cross–
presentation.
The second part of this thesis starts with a review on the status of MHC multimer technology 
as a tool to analyze antigen specific T cell populations. Chapter five then describes a high–
throughput approach to generate a vast array of different peptide–MHC complexes for several 
human MHC alleles, allowing for faster and more complex applications of MHC multimer 
technology. In the next chapter, the peptide–exchange technology of chapter 5 is used for 
the development of another novel strategy: multidimensional encoding of peptide–MHC 
complexes. This chapter describes the development, validation and use of this encoding 
technique that allows the parallel detection of antigen–specific T cell responses of up to 25 
T cell populations in one single sample.
Finally, this thesis concludes with a summary and discussion chapter, giving a short overview 
of the presented data and discussing its relevance in the field of antigen presentation.
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Innate and adaptive immunity
The immune system protects the body 
from pathogenic threats such as viruses, 
parasites and bacteria. Basal immunity 
in the first place operates by keeping 
a potentially dangerous pathogen out. 
The skin, mucus and nasal hair are all 
examples of providing a barrier between 
the body and the outside world. However, 
once a microbe or virus has entered the 
body many defense mechanisms work 
to eliminate this potential threat. The 
basis of the immune system lies in the 
recognition of self versus non–self and can 
be separated into two distinct mechanisms: 
a general defense mechanism against 
broad classes of organisms and pathogens 
called the innate immune response, and 
a more specific response that reacts 
based on the individual types of invading 
pathogens called adaptive immunity. Both 
mechanisms operate by recognizing that 
something does not belong inside the body. 
However, innate and adaptive immunity 
have two fundamentally different methods 
to recognize this: the innate immune 
system operates by specifically knowing 
what should be considered ‘non–self’ and 
adaptive immunity works by specifically 
knowing what should be considered ‘self’.
In order to detect non–self, cells 
of the innate immune system contain 
pathogen recognition receptors that 
recognize molecular motifs associated 
with pathogens, the so–called pathogen–
associated molecular patterns (PAMPs). 
These receptors, of which the most well 
known are the Toll like receptors (TLRs) 
(1) and a recently discovered set of RIG–
like helicases (2,3), exist both on the 
outside and inside of the cell. Examples of 
PAMPs that can be recognized are bacterial 
lipopolysaccharides, viral single–stranded 
RNA and specific DNA motifs that are more 
prevalent in bacteria than in mammals. 
After triggering of these receptors, 
inflammatory and signal molecules will be 
generated. Some of these molecules, such 
as histamine and cytokines produced by 
mast cells and basophils, can recruit more 
cells of the immune response while other 
molecules, such as RNAses and peroxidases 
produced by eosinophils, will help to 
destroy microbes and viruses. In addition, 
microbes can be eliminated by specialized 
cells such as neutrophils and macrophages 
after internalization via a process called 
phagocytosis. All in all the responses 
attributed to the innate immune system 
can be described as static; they are based 
on specific molecular motifs rather than 
individual pathogens and do not change 
during the lifetime of an organism.
The adaptive immune system also 
responds to a pathogen with the main 
goal to clear it from the system. But it 
aims for an important additional effect: to 
improve the host’s defense for whenever the 
same pathogen is encountered again and 
therefore is more specific in its response 
than innate immunity. This so–called 
immunological memory is one of the most 
important aspects of adaptive immunity. 
The main cell types of the adaptive immune 
response are T and B lymphocytes. Both 
display an antigen receptor on their cell 
surface that needs to be triggered by 
recognition of specific pathogen–derived 
molecules in order to activate the cell. A 
key aspect of the adaptive immune system 
is the ability to generate a vast amount of 
different antigen receptors on the surface 
of T and B cells (although each individual 
cell will generally display only a single type 
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of receptor). This large potential repertoire 
of antigen receptors (estimated for T cells 
to be 1013–1015 in mouse and 1016–1018 in 
humans (4–6)) aims for the recognition of 
any potential pathogen that might invade 
the body. Any molecular structure that 
is recognized by the immune response is 
called an antigen (hence the name antigen 
receptor), while the small fragment of an 
antigen that actually triggers a T cell receptor 
(TCR) or B cell receptor (BCR) is called an 
epitope. Antigens can be many structures 
such as proteins, lipids, polysaccharides 
and nucleic acids. This thesis however will 
exclusively focus on proteinaceous antigens 
and epitopes. Furthermore, the recognition 
of pathogens by and activation of B cells via 
their B cell receptor lies beyond the scope of 
this thesis, and the focus will mainly lie on 
the generation of epitopes and processing of 
antigens in the context of T cells and their 
T cell receptors.
T cells recognize epitopes that are 
presented to them by other cells of the body. 
The epitopes are embedded in a molecular 
complex on the cell surface called Major 
Histocompatibility Complex, or MHC. This 
complex comes in two forms: MHC class I 
and MHC class II. MHC class I complexes 
are present on all nucleated cells, while 
MHC class II complexes primarily exist on 
specialized cells of the immune system called 
antigen presenting cells (APCs). In most 
cells of the body, MHC class I complexes at 
the cell surface display a sample of peptides 
that are generated from proteins inside 
the cell itself. This means that at any given 
time, epitopes presented by MHC class I 
on the cell surface represent a blueprint of 
the internal status of that particular cell. 
In addition, APCs present peptides on their 
MHC class II complexes that have been 
generated from internalized proteins. MHC 
class II–bound epitopes therefore represent 
the status of the extracellular environment 
of the APC. Certain specialized APCs also 
have the ability to bind epitopes generated 
from extracellular material to their MHC 
class I molecules, through a process called 
cross–presentation.
T cells can be divided in two distinct 
subtypes based on their MHC recognition, 
with each type named after a co–receptor 
involved in MHC–TCR interactions on the cell 
surface: CD4+ T cells recognize epitopes in 
the context of MHC class II, while CD8+ T 
cells interact with MHC class I complexes. 
After activation, CD8+ T cells (also called 
cytotoxic T cells) have the ability to 
directly kill infected cells that present the 
appropriate epitope on their surface. CD4+ 
cells (or helper T cells) on the other hand 
aid the immune response with cytokine 
production and the transfer of activation 
signals after they have recognized their 
cognate epitope.
How are T cells able to distinguish 
between peptides on the cell surface that 
are derived from host proteins (self) and 
those derived from pathogens (non–self)? 
After all, only the latter should activate 
the immune response. The basis of this 
distinction originates from the method 
by which the T cells are generated in the 
thymus. During T cell development the T 
cell receptor locus of both CD4+ and CD8+ T 
cells undergoes genetic rearrangement. This 
process of V(D)J recombination results in a 
wide range of different TCRs on individual 
T cells with a semi–random specificity. 
After expression of the rearranged TCR, 
the cells are tested whether the receptor 
has high enough affinity to interact with 
MHC complexes. Only T cells that have the 
intrinsic ability to recognize MHC complexes 
will survive this positive selection step. 
Next, T cells in the thymus that recognize 
endogenous peptides on MHC complexes 
will be deleted. This process of negative 
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selection is facilitated by the fact that thymic 
epithelial cells display a wide range of pMHC 
complexes with endogenous peripheral 
peptides (7). Only T cells that have high 
enough affinity for pMHC complexes and 
do not respond to endogenous pMHC 
complexes will develop into mature T cells. 
This process of T cell selection thus ensures 
that T cells in the periphery do not recognize 
endogenous peptides, but only get activated 
when unknown foreign material is presented 
to them. Or in other words, the T cell pool 
knows what is self and will react to anything 
that is not part of this self repertoire. Any 
defects in the thymic T cell selection steps 
can lead to autoimmune diseases in which 
T cells attack non–infected tissues. One of 
the most well known examples of this is 
type I diabetes mellitus.
This thesis is about the generation and 
use of epitopes in the context of MHC class 
I and class II. In the following parts of this 
introduction the different mechanisms of 
antigen processing and epitope generation 
will be discussed as well as the cell types 
that play a role in generating these antigens.
MHC class I antigen presentation
MHC class I molecules are heterotrimeric 
complexes consisting of a polymorphic 
heavy chain (HC), an invariant light chain 
called ß2–microglobulin (ß2m) and a peptide 
ligand –the epitope– of approximately 8–11 
amino–acid long. These peptide–MHC 
(pMHC) complexes are recognized by the 
TCR of CD8+ T cells in a peptide–specific 
fashion, and this interaction forms the 
molecular basis of antigen recognition by 
CD8+ T cells. Three polymorphic genes code 
for MHC class I heavy chains: HLA–A, –B 
and –C in humans and H2–K, –D and –L 
in mice, and consequently each individual 
has 3–6 different types of MHC class I 
complexes for peptide presentation to T 
cells. To date, over 2000 different MHC class 
I alleles have been identified (http://www.
ebi.ac.uk/imgt/hla/stats.html). The HC and 
ß2m are cotranslationally translocated into 
the endoplasmic reticulum (ER), where they 
are incorporated into the peptide–loading 
complex (PLC). This protein complex is 
a multi subunit structure containing the 
proteins HC, ß2m, TAP, calreticulin, ERp57, 
tapasin (8,9), and, possibly, PDI (10,11). 
The PLC maintains disulfide bond formation 
of the MHC complex (11–13) and stabilizes 
HC and ß2m in the absence of peptide (14). 
The PLC also facilitates peptide loading 
by keeping the peptide–binding groove of 
the MHC complex into a peptide–receptive 
state, favors binding of high affinity 
peptides (15–18) and brings HC and ß2m 
in the vicinity of the peptides that are 
transported into the ER by TAP. After MHC 
has associated with a high affinity peptide, 
the PLC dissociates and the pMHC complex 
is transported to the cell surface via the 
golgi apparatus, where it can present the 
peptide to CD8+ T cells.
Peptides that are loaded onto MHC 
class I are generated from endogenous 
proteins (and cross–presented material, 
see section below) marked for degradation. 
This includes cytosolic proteins at the 
end of their functional lifespan, misfolded 
ribosomal products and ER–resident proteins 
retrotranslocated back into the cytosol. 
These products are all targeted to the 
default ubiquitin–proteasome degradation 
pathway regulating protein turnover and 
amino acid recycling. As an intrinsic part 
of the degradation process, antigenic 
peptides will be generated for presentation 
on MHC class I complexes. The key protease 
involved in cellular protein degradation and 
peptide generation is the proteasome. This 
cytosolic complex is capable of degrading 
large protein structures into fragments of 
2–25 amino acids (19,20) and is the only 
protease in the cytosol able to generate 
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carboxi–termini of MHC class I binding 
peptides (21). Recently it was established 
that fragments longer than 15 amino 
acids are subsequently processed by 
the peptidase TPP2 (22,23) and several 
cytosolic aminopeptidases, such as TOP 
and LAP, can further degrade the fragments 
into even smaller products for recycling. 
Peptides of 8–16 amino acids long that are 
generated during these degradation steps 
can be transported into the ER via the 
transporter TAP (24,25), after which they 
are available for MHC binding in the PLC. 
The ER–resident aminopeptidase ERAAP 
has recently been shown to further trim 
peptides to 8–10 amino acids (26–28) in 
agreement with the fact that MHC class 
I molecules bind peptides of 8–11 amino 
acids long (29). Only a small portion of total 
protein content will be turned into antigenic 
peptides, while the majority of products will 
be degraded. It is estimated that from all 
the peptides generated during proteasomal 
processing, less than 0.1% ultimately bind 
to MHC class I (30–35). 
Since epitopes are generated by 
proteolysis, two sources of these peptides 
can be distinguished: native proteins that 
are degraded at the end of their functional 
lifespan, and faulty translation products 
tagged for destruction. This latter group 
is commonly referred to as defective 
ribosomal products (DRiPs) (36). While the 
kinetics with which peptides are derived 
from DRiPs will be rapid, since destruction 
of defective proteins occurs within hours 
after translation, epitopes originating from 
stable proteins are generated depending 
on their cellular stability, with half–lives 
ranging between 10 minutes to 2 weeks 
and the average being around 1–2 days 
(37). Considering that the goal of antigen 
presentation is to display internal pathogenic 
infections to the outside world, it is 
important that peptides are generated from 
pathogenic material rapidly after infection. 
Indeed, peptides derived from several viral 
proteins are displayed on the cell surface 
within hours after infection, despite the 
long–lived nature of the native source 
proteins (38–40). In addition, experiments 
examining the fraction of newly synthesized 
host proteins that is degraded faster than 
the half–life of the mature protein indicate 
that the rapid generation of antigenic 
peptides is not limited to pathogenic 
material (41–43). This is in agreement 
with the ‘DRiP hypothesis’ postulating that 
the majority of antigenic epitopes originate 
from newly synthesized polypeptides that 
are degraded shortly after their translation 
rather than from long–lived native proteins 
(36,43). Recently this hypothesis has been 
expanded with the suggestion that proteins 
should be divided in rapidly and slowly 
degrading polypeptides (RDP and SDP, 
respectively), regardless whether proteins 
are folded correctly or not (44). The model 
proposes that RDPs contribute the bulk of 
antigenic epitopes. This might be possible 
due to the presence of currently completely 
hypothetical immunoribosomes (44) 
specialized in generating epitopes for MHC 
binding. Whether these immunoribosomes 
will explain the observed correlation 
between protein synthesis and epitope 
generation remains to be seen and to date 
no single DRiP has been identified (45), 
leading to doubts whether this specialized 
mechanism of epitope generation actually 
exists (46).
With the display of antigenic peptides 
on the cell surface that reflect the inner 
status of that cell, the immune system has 
developed a way to monitor for potential 
pathogens infecting cells of the body. 
Cellular pathogens such as bacteria and 
viruses make use of the protein synthesis 
mechanism of the host they have infected, 
and protein turnover is similarly mediated 
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by the host’s proteasomal degradation 
pathway described above. Therefore, 
epitopes presented to CD8+ T cells by an 
infected cell will also contain peptides 
derived from a pathogen inside. Since CD8+ 
T cells that recognize epitopes from self–
tissue have been eliminated in the thymus 
during negative selection, it is exactly these 
foreign peptides bound to MHC class I that 
will be recognized by cytotoxic T cells, 
leading to the destruction of that particular 
cell, ensuring an effective T cell–mediated 
adaptive immune response.
MHC class II antigen presentation
MHC class II complexes are heterotrimers 
structurally similar to class I, with two 
membrane–anchored heavy chains, the 
a– and ß–chain. The peptide–binding 
groove formed by these two chains differs 
in that fact that the C– and N–termini 
of peptides are not buried in the groove 
and therefore allows for longer peptides 
to bind. Generally, MHC class II–bound 
antigenic peptides are 15–24 amino 
acids long. There are 3 different class II 
alleles in human: HLA–DQ, HLA–DP and 
HLA–DR, while mouse has two: H2–A and 
H2–E (or I–A and I–E, respectively). MHC 
class II complexes are primarily present 
on specialized cells that have the ability 
to sample the extracellular environment. 
These antigen presenting cells (APCs) 
can take up both soluble and particulate 
material and include dendritic cells (DCs), 
macrophages and B cells. The process of 
taking up extracellular material is called 
endocytosis, and the cellular route that this 
material traverses inside a cell is called the 
endocytic pathway. Binding of antigenic 
peptides by MHC class II also takes place 
in compartments of the endocytic pathway, 
but the alfa and beta chain are assembled in 
the ER. Therefore, the mechanism of loading 
MHC class II molecules with antigenic 
peptides is fundamentally different than 
that of MHC class I. To prevent ER–resident 
peptides from binding to MHC class II, the 
peptide binding groove is occupied by a 
transmembrane protein called the invariant 
chain (Ii) during assembly of the two heavy 
chains. Ii also aids with the folding of 
the MHC class II molecule, and mediates 
transport from the ER to the endocytic 
pathway (47,48). This latter process 
is initiated after Ii trimerizes, forming 
nonamers of three MHC class II molecules. 
This large complex is then transported 
to the MHC class II compartment (MIIC) 
(49,50), where Ii is processed by proteases 
such as cathepsins (Cat) S and L and AEP 
(51). This results in a small portion of Ii 
that remains bound to the peptide binding 
groove of MHC called CLIP. An MHC–like 
protein called HLA–DM (H–2M in mice) then 
mediates removal of CLIP and assists in 
keeping the peptide binding groove open 
(52). Peptides that have been generated 
in the endocytic pathway and survived 
complete degradation can then bind to MHC 
class II and it is believed that HLA–DM also 
plays a role in this binding step, ensuring 
that high affinity peptides bind over low 
affinity epitopes (53). However, the exact 
mechanisms of peptide binding to MHC class 
II complexes and displacement of Ii remain 
incompletely understood (10).
APC display a wide–range of mechanisms 
to take up extracellular antigen. Examples 
are receptor–mediated endocytosis, 
phagocytosis, and macropinocytosis. 
All internalized material ends up in the 
endocytic pathway. This pathway consists 
of a network of intracellular vesicles that 
have the ability to fuse with one another. 
Although the endocytic pathway is not linear 
and contains several points where vesicles 
can fuse or branch off, the pathway can 
be roughly subdivided in 3 stages. Each 
part is defined by the internal acidity of 
the vesicles, where the pH progressively 
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decreases further down the pathway. 
Early endosomes have a pH of around 6.0, 
which is lowered via late endosomes (pH 
5.0–6.0) to a pH of 4.5–5.0 in lysosomes. 
Material that ends up in lysosomes is rapidly 
degraded by the protease content of these 
vesicles and lysosomes play a large role in 
degradation and recycling of proteinaceous 
material. As mentioned, the endocytic 
pathway is not strictly linear: differential 
modes of uptake can target material to 
different parts of the pathway (54–57) and 
more vesicle types exist than the three 
mentioned above (50,58), but how this 
differentiation is regulated remains largely 
unclear. 
A variety of proteases reside in the 
different vesicles of the endocytic pathway, 
ranging from aspartic proteases (CatD) 
to cysteine proteases (CatB, F, L, S, Z 
and AEP). Most of these are generated 
in the ER as inactive proenzymes and 
become active by pH–dependent cleavage 
of a propiece, ensuring activity only in 
the appropriate compartments (59,60). 
Processing of extracellular material in the 
endocytic pathway into antigenic peptides is 
dependent on the activity of these different 
proteases in the different compartments 
of the endocytic route. One of the first 
step in antigen processing is the reduction 
of possible disulfide bonds (61). This is 
mediated by the enzyme GILT (62), although 
there are most likely other unidentified 
factors involved (63). After this step the 
antigen is structurally more accessible for 
proteolysis by the different enzymes. In this 
unfolded state, however, the core of the 
protein will in most cases not be accessible 
for cleavage since most proteases in the 
endocytic route are exoproteases. Indeed, 
an ‘unlocking’ step by the endopeptidase 
AEP has been shown to be important for 
the generation of several MHC class II 
epitopes (64,65), although, as with GILT, 
this protease is not essential for epitope 
generation (66). Many exoproteases have 
been identified that play a role in antigen 
processing, of which the cysteine proteases 
comprise the largest fraction. The different 
proteases process internalized antigen while 
it traverses the endocytic route. Several 
proteases only act in a strict pH range 
making them active in specific sections of 
the endocytic route. Interestingly though, to 
date none of the proteases that are active 
in MHC class II related antigen processing 
have been identified to have a substantial 
nonredundant function in peptide generation 
(10). This could mean that the activity of 
the different proteases in each endocytic 
compartment overlaps in the generation of 
antigenic peptides. Or this could mean that 
the role of a protease in one compartment 
can be taken over by another in a different 
section of the endocytic route. Although 
it has been shown that in the absence of 
several cathepsins the same MHC class II 
epitopes can still be generated as in wild 
type cells, the quantity of these epitopes 
has not been investigated in great detail. 
It remains unclear by what mechanism the 
observed redundancy takes place.
As with MHC class I, there needs to be 
a balance between destruction of material 
and generation of antigenic peptides 
(67). Before antigenic material reaches 
the lysosomal compartment where final 
destruction takes place in the highly acidic 
environment, the endocytic pathway 
intersects with the transport route of MHC 
class II molecules and MIIC compartments 
can be formed. These contain both antigenic 
material and the MHC molecules and here 
CLIP is exchanged with epitopes by HLA–DM 
as described above. Once a stable MHC 
complex is formed, transport to the cell 
surface is initiated after which epitopes can 
be presented to CD4+ T cells.
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In recent years it has become apparent 
that different cell types will process 
extracellular antigens differently after 
uptake, which has a direct effect on the 
generation of MHC class II epitopes. 
Macrophages, B cells and DCs have 
long been indicated as the key APCs for 
triggering CD4 T cell responses. However, 
these cell types differ in the speed with 
which material is internalized, degraded 
and processed ((68) and this thesis) and 
different modes of uptake will target 
material to different compartments (54–
56). Rather than a model in which several 
cell types play similar roles in eliciting an 
immune response, each APC is more and 
more emerging as a specialized player in 
immunity. Macrophages seem to be more 
important for degrading material, removing 
extracellular debris and encapsulating 
extracellular bacteria than triggering the 
adaptive immune system. Additionally, 
some macrophages are providing antigenic 
material to B cells rather than T cells (69). In 
B cells, the circumstances under which the 
BCR is triggered has direct influence on MHC 
class II loading (70). And DCs are especially 
capable of migrating to lymphoid organs, 
plus the transition from an immature to a 
mature phenotype is accompanied by strong 
upregulation of   co–stimulatory molecules 
and MHC class II surface expression 
(71,72). This makes them quite suited 
for T cell activation. Finally, the different 
APCs express a different protease profile. 
Cat L is absent in B cells and DCs, while 
Cat S is predominantly expressed in these 
cells. In macrophages on the other hand 
both cysteine proteases are present (73). 
Although the basic mechanism of MHC 
class II loading and peptide generation is 
similar in these cells, the fact that individual 
APC types perform specialized functions is 
reflected by the fact that they differ in their 
methods of MHC class II–related antigen 
processing. What the exact differences 
between APC types are and how they are 
unique in the generation of epitopes from 
extracellular material is something that is 
currently investigated by many research 
groups.
Cross–presentation
The generation of epitopes as described 
thus far, in which endogenous proteins are 
the sole source of epitopes for MHC class I 
molecules and MHC class II molecules are 
occupied with exogenous material, does 
not hold true for all cells involved in the 
adaptive immune response. Considering 
that naïve CD8+ T cells reside in the 
lymphoid organs while pathogens generally 
infect cells in the periphery there is a 
spatial incompatibility for the initiation of 
the adaptive immune response through 
antigen presentation. Additionally, in 
order to activate CD8+ T cells interactions 
between the MHC class I complex and the 
TCR alone are not sufficient; interactions 
between co–stimulatory molecules play a 
crucial role as well. These co–stimulatory 
molecules are only present on specific cell 
subsets in the body and most notably on 
APCs. Therefore, a primary infection in the 
periphery in most cases will not directly 
trigger a CD8+ response, even if pathogen 
derived epitopes are presented by MHC 
class I complexes of the infected cells. The 
T cells in the lymphoid organs with the 
appropriate TCR first require a signal that 
they are needed, after which they will get 
activated and leave the lymphoid organs. In 
order to achieve this, a mechanism called 
cross–priming exists, where naïve CD8+ T 
cells in the lymphoid organs are activated by 
APCs that are not infected themselves (74).
As mentioned above, dendritic cells 
are capable of internalizing and processing 
exogenous material for presentation on 
MHC class II molecules. These cells are at 
the same time also capable of processing 
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extracellular antigen for presentation on 
MHC class I complexes (75–77). Although 
other APCs than DCs are able to cross–
present antigens (78–82), only DC possess 
all the mechanisms needed to activate 
naive CD8+ T cells, such as maturation, co–
stimulation and migration after an encounter 
with pathogens or their associated PAMPs 
(71,72). Therefore it is generally accepted 
that DCs are the most relevant cross–
priming cell type to activate CD8+ T cells 
in vivo. It is well established that cross–
priming plays a key role in activating CD8+ 
T cells (83–88), although direct priming of 
T cells also takes places in the initiation 
of an immune response (89–92). What 
remains unclear and is currently hotly 
debated is the mechanism through which 
external antigens are processed into MHC 
class I epitopes. Which proteases process 
external epitopes for presentation on class 
I? Does a distinct mechanism exist, or are 
the previously described class I and class II 
pathways sufficient? And finally, where are 
the epitopes bound to MHC class I?
It is important to consider in what form 
cross–presented material enters DCs. Over 
the years, many forms of antigen have 
been shown to be cross–presented: soluble 
proteins (77,93–95) immune complexes 
(96–98), and cell–associated antigens 
(82,86,88,99–100) are all examples of 
material that can be cross–presented by 
DCs. Cell–associated material was the 
first form of antigen described for cross–
presentation in vivo (74) and has also been 
established as the most efficient form of 
antigen to be cross–presented. Soluble 
material can also be cross–presented 
(77,93–95) but with much lower efficiency 
than cell–associated material (99). Several 
publications have proposed that cross–
presented material is coupled to chaperones 
such as heat shock proteins and that by 
this process oligopeptides are a source 
for cross–presentation as well (101,102). 
However, several other groups have 
not been able to verify and confirm the 
relevance of this mode of transfer (103). 
As an alternative mode, this thesis and 
work done by several other labs provide 
evidence that proteasomal substrates rather 
than proteasomal products are the source 
of cross–presented material (104–108 and 
this thesis), arguing that stable proteins 
are the predominant source of antigen 
for cross–presentation (105,109 and this 
thesis). At present this is indeed the most 
commonly endorsed hypothesis. The group 
of Yewdell recently expanded on this notion 
and shows that stability is a crucial factor in 
cross–presentation (110): an exceptionally 
stable oligopeptide is quite capable of being 
cross–presented and interestingly, this 
required the heat shock protein HSP90. 
Whether this will reignite the debate on 
the role of chaperones in cross–priming 
remains to be seen. Another mechanism 
through which oligopeptides potentially 
can be transferred between cells for cross–
presentation has been put forth by the 
lab of Neefjes, where connexin–mediated 
gap–junctions play a role in peptide–
transfer between cells (111). It must be 
said however that to date this mechanism 
has only been shown in cultured cells (112) 
and other groups have failed to establish the 
same pathway in Langerhans cells (113). 
More work needs to be done to verify the in 
vivo relevance of this mechanism. Despite 
all these remaining uncertainties and 
different potential mechanisms, it is clear 
that protein levels in donor cells are a key 
factor in cross–presentation and changes 
in the stability of the cross–presented 
material directly affect the efficiency of 
cross–priming.
Another controversy is the mechanism 
through which cross–presented material is 
converted to MHC class I epitopes. Since in 
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general proteins rather than oligopeptides 
are the transferred material, proteolytic 
processing needs to take place in the DC 
after uptake. Regardless whether soluble 
or cellular antigens are internalized, the 
material ends up in the endocytic pathway 
through the uptake process described 
above, where a multitude of proteases 
are active. However, the protease that 
is predominantly responsible for the 
generation of MHC class I products from 
endogenous proteins, the proteasome, 
resides in the cytoplasm. It seems likely that 
the proteasome is involved in the generation 
of cross–presented epitopes, since for an 
effective CD8+ T cell response the epitopes 
generated by cross–presentation and direct 
presentation need to be the same. Indeed, 
several groups have reported a requirement 
for the proteasome in the generation 
of cross–presented epitopes (94,114). 
Similarly, TAP–dependency has also been 
described (94,96,114,115) although quite 
a number of reports show TAP independent 
cross–presentation does exist (116–118). 
Endocytic protease activity plays a role in 
generating epitopes via cross–presentation 
as well. Inhibition of endocytic hydrolases 
enhances cross–presentation (119,120), 
while for some epitopes a dependency on 
CatS has been found (121). It currently 
remains unclear what the exact roles of 
the different proteases are in generating 
epitopes via cross–presentation, but as said, 
it is generally believed that proteasomal 
cleavage plays a major role at one point in 
the process. This raises the next question: 
how does cross–presented material reach 
the proteasome and where are the epitopes 
bound to MHC class I molecules?  In 
2002 and 2003 several papers shook 
the field by describing a mechanism in 
which the ER–membrane and phagocytic 
vesicles fuse to form an endocytic vesicle 
equipped with all the components of the 
previously described peptide–loading 
complex PLC, including TAP (58,122–124). 
This ER–phagosome fusion would allow 
for a self–sufficient mechanism where 
phagosomes are completely equipped for 
processing of external antigens and loading 
of epitopes onto MHC class I molecules. A 
model emerged where proteasomes were 
associated to these ER–phagosomes and 
the transporter Sec61 would transport 
antigens outside the vesicles, after which 
proteasomal cleavage could take place. 
Transport via TAP back into the vesicle would 
then allow for binding to MHC class I. This 
is an attractive model, but several issues 
remain. It has been questioned whether ER–
phagosome fusion actually takes place (125) 
and its critics argue that indeed all groups 
describing the fusion model have generally 
used the same technique to analyze the 
vesicles. On top of that, the size of the 
proposed channel Sec61 would only allow 
for small antigens to be transported to the 
cytosol (126), thereby limiting the range of 
epitopes that can be generated, which does 
not agree with the experimentally found 
range of epitopes. It is of course possible 
that other transporters are involved, such 
as those of the Derlin family (8,127,128), 
or that pre–processing takes place inside 
the ER–phagosome. Despite the issue of 
transporter size, the evidence for a role of 
the retrograde translocation machinery is 
compelling, especially in the case of soluble 
antigens. Soluble antigens could directly 
access the ER and enter the cytosol through 
the Sec61 channel there (95,129). And it is 
entirely possible that the specific mode of 
uptake of the antigen plays a crucial role in 
this differential processing (130). 
Despite the many questions that remain 
it is quite clear that cross–presentation 
plays a crucial role in initiating an effective 
immune response besides the ‘more 
traditional’ forms of antigen presentation by 
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Here, we describe a new approach designed to monitor the proteolytic activity of maturing
phagosomes in live antigen-presenting cells. We find that an ingested particle sequentially en-
counters distinct protease activities during phagosomal maturation. Incorporation of active pro-
teases into the phagosome of the macrophage cell line J774 indicates that phagosome maturation
involves progressive fusion with early and late endocytic compartments. In contrast, phagosome
biogenesis in bone marrow–derived dendritic cells (DCs) and macrophages preferentially involves
endocytic compartments enriched in cathepsin S. Kinetics of phagosomal maturation is faster in
macrophages than in DCs. Furthermore, the delivery of active proteases to the phagosome is sig-
nificantly reduced after the activation of DCs with lipopolysaccharide. This observation is in
agreement with the notion that DCs prevent the premature destruction of antigenic determinants
to optimize T cell activation. Phagosomal maturation is therefore a tightly regulated process that
varies according to the type and differentiation stage of the phagocyte.





MHC class II molecules expressed on the surface of APCs





peptides are produced mainly from antigens that have been
internalized and processed in the endocytic pathway of
APCs, where they meet class II molecules en route to the
cell surface (1, 2). APCs acquire antigens via endocytosis, ei-
ther nonspecifically or through receptors expressed on their
surface (1, 3). The main function of antigen receptors is to
target and concentrate antigen in intracellular compartments
competent for processing and for interaction of the resulting
digestion products with class II molecules (1, 3).
Endocytic proteases play a key role in two different steps
of MHC class II–restricted antigen presentation: invariant
chain cleavage and antigen degradation. Indeed, invariant
chain, which directs class II molecules to the endocytic
pathway and protects them from premature peptide bind-
ing, must be proteolyzed in endosomal compartments to





S and CatL are implicated in this
process (4–6). Antigen processing involves many hydrolase
activities present along the endocytic pathway of APCs (6–





lysosomal thiol reductase (9, 10), and several cysteine pro-
teases including CatB, CatS, CatL, and asparaginyl en-
dopeptidase (4–8). Limited proteolysis rather than total
breakdown of antigens is the rule, because MHC class II





cells (2). Therefore, a balanced proteolytic environment is
required to ensure adequate processing while preventing
complete destruction. The molecular mechanisms that
control trafficking and exposure of antigens to endocytic
proteases are poorly understood.
Phagocytosis is probably a dominant mode of antigen
uptake in vivo for professional APCs such as dendritic cells
(DCs) and macrophages (11). Phagosomes formed by APCs
after uptake of latex beads have been shown to be fully
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Protease Activity in Live APCs
 
equipped for antigen processing and peptide loading (12).
How do phagosomes acquire the proteolytic activities nec-
essary to degrade antigens? The macrophage cell line J774
is a well-characterized model for analysis of phagosome
biogenesis (13, 14). In J774 cells, newly formed phago-
somes undergo progressive maturation by fusing sequen-
tially with the early endosomal, late endosomal, and lysoso-
mal compartments (13). A proteomic analysis of latex





proteins detected at different stages of phagosomal biogene-
sis (15). In particular, endocytic proteases from the Cat
family are gradually incorporated into the phagosome dur-
ing its maturation, suggesting that these proteases are found
all along the endocytic edge, including early endosomes
(15). However, whether these enzymes are active in these
nonacidic compartments remains to be addressed.
Endocytic proteases are synthesized as inactive zymogens,





the protein and occupies their active site, thus preventing
premature enzymatic activity (6–8). Once in endosomal
compartments, the drop in the pH promotes the removal of
the propeptide and conversion to the active, mature protease
(6–8). The molecular weight of endosomal proteases can
therefore be indicative of their state of activation. However,
the activity of these enzymes is also set by the milieu in
which they function (pH conditions and the presence of
small competitive inhibitors; references 6, 7, and 16). The
activity of cysteine proteases can be visualized ex vivo in
crude cell extracts using fluorescent substrates or active site–
directed probes (17). The latter correspond to electrophilic
substrate analogs that are subject to nucleophilic attack by the
cysteine residue in the protease active site. This reaction
modifies the enzyme so that it is now covalently and irre-
versibly attached to the probe. Because the covalent modifi-
cation by these probes is mechanism-based, the intensity of
labeling is proportional to protease activity (17, 18).
Here, we describe an in vivo approach to monitor the
proteolytic environment encountered by phagocytosed
particles upon internalization into the APC. By loading la-
tex beads with an active site–directed probe, we analyzed
the activity of the proteases incorporated into the phago-
some during biogenesis. This method was first validated us-
ing the monocytic cell line J774, and then applied to peri-
toneal macrophages, bone marrow–derived macrophages,
and DCs. Our results indicate that the proteolytic contents
of the phagosome depend on both the differentiation stage
of the APC and the extracellular stimuli. This implies that
the proteolytic environment to which particulate antigens






C57BL/6 mice were purchased from The Jackson Lab-
oratory. CatB, CatS, and CatL knockout mice have been previ-
ously described (19).
 
Cells and Culture Conditions.
 
J774, a mouse promonocytic
cell line, and RAW264.7, a mouse monocyte/macrophage cell
line, were obtained from the American Type Culture Collection
and were cultured in RPMI 1640 supplemented with 2 mM glu-
tamine, 10% FCS, and antibiotics.
For the preparation of bone marrow–derived APCs, bone mar-
row was obtained from 2–4-mo-old mice and APCs were pre-
pared as previously described (20), by culturing in RPMI 1640
with 10% FCS supplemented with 10 ng/ml recombinant mouse
GM-CSF (PeproTech). Culture medium was changed at days 2
and 4, and cells were harvested at day 5 or 6. Magnetic cell sorting
with anti-CD11c antibody–coated beads was used to separate bone
marrow–derived DCs from macrophages according to the manu-
facturer’s protocol (magnetic-activated cell sorting [MACS]; Mil-
tenyi Biotec). Single cell suspensions were preincubated with goat










antibodies (BD Biosciences) and cytofluoro-
metric analysis was performed on a FACScan™ using CELL
Quest™ software (Becton Dickinson). Inflammatory peritoneal
macrophages were generated as previously described (21).
 
Active Site Labeling of Cysteine Proteases in Cell Lysates.
 
JPM-
565 and DCG-04 were synthesized and purified as previously
described (18, 22). Cell lysates were prepared in lysis buffer (50




, 0.5% NP-40) and
protein concentration was measured using the Bi-cinchonic acid










boiling in reducing sample buffer for 10 min, samples were ana-
lyzed by 12.5% SDS-PAGE and transferred to a polyvinylidene
membrane. After blocking with PBS-10% nonfat milk, the
membrane was probed with a 1:1,000 dilution of streptavidin–
horseradish peroxidase (Amersham Biosciences) in PBS-0.2%
Tween 20 for 60 min followed by five washes with PBS-0.2%
Tween 20. Enhanced chemiluminescence was used for visual-
ization. We did not observe any difference in the labeling pat-









g protein) were incu-













C. SDS was added to a final concentration of 1%. Sam-
ples were boiled for 5 min and the volume was adjusted to 1.5 ml









 Immunoprecipitations were performed as




l anti-CatL (provided by A.
Erikson, University of North Carolina, Chapel Hill, NC; refer-




l anti-CatB serum, or 1 ml of the cell culture super-
natant from a hybridoma producing an anti-CatS mAb. Samples
were analyzed by 12.5% SDS-PAGE and streptavidin blotting.
 
Purification and Identification of Cysteine Proteases.
 
J774 cell ly-














M JPM-565 for 60 min before the addition of DCG-
04, and for another sample the addition of DCG-04 was omitted.
Purification of DCG-04–labeled cysteine proteases was per-
formed with streptavidin agarose as previously described (18), ex-
cept that 0.5% SDS was added and the samples were boiled be-
fore purification over the PD-10 column. Samples were run on a
12.5% SDS-PAGE. 1/25 was used for detection by streptavidin
blotting. The remainder was Coomassie stained as follows: the gel




O/25% isopropanol/10% acetic acid for 45 min,
stained with 10% acetic acid/0.006% Coomassie brilliant blue G
(Sigma-Aldrich) overnight, and destained with 10% acetic acid
for 2 h. Polypeptides retrieved on the DCG-04 matrix were ex-
cised, digested with trypsin, and analyzed by mass spectrometry
using an ion trap liquid chromatography tandem mass spectrome-
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J774 cells were grown in 20-cm



























containing compartments were isolated on a sucrose gradient as
previously described (13). After centrifugation, both the fluores-
cent bead–containing compartments and the membranes free of
beads were collected, and reducing SDS sample buffer was added.
After boiling, proteins were separated by 12.5% SDS-PAGE and
streptavidin blotting.
 
Active Site Labeling of Cysteine Proteases in Live Cells.
 
Cell








cells/well) 1 d be-





m diameter; Polysciences) were incubated with DCG-
04 for 60 min at room temperature. Beads were washed twice
with PBS and resuspended in complete culture medium. Plated









taining DCG-04–coated beads for different times. Cells were
then washed three times with medium by agitation to remove



















M free JPM-565. Lysates were harvested, boiled, and the
DNA was sheared with a syringe or sonication. Samples were an-
alyzed by 12.5% SDS-PAGE and streptavidin blotting.
Bone marrow GM-CSF cultures were harvested after 5 or 6 d









g/ml LPS was added to the
cells during the pulse. After the pulse, excess beads were removed













cells were separated by MACS.




) of both populations were incubated for




C. Cells were centri-













M JPM-565. The lysates
were harvested, boiled, and the DNA was sheared with a syringe
or sonication. Half of the sample was analyzed by 12.5% SDS-
PAGE and streptavidin blotting. Identical experiments were per-





We devised a strategy to sample the proteolytic environ-
ment encountered by phagocytosed antigens in professional
APCs. For this purpose, we used the biotinylated active site–
directed probe, DCG-04, coupled to streptavidin-coated la-
tex beads. DCG-04 is a derivative of the peptide epoxide
JPM-565 and specifically targets cysteine proteases (Fig. 1 B;
reference 18). Probe-coated beads are internalized by APCs
through phagocytosis. Bead-containing phagosomes un-
dergo maturation by fusion with the different endocytic
compartments of the APC. Once inside the cell, the active
site–directed probe senses its proteolytic environment by re-
acting with active proteases incorporated into the phago-
some (Fig. 1 A). This scenario presupposes that probes im-
mobilized via biotin to the latex beads remain available for
interaction with proteases via their COOH-terminal ep-
oxide moiety. Because binding of the probe to the protease
active site is covalent and irreversible, proteases labeled in
vivo can then be visualized after direct lysis of the phagocytes
in SDS sample buffer, followed by simple electrophoresis and
streptavidin blotting. For a given protease, different labeling
intensities correspond directly to differences in activity levels.
This approach should therefore allow us to evaluate the ac-
tivity of individual cysteine proteases delivered to the phago-
some of APCs during its maturation.
 
Cysteine Proteases Recognized by the Active Site–directed
Probe DCG-04 in Macrophages.
 
The active site–directed
probes JPM-565 and its biotinylated version DCG-04 con-
sist of an epoxide moiety linked to a tyrosine and leucine
residue with the biotinylated form containing an additional
lysine for the attachment of the biotin moiety (Fig. 1 B;
references 17, 18, and 22). In crude cell extracts, JPM-565
is a specific inhibitor of cysteine proteases of the papain
family including CatB, CatL, and CatS (17). DCG-04 has a
specificity very similar to that of JPM-565 and labels CatB,
CatH, CatL, CatZ, and CatC in rat liver cell extracts (18).
Neither JPM-565 nor DCG-04 are cell permeable as such.
To establish our in vivo protease labeling assay, we used
the J774 monocytic cell line, which has been extensively
characterized in terms of phagosomal biogenesis using latex
beads (13, 15). To identify the targets of DCG-04 in J774
cells, lysates were prepared at pH 5 and incubated with an
increasing amount of the DCG-04, followed by SDS-PAGE
and streptavidin blotting (Fig. 1 C). At least seven distinct
polypeptides were detected in the 20–40-kD range, where
most of the known active cysteine proteases are expected to
migrate. To identify these proteases, DCG-04–labeled cell
lysates were immunoprecipitated with antibodies directed
against CatB, CatL, and CatS. This allowed the identifica-
tion of three major DCG-04–labeled species as being CatB,
CatL, and CatS (Fig. 1 D). The identity of these enzymes
was additionally confirmed by comparing the labeling pat-
tern of WT and CatB-, CatS-, or CatL-deficient cells (Fig. 4
B). The polypeptide strongly reactive with DCG-04 and of a
mass slightly larger than that of CatB did not react with any
of the antibodies tested (Fig. 1 C), including a CatH antise-
rum (unpublished data). DCG-04–labeled cell lysates were
therefore incubated with streptavidin-coated agarose beads
on a preparative scale and bound material was resolved
by electrophoresis followed by Coomassie staining. The
polypeptide of interest was excised, digested with trypsin,
and analyzed by microbore and electron spray mass spec-
trometry, allowing its unambiguous identification as CatZ.
The three top bands detected in J774 lysates (Fig. 1, C and
D) were not considered in our analysis because they were
never detected in in vivo labeling assays (see below).
In conclusion, DCG-04 recognizes CatB, CatS, CatL,
and CatZ in crude cell extracts from J774 cells. Proteomic
analysis of latex bead–containing phagosomes in the J774
cell line has shown that CatB, CatS, CatL, and CatZ are in-
deed the most abundant cysteine proteases incorporated
into the phagosome during maturation (15), although the
activity of these proteases could not directly be assessed by
this proteomic approach. Therefore, DCG-04 is a probe
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suitable for sampling phagosomal proteolytic activities in
live phagocytes.
 
Visualization of Phagosomal Proteolytic Activity In Vivo.
 
To check whether DCG-04–loaded streptavidin-coated
beads can be acquired by phagocytes and target cysteine
proteases in endosomal compartments, J774 cells were in-
cubated with DCG-04–coated beads according to the pro-
cedure outlined in Fig. 2 A. To ensure that an adequate
amount of beads was taken up, cells were pulsed with
DCG-04–coated beads for 30 min. Excess beads were re-
moved by washing and cells were chased for 60 min to al-
low the beads to reach the relevant endocytic compart-
ments. At the end of the chase, cells were lysed in reducing
SDS sample buffer immediately followed by heating to pre-
vent postlysis modification of proteases by the probe. Sam-
ples were resolved by electrophoresis and analyzed by
streptavidin blotting to visualize the DCG-04–modified
polypeptides. DCG-04 coupled to beads labeled CatZ,
CatB, CatS, and CatL, demonstrating that the activity of
these four enzymes can indeed be visualized in phagosomes
of live cells (Fig. 2 B). By loading the latex beads with in-
creasing concentrations of DCG-04, the signal could be





DCG-04 (Fig. 2 B).
We performed control experiments to ascertain that the
detected proteases were indeed being labeled by the DCG-
04 immobilized on the beads. DCG-04 in solution was
added to J774 cells to determine if the free compound can
be delivered to cysteine proteases by fluid phase endocyto-
sis. We did not detect labeled Cats (Fig. 2 B). To exclude
Figure 1. Cysteine proteases recognized by the active site–directed probe DCG-04 in macrophage cell lysates. (A) Schematic overview of the approach
designed to examine phagosomal proteolytic contents. To target phagosomal proteases, biotinylated active site–directed probes are coupled to streptavidin-
coated latex beads. Upon phagocytosis of the beads, the probe reacts with the active proteases it encounters. Analysis of the modified enzymes at different
time points allows a sampling of the proteolytic activities acquired by the phagosome upon fusion with the various endosomal compartments. (B–D) Proteins
were separated by SDS-PAGE on a 12.5% gel and reactive proteases were visualized by streptavidin blotting. (B) Structure of the active site–directed probe
JPM-565 and its biotinylated derivative DCG-04. (C) Titration of DCG-04 for the labeling of the total cell lysates from J774 cells (pH 5). Lysates were incu-
bated with increasing concentrations of DCG-04. Only the bands in the 15–40-kD range are shown because the larger polypeptides have been shown to be
contaminants (reference 18). (D) Identification of individual cysteine proteases labeled by DCG-04. Total extracts from J774 cells (pH 5) were incubated
with 5 �M DCG-04 and subjected to immunoprecipitation using anti-CatB, anti-CatL, or anti-CatS antibodies.
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the possibility that proteases liberated upon cell lysis could
bind to the probe despite the fully denaturing conditions of
the sample buffer, we added DCG-04–loaded beads to cells
just before lysis (Fig. 2 B). A very faint band of CatB was
detected under these conditions, suggesting that a small
fraction of this protease reacts with the probe at the time of
lysis (Fig. 2 B). This postlysis labeling could be suppressed
when cells were lysed in SDS sample buffer, to which an
excess of nonbiotinylated JPM-565 had been added (Fig. 2
B). For subsequent experiments, an excess of JPM-565 was









M DCG-04 was saturating





(Fig. 2 C). We concluded that the amount of protease ac-
tivities detected is proportional to the amount of probe










04, and cells were lysed in reducing sample buffer contain-
ing an excess of JPM-565.
Additional controls exploring pharmacological inhibitors
(Cytochalasin D, Concanamycin B [ConB], and leupeptin)
or low temperature demonstrated that protease labeling was
dependent on phagocytosis of the DCG-04–coated beads.
Cells were incubated with DCG-04–coated beads and




C (Fig. 2 D).
Whole cell lysates from each sample were labeled separately
with DCG-04 in solution to determine that the inhibitory
effect was due to suppression of phagocytosis rather than a
mere reduction in cysteine protease activity (Fig. 2 D). In
parallel, fluorescent beads were used to verify whether in-





C in the presence of Cytochalasin D, an in-
hibitor of actin polymerization (12), as observed by the
absence of colocalization of the fluorescent beads with the
lysosomal marker Lamp1 under these conditions (un-





C or in Cytochalasin D–treated cells (Fig. 2 D),
even though their total activity remained unaffected as
shown by labeling of whole cell lysates with DCG-04 in
solution (Fig. 2 D). As expected, colocalization of fluores-
cent beads with Lamp1 was strongly reduced in the pres-




proton–pumping ATPase that blocks orderly transport
along the endocytic pathway, especially at the early to late
endosome transition (25, 26). ConB itself did not affect the
activity of cysteine proteases in lysates as measured by label-
ing with DCG-04 (Fig. 2 D). When cells were incubated
with DCG-04–coated beads and chased in the presence of
ConB, the activity of CatS and CatL was no longer de-
tected in the phagosome, whereas CatB activity was greatly
reduced (Fig. 2 D). In contrast, CatZ activity was only
slightly reduced by exposure to ConB (Fig. 2 D). This is in
agreement with the previous observation that CatZ is in-
corporated into the phagosome early during maturation
Figure 2. Visualization of phagoso-
mal cysteine protease activity in vivo.
(A) Schematic outline of the experi-
mental design. (B–D) Proteins were
separated by SDS-PAGE on a 12.5%
gel and reactive proteases were visual-
ized by streptavidin blotting. (B) Anal-
ysis of phagosomal proteases. J774 cells
were incubated for 30 min at 37�C
with latex beads previously coated
with different concentrations of
DCG-04 (pulse). After the removal of
excess beads, cells were additionally
incubated for 1 h at 37�C (chase).
Cells were then directly lysed in 2�
concentrated reducing sample buffer.
Controls: on the left, cells were treated
as in A, but free soluble DCG-04 was
added during the pulse instead of
DCG-04 coupled to beads, and on the
right, cells were treated as in A, but
DCG-04–coated beads were added
just before lysis in the presence or ab-
sence of 100 �M JPM-565. (C) Anal-
ysis of phagosomal proteases compar-
ing beads of 1- and 2-�m diameter.
J774 cells were incubated for 30 min
at 37�C with various concentrations of
DCG-04 coupled to latex beads. Cells
were then washed in PBS, incubated
for an additional 60 min at 37�C, and lysed in sample buffer containing 100 �M JPM-565. (D) Labeling of phagosomal proteases requires phagocytosis.
On the left, J774 cells were pretreated with the indicated inhibitors for 60 min (10�g/ml Cytochalasin D, 1mM Leupeptin, or 20 nM ConB), pulsed
with beads coupled to 0.1 �M DCG-04 for 30 min at 37�C (lanes 1, 3, 4, and 5) or 4�C (lane 2), washed in PBS, and chased for 60 min at 37�C or 4�C
before lysis in reducing sample buffer containing 100 �M JPM-565. On the right, cells were treated as shown on the left except that they were lysed at
pH 5. Cell lysates were incubated with 10 �M DCG-04 for 60 min at 37�C. Note that the two differentially glycosylated forms of CatB appear as a dou-
blet at low expression levels (left).
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(15) and would therefore be predicted to be resistant to the




-ATPase inhibitors. The protease labeling
approach used here indicates that the bulk of CatZ is active
in early endosomes, even though the pH in these compart-
ments is only mildly acidic. As expected, although leupep-
tin, a cell-permeable inhibitor of cysteine proteases (27),
had no effect on phagocytosis as assessed by the uptake of
beads (unpublished data), it completely abolished DCG-04
labeling in vivo and partially in vitro (Fig. 2 D). We con-
clude that the labeling of phagosomal proteases by DCG-
04–coated beads in living cells is strictly dependent on
phagocytosis. Therefore, our approach is suitable to analyze
the proteolytic activities to which particles that have been
captured by APCs are exposed.
 
Monitoring Protease Activity During Phagosome Biogenesis.
 
To monitor the activity of individual cysteine proteases at
different stages of phagosome maturation, J774 cells were
pulsed and chased with DCG-04–coated beads for different
times. We observed a time-dependent increase in active pro-
tease labeling (Fig. 3 A). As previously shown by Garin et al.
(15), this suggests that active cysteine proteases are not deliv-
ered into the phagosome synchronously, but rather incorpo-
rated gradually. CatZ and CatB activities were the first de-
tected by DCG-04 labeling (Fig. 3 A), which is consistent
with the previous observation that both enzymes are present
in early endosomes (15). When cells were chased for longer
periods, an increase in total labeling was observed, indicating
that the more mature phagosomes were also more proteolyt-
ically active. Compared with CatZ, the increase in activity of
CatB was more substantial at the later time points, consistent
with a continuous delivery of active CatB into the maturing
phagosome as previously observed (Fig. 3 A; reference 15).
We detected active CatS and CatL only after a 15-min pulse
and a 30-min chase, with an additional increase at later chase
times (Fig. 3 A). After 2 h of chase, CatB, CatS, CatL, and
CatZ activities were all established components of phagoso-
mal proteolytic content (Fig. 3 A). No additional increase in
signal was observed between 60 and 120 min of chase (Fig. 3
A). This suggests that DCG-04–coated beads may have
reached saturation after these longer chase periods (Fig. 3 A),
as it was previously shown that CatS is still delivered 12 h af-
ter phagosome formation (15).
Do the observed protease activities reflect phagosomal
proteolytic content, rather than diffusion of the probe to
acidic endosomal compartments? In other words, does
DCG-04 remain attached to the beads during endocytic
transport? To address these questions, we isolated the bead-
containing compartments by a flotation technique (13).
Both the compartments that contain DCG-04–coated
beads and the remaining membranes were analyzed for
protease content by electrophoresis and streptavidin blot-
ting (Fig. 3 B). Although this method allowed us to visual-
ize active proteases targeted by DCG-04, the procedure
was less efficient than the more direct phagocytosis assay
(Fig. 3 B). Not until 7.5 min of pulse and 60 min of chase
was a signal observed (Fig. 3 B), even though sixfold more
cells and beads were used than in the experiment shown in
Fig. 3 A. Nonetheless, this experiment showed that DCG-
04 remains bound to the beads throughout phagolysosomal
maturation, because no signal is observed in fractions that
lack beads, even though they contain far more protein (Fig.
3 B). We conclude that the protease activities detected by
in vivo labeling correspond to active hydrolases incorpo-
rated into the phagosome during its maturation.
When we compared lysates prepared from J774 and
RAW264.7 cells (a different mouse macrophage cell line)
for labeling with increasing amounts of DCG-04, we ob-
served a distinct pattern of labeled proteases. CatB and
CatL were more active in RAW264.7 compared with J774
crude cell extracts, whereas there was less CatZ activity
Figure 3. Changes in cysteine protease activity during phagosome bio-
genesis. (A–D) Proteins were separated by SDS-PAGE on a reducing
12.5% SDS gel and reactive proteins were visualized by streptavidin
blotting. (A) Analysis of proteolytic activities incorporated into the
phagosome of J774 cells during maturation. Cells were incubated at 37�C
with latex beads coupled to DCG-04 as indicated for different periods of
time (pulse). After removing excess beads, cells were additionally incu-
bated at 37�C (chase). After each time point, cells were lysed in reducing
sample buffer containing 100 �M JPM-565. (B) Purification of phago-
somes and analysis of their proteolytic contents. J774 cells were incubated
for 7.5 min at 37�C with DCG-04–coated beads (pulse). After removal of
excess beads, cells were incubated for the times indicated at 37�C (chase).
Subcellular fractionation was then performed using a sucrose gradient.
Both phagosomal (�beads) and nonphagosomal fractions (�beads) were
recovered and directly lysed in reducing SDS sample buffer. (C) Compar-
ison of the total contents in cysteine proteases of J774 and RAW264.7
(Raw) cells. Lysates (pH 5) were incubated with various concentrations of
DCG-04 for 1 h at 37�C. (D) Analysis of proteolytic activities incorpo-
rated into the phagosome of RAW264.7 cells during maturation. Cells
were treated as in A.
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(Fig. 3 C). Labeling of CatS in RAW264.7 cells was only





M), indicating that RAW264.7 has a lower level of
active CatS than J774 cells (Fig. 3 C). RAW264.7 cells
were then incubated with DCG-04–coated beads and
chased for different time periods (Fig. 3 D). As for the J774
cell line, the profile of proteases observed in mature phago-
some from RAW264.7 cells is comparable to that seen in
total cell extracts labeled with DCG-04 (compare the latest
chase points from Fig. 3 A and D with Fig. 3 C). This sug-
gests that in these cells, all endosomal compartments con-
taining cysteine proteases fuse with the phagosome during
biogenesis. Our results are therefore consistent with pro-
gressive phagosomal maturation in these cell lines, involv-
ing distinct endocytic compartments rather than one fusion
event with a single target destination, such as the lysosome.
 
The Phagosome of Primary APCs Selectively Acquires
CatS.
 
Do different types of professional APCs use a simi-
lar set of endocytic proteases to carry out antigen presenta-
tion by class II molecules? Are these proteases accessed in a
similar time-dependent manner by internalized particles?
How do the distinct APCs modulate the environment of
antigens captured by phagocytosis in terms of the proteases
they will be exposed to? Having established the methodol-
ogy for sampling the relevant phagosomal compartments,
we applied our protease labeling approach to primary APCs
to address these questions.
Mouse bone marrow cells were cultured in GM-CSF, al-
lowing the isolation of two distinct types of professional
APCs: DCs (CD11c�) and macrophages (CD11c�; see Fig.
5). The CD11c� cell population may also contain neutro-
phils from the granulocyte lineage whose development is
equally promoted by GM-CSF. Like macrophages, neutro-
phils are highly phagocytic cells that are part of the innate
immune system but also have the ability to mediate antigen
processing and presentation (28). To first analyze the cysteine
protease content of bone marrow–derived APCs, day-6 cul-
tures were directly lysed at pH 5 and labeled with soluble
DCG-04. Although the activity of CatZ, CatB, CatS, and
CatL was detected in these primary APCs, they displayed a
more complex pattern of active cysteine proteases than the
J774 and RAW264.7 cell lines. In particular, we observed an
additional labeled protein migrating at a mass slightly larger
than CatS, which was not seen in J774 and RAW264.7 cell
lysates (Fig. 4). DCG-04 modification followed by streptavi-
din-mediated retrieval of the polypeptide and mass spec-
trometry allowed us to identify it as CatH. The labeling of
cells from CatB, CatS, and CatL knockout mice showed that
the labeled polypeptides identified as corresponding to these
enzymes by immunoprecipitation do not include any other
protease (Fig. 4 B). In addition, the presence in bone mar-
row APC lysates of a labeled polypeptide that comigrates
with CatL could be inferred from labeling bone marrow
APCs from CatL knockout mice (longer exposed blots; un-
published data). Additional analysis will be needed to estab-
lish the identity of this protease.
Next, we performed an in vivo analysis of individual pro-
tease activities incorporated into the maturing phagosome of
bone marrow–derived APCs. As observed for J774 and
RAW264.7 cells, the intensity of the signal increases in a
time-dependent manner (Fig. 4 B), demonstrating that ac-
tive proteases are progressively delivered to the phagosomal
compartment. However, the relative amount of active CatZ
incorporated into the phagosome was considerably lower
than the total amount of active CatZ detected in whole cell
lysates (Fig. 4, A and B). This indicates that phagosomes of
primary APCs show only limited fusion with compartments
containing CatZ compared to what we observed in J774
and RAW264.7 cells. Although the same applies to CatH,
the opposite is true for the late endocytic protease CatS.
Even though little CatS activity is detected in whole cell ly-
sates (Fig. 4 A), relatively large amounts of active CatS are
Figure 4. Cysteine protease activity in bone marrow–derived APCs.
(A–C) Proteins were separated by SDS-PAGE on a reducing 12.5% SDS
gel and reactive proteins were visualized by streptavidin blotting. (A)
Analysis of the total contents in cysteine proteases of primary APCs. Total
extracts (pH 5) from bone marrow cells cultured in GM-CSF for 6 d
were incubated with 0.1 �M DCG-04 for 1 h at 37�C (left). Total ex-
tracts (pH 5) were incubated with 5 �M DCG-04 and subjected to immu-
noprecipitation using anti-CatB, anti-CatS, or anti-CatL antibodies
(right). *, a labeled protease of unknown identity specific for bone mar-
row–derived APCs. (B) Analysis of the total contents in cysteine proteases
of primary APCs from WT and Cat-deficient mice. Total extracts (pH 5)
from bone marrow cells cultured in GM-CSF for 5 d were incubated
with 0.1 �M DCG-04 for 1 h at 37�C. (C) Analysis of proteases incorpo-
rated into the phagosome of bone marrow–derived APCs during matura-
tion. Cells cultured in GM-CSF for 6 d were incubated at 37�C with la-
tex beads coupled to DCG-04 for 5 min. After the removal of excess
beads, cells were additionally incubated at 37�C (chase). After each time
point, cells were lysed in reducing sample buffer containing 100 �M
JPM-565.
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detected in the phagosome (Fig. 4 C). Furthermore, CatS
activity is detected earlier during phagosomal biogenesis in
primary APCs compared with the macrophage cell lines
(compare Fig. 3 and Fig. 4 C). Thus, we conclude that in
primary APCs, phagolysosomal fusion preferentially in-
volves endocytic compartments enriched in CatS.
Delivery of Proteases to Phagosomes Is Down Modulated in
LPS-activated APCs As mentioned above, mouse bone
marrow cells cultured in GM-CSF allow the isolation of
two distinct types of professional APCs: DCs (CD11c,
MHC class II) and macrophages (CD11c, MHC class
II; Fig. 5 A and unpublished data). Expression of MHC
class II was induced in the macrophage population by
IFN (unpublished data).
Do DCs and macrophages display different kinetics of
phagolysosomal fusion? To address this question, d6-bone
marrow–derived APCs were pulsed with DCG-04–coated
beads. After the removal of excess beads by washing, cells
were separated by MACS for differential CD11c expression.
Separations were performed at 4C to prevent phagosomal
maturation. The CD11c and CD11c populations of cells
were analyzed by FACS® to verify correct cell separation
(Fig. 5 A). A comparison of the DC and macrophage samples
(Fig. 5 C) showed that phagosomal maturation occurs more
rapidly in macrophages compared with DCs, with maximum
levels of protease activity already reached after 20 min of
chase (Fig. 5 C). In contrast, the maturation of the DC
phagosome progresses more slowly because an increase in
CatB and CatL activity is still observed after a chase of 45
min (Fig. 5 C). The difference between macrophages and
DCs is not attributable to different amounts of beads having
been acquired by these two cell populations, as shown by
FACS® analysis of the uptake of fluorescent beads (Fig. 5 B).
In fact, when equal amounts of bead-containing cells were
lysed at pH 5 and labeled with soluble DCG-04, it was ob-
served that CD11c cells contain more active cysteine pro-
teases than CD11c cells (Fig. 5 D). This observation effec-
tively rules out the possibility that the differences observed in
the kinetics of phagolysosomal maturation are due to differ-
ences in total protease content. Phagolysosomal fusion there-
fore appears to be a regulated process that varies according to
the type of the phagocyte examined.
A remarkable trait of DCs is the phenotypic and func-
tional change evoked by the exposure to inflammatory
stimuli, such as bacterial products, e.g., LPS. Indeed, LPS
increased B7.2 and MHC class II expression at the surface of
our bone marrow–derived DCs (29 and unpublished data).
To explore whether phagosome biogenesis in DCs is also
modulated by exposure to LPS, day-6 bone marrow cul-
tures were pulsed with DCG-04–coated beads in the pres-
ence or absence of LPS for 5 min. After removing excess
beads, CD11c cells were isolated and chased at 37C. The
comparison of untreated and LPS-treated cells revealed
drastic differences in the rates of phagosome maturation
(Fig. 6 A). Indeed, the delivery of active proteases to the
phagosome is considerably delayed in DCs pulsed in the
presence of LPS because even after 60 and 120 min of
chase, beads have not yet reached saturation (Fig. 6 A and
unpublished data). This difference between LPS-treated and
control cells does not result from reduced bead uptake by
the cells pulsed in the presence of LPS (Fig. 6 C), nor from
different amounts of active cysteine proteases (Fig. 6 B).
We were also interested in defining whether the LPS-
induced delay in phagosomal maturation is a DC-specific
Figure 5. Different rates of protease acquisition by the phagosome of
macrophages and DCs. (A) Surface expression of CD11c (top) and MHC
class II (bottom) surface in sorted bone marrow–derived APCs. Cells
were treated as described in C (see below), incubated with the appropri-
ate antibody, and analyzed by cytofluorometry. Dotted line in top shows
isotype control antibody. (B) Uptake of fluorescent latex beads by sorted
bone marrow–derived APCs. Cells were treated as described in C. The
cells that did not internalize beads (50%) are not depicted in the histo-
gram because FACS® settings were chosen to visualize the high fluores-
cence population only. (C–D) Proteins were separated by SDS-PAGE on
a 12.5% gel and reactive proteases were visualized by streptavidin blotting.
(C) Analysis of proteases incorporated into the phagosome of macro-
phages (CD11c) and DCs (CD11c). Cells cultured in GM-CSF for 6 d
were incubated for 5 min at 37C with fluorescent yellow beads coupled
to DCG-04. Excess beads were removed and cells were separated into
CD11c and CD11c cells by MACS at 4C. Equal cell numbers were
additionally incubated at 37C (chase). After the chase, cells were lysed in
reducing sample buffer containing 100 M JPM-565. (D) Analysis of the
total content of cysteine proteases of macrophages (CD11c) and DCs
(CD11c). Cells were treated as described in C. CD11c and CD11c
cells were lysed at pH 5 and incubated for 60 min with 5 M DCG-04
at 37C.
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feature or can be extended to other primary APCs as well. To
address this question, we isolated immature peritoneal mac-
rophages and performed uptake experiments with DCG-
04–coated beads in the presence or absence o of LPS. In
line with the results obtained for DCs, LPS treatment of
peritoneal macrophages delayed phagosomal maturation
when compared with unstimulated cells (Fig. 6 D). The ef-
fect was less dramatic in macrophages than in DCs. After a
60-min chase, the proteolytic content of nontreated and
LPS-stimulated macrophages were almost equivalent (Fig.
6 D). We conclude that phagolysosomal fusion, and hence
exposure of antigen to the proteases in charge of processing
them, is regulated by both the type of APC and the extra-
cellular stimuli they encounter.
Discussion
Here, we describe an approach to directly visualize the
activity of proteases that are incorporated into the phago-
some at different stages of maturation. Only small numbers
of phagocytes are required and there is no need to isolate
individual endosomal compartments before analysis. This
method is sensitive enough to allow an examination of pri-
mary cultures of professional APC, including DCs. Fur-
thermore, the use of covalent active site–directed probes in
conjunction with electrophoresis ensures specificity. Meth-
ods that employ fluorogenic substrates to detect protease
activity suffer from the drawback that more than one en-
zyme can usually cleave a given peptide substrate. Analysis
of the delivery of active hydrolases to the phagosome
helped clarify both the distribution of cysteine protease ac-
tivities among the different endocytic organelles and the
dynamics of phagosomal maturation in primary cultures of
professional APCs.
We validated our method of in vivo labeling of phago-
somal proteolytic activities on the mouse monocytic cell
line J774, whose phagosomal protein content has been ex-
tensively characterized (15). As shown by others, we found
that cysteine proteases are acquired by the maturing
phagosome of J774 cells sequentially in a time-dependent
manner, and not by delivery together (15). We observed a
gradual increase in the phagosomal activity of CatZ, CatB,
CatS, and CatL, but the rate of increase was different for
the four enzymes examined. We detected CatZ activity
early during maturation, which is in agreement with the
data of Garin et al. (15) who showed that CatZ is one of
the first proteases incorporated into the phagosome. Here,
we show that CatZ is not only present but also highly ac-
tive at this early stage of phagosomal biogenesis even
though early endosomes are only mildly acidic, an envi-
ronment not considered optimal for most lysosomal/endo-
somal hydrolases. By using a fluorogenic substrate, high
levels of CatH activity were observed in the early phago-
some (30). However, we did not detect any mature CatH
in either J774 phagosomes or crude extracts by our
method (unpublished data). Moreover, in the proteomic
study performed on J774 phagosomes, CatH was not iden-
tified as a phagosomal constituent (15). Because CatH and
CatZ show strong sequence homology, we think it is pos-
sible that both the fluorogenic substrate and the antibody
used to identify CatH activity cross reacted with active
CatZ. Although CatS is known to be stable and active at
neutral pH in vitro (31), we did detect CatS activity only
at later stages of phagosomal maturation. A similar pattern
of activity was displayed by CatL, whereas CatB was con-
tinuously incorporated into the phagosome. This suggests
that active CatL and CatS are present in late endosomal or
lysosomal compartments, whereas CatB is active all along
the endocytic pathway. These results are in total agree-
Figure 6. LPS delays phagosome maturation in APCs. (A, B, and D)
Labeled proteases were analyzed by SDS-PAGE on 12.5% reducing gel
followed by streptavidin blotting. (A) Analysis of proteases incorporated
into the phagosome of DCs (CD11c) upon activation. Bone marrow
cells cultured in GM-CSF for 6 d were incubated for 5 min at 37C with
fluorescent yellow beads coupled to DCG-04 in the presence or absence
of 0.1 g/ml LPS. Excess beads were removed and CD11c and CD11c
cells were separated. CD11c cells were additionally chased at 37C. After
chase, cells were lysed in reducing sample buffer containing 100 M
JPM-565. (B) Analysis of the total contents in cysteine proteases of DCs
treated or not with LPS during a 5-min pulse. Cells were treated as de-
scribed in A. CD11c cells were lysed at pH 5 and incubated for 60 min
with 5 M DCG-04 at 37C. (C) Uptake of fluorescent latex beads by
bone marrow–derived DCs treated or not with LPS during a 5-min pulse.
Cells were treated as described in A. The cells that did not internalize
beads (50%) are not depicted in the histogram because FACS® settings
were chosen to visualize the high fluorescence population only. (D) Anal-
ysis of proteases incorporated into phagosomes of peritoneal macrophages
upon LPS activation. Experiments were conducted as described in A.
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ment with the recently published proteasome analysis of
the J774 phagosome (13).
We analyzed bone marrow–derived macrophages and
DCs by both in vitro and in vivo active site labeling exper-
iments. In vitro labeling of cell lysates with DCG-04 re-
vealed a more complex pattern of proteases in primary
APCs compared with the macrophage cell lines analyzed.
In both primary macrophages and DCs, we not only de-
tected the activity of CatZ, CatB, CatS, CatH, and CatL,
but also that of several additional species of yet unknown
identity. By comparing macrophages and DCs, we found
that both APC types display an overall similar pattern of ac-
tive cysteine hydrolases with certain protease activities be-
ing higher in DCs. This applied in particular to CatS,
which was barely detectable when labeling macrophage cell
lysates. In contrast, the levels of CatZ were only slightly in-
creased in DCs.
Application of our in vivo method showed that in con-
trast to the macrophage cell lines, there is a selective deliv-
ery of proteases to the phagosome of primary APCs. In
particular, the relative amount of active CatZ incorporated
is considerably lower than the amount of active CatZ de-
tected in whole cell lysates. The opposite was observed for
CatS. Even though little CatS activity was detected in
whole cell lysates, relatively high levels of CatS activity
were detected in the phagosome. Labeling intensities for
different proteases cannot be directly related to absolute ac-
tivities, but changes in the ratios of labeling intensities must
correspond to shifts in the protease balance. We estimate
that the ratio of CatZ to CatS labeling intensity is 10 in
cell lysates, whereas it is 1 when examining phagosomes.
Phagosomes from primary APCs must therefore fuse pref-
erentially with endocytic compartments enriched in CatS.
This finding raises interesting questions about the relevance
of CatZ activity for processing of phagocytosed material. A
similar observation was made for CatH, whose labeling ra-
tio to CatS is about 10 in cell lysates, whereas it is 1 in
the phagosome. Because in J774 cells most CatZ has been
found to reside in early endocytic compartments (15 and
this study), phagosomes from primary APCs may undergo
only limited fusion with early endosomes. However, we
cannot exclude that the subcellular distribution of CatZ in
primary APCs is different than in J774 cells. Nonetheless,
our data show that the incorporation of active proteases
into the phagosome of primary APCs is a selective process
that ensures delivery of CatS.
We show that phagosomal maturation occurs more rap-
idly in macrophages than in DCs. Furthermore, we ob-
served a substantial down-regulation of phagosome matu-
ration in DCs exposed to LPS and to a lesser extent, in
LPS-treated macrophages. It is possible that this observa-
tion results from the ability of such a stimulus to down-reg-
ulate endocytosis in DCs. Indeed, a delay in phagolysoso-
mal fusion could result from a more global decrease in the
rates of transport along the endocytic axis. The appearance
of class II vesicle–like compartments (32) enriched in
MHC class II molecules and early endocytic markers has
been reported during DC activation (29). This would allow
DCs to acquire antigen while minimizing the complete de-
struction of peptide determinants and therefore be benefi-
cial to ensure T cell activation upon arrival in the lymph
node (11). In contrast, macrophages are essential players of
the innate immune system, can be microbicidal, and consti-
tute an early barrier against infectious agents. Our measure-
ments of protease activity are consistent with these notions.
Based on the usefulness of active site–directed probes for
the analysis of protease activity in live cells, we envision the
development of a new generation of compounds that can
be coupled directly to antigens of immunological rele-
vance, such as intracellular pathogens, apoptotic cells, or
single protein antigens. Analysis of the proteolytic environ-
ment to which such materials are exposed upon internaliza-
tion into the APC should help identify the players involved
and the sequence in which they act. Do antigens meet pro-
teases immediately after internalization? Does the pro-
teolytic environment to which antigens are targeted differ
for distinct APCs and/or modes of internalization? Do fea-
tures of the antigen itself or extracellular stimuli affect the
proteases to which it is exposed in the APC? Certain
pathogens not only inhibit phagolysosomal fusion, but may
also encode protease inhibitor homologues that could di-
rectly affect the activity of surrounding hydrolases (33).
These questions may now be addressed by exploring the
proteolytic environment encountered by antigen in the
course of trafficking in the APC using methodology similar
to that reported here.
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A correction has been published for this article in Science. 2004 Sep 24;305(5692):1912: “Antigen bias in T cell cross–
priming” by M. C. Wolkers et al. (28 May, p. 1314). Two of the symbols in Fig. 3B were denoted incorrectly. The closed 
triangles represent RMA–S sE7–GFP–NP cells, and the closed circles represent RMA–S sNP–GFP–E7 cells.
In contrast to catenane 6, catenane 5 with two
“missing” alkyl loops shows broad unresolved
signals for aromatic moieties and urea groups in
pyridine-d5 at 25°C. At high temperature (100°C),
however, the observed pattern for NH signals
(three singlets in the ratio 2:1:1) and for the
signals of calixarene methylene bridges ArCH2Ar
(three pairs of doublets in the ratio 2:1:1) is in
accordance with the time-averaged C2v symmetry
expected for the case where the hydrogen-bonded
belt changes its directionality quickly on the NMR
time scale (22).
Molecules of types 5 and 6 appear to be
unprecedented in their connectivity. Considering
just the interlocked rings, the molecules can be
regarded as bis-[3]catenane, and [8]catenane, re-
spectively. The principle discussed and described
above for their synthesis implies the selective
heterodimerization of a bis- or tetra-loop tetraurea
calix[4]arene with a reactive open-chain tetraurea
calix[4]arene. We are convinced that this principle
can also be applied to tetraurea derivatives with
other loops, to other ring closure reactions, and to
the formation of novel rotaxanes.
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Antigen Bias in T Cell Cross-Priming
Monika C. Wolkers, Nathalie Brouwenstijn,* Arnold H. Bakker,*
Mireille Toebes, Ton N. M. Schumacher†
Activated CD8 T cells detect virally infected cells and tumor cells by recognition
of major histocompatibility complex class I–bound peptides derived from degrad-
ed, endogenously produced proteins. In contrast, CD8 T cell activation often
occurs through interaction with specialized antigen-presenting cells displaying
peptides acquired from an exogenous cellular source, a process termed cross-
priming. Here, we observed a marked inefficiency in exogenous presentation of
epitopes derived from signal sequences in mouse models. These data indicate that
certain virus- and tumor-associated antigens may not be detected by CD8 T cells
because of impaired cross-priming. Such differences in the ability to cross-present
antigens should form important considerations in vaccine design.
Cytotoxic CD8 T cells recognize pep-
tides that are presented on the cell surface
by major histocompatibility complex
(MHC) class I molecules. Two cellular
pathways lead to this form of presentation.
In classical antigen presentation, MHC
class I molecules bind peptides that are
generated via degradation of endogenous
proteins (1). In an alternative pathway, pro-
fessional antigen-presenting cells (APCs)
internalize material derived from virally
infected or transformed cells and then
present the exogenously derived antigens to
naı̈ve CD8 T cells, a process referred to as
cross-presentation (2). T cell activation
through cross-presentation (cross-priming),
can be readily demonstrated for a number
of antigens (3–5) but has not been observed
for all antigens, including those that are
efficiently presented through the endoge-
nous pathway (6, 7).
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Fig. 3. Space-filling rep-
resentation of the mo-
lecular structure of 6 in
the crystalline state.
(Left) Top view. Me-
thoxy groups of one
calix[4]arene are point-
ing toward the reader.
(Right) Side view. The
two multimacrocyclic
calix[4]arenes are col-
ored blue and red. Hy-
drogen atoms are omit-
ted for clarity.
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Whether the parameters governing effi-
cient exogenous and endogenous antigen
presentation are equivalent is not clear. To
investigate this issue, we generated two
green fluorescent protein (GFP) fusion
gene constructs that both encode two MHC
class I Db-restricted epitopes. In the first
construct (sNP366-GFP-E749), the epitope
NP366 (derived from influenza A) was in-
serted into the N terminus of the signal
peptide of a secreted GFP molecule. The
second epitope, the antigen E749 (derived
from human papilloma virus 16), was in-
serted close to the C terminus of GFP (Fig.
1A) (8). In the second construct, the same
epitopes were introduced but in reverse
order (sE749-GFP-NP366) (Fig. 1A). The
introduction of each CTL (cytotoxic T lym-
phocyte) epitope into the hydrophilic frag-
ment of the signal peptide did not affect
signal peptide cleavage or intracellular
transport of GFP when compared with a
GFP molecule harboring an uninterrupted
wild-type signal peptide (sGFP-NP) (Fig.
1, B and C) (figs. S1 and S2). This intro-
duction of NP366 and E749 epitopes into the
GFP fusion genes allowed us to monitor
antigen presentation of two epitopes
present in the same protein synthesis prod-
uct but located in two different protein
fragments. Assessing the presentation of
signal peptide– encoded epitopes seemed
particularly useful because signal peptides
represent an important source of endog-
enously produced MHC class I–binding
peptides (9–12).
Presentation of the NP366 and E749
epitopes via the endogenous pathway was
examined by introducing the GFP fusion
genes into the RMA tumor cell line (13).
Cells containing GFP with the NP366
epitope located in either the signal peptide
or the mature protein were recognized
equally well by NP366-specific CD8
 T
cells (Fig. 1D) (8). Similarly, the E749
epitope was presented efficiently to
antigen-specific T cells, whether located in
the signal peptide or the mature protein
(14). Because saturation of T cell recogni-
tion at high antigen densities could poten-
tially mask differences in presentation effi-
ciency, a more quantitative measure of the
antigen processing of T cell epitopes was
required. To achieve this, we isolated pep-
tides from each transfected cell line by acid
elution and used them to sensitize target
cells for CTL recognition. In this system,
the epitopes contained in the mature protein
fragment or in the signal peptide were
again presented with comparable efficiency
(Fig. 1E). Hence, for this antigen, location
within the signal peptide or GFP moiety
apparently does not affect the efficiency of
endogenous presentation. Endogenous pre-
sentation of the NP366 epitope present with-
in the hydrophilic segment of the signal
peptide was in large part dependent on the
transporter associated with antigen process-
ing (TAP), because presentation of NP366
by TAP-deficient RMA-S cells containing
sNP366-GFP-E749 was inefficient (Fig. 1, D
and E) (9, 15). Similarly, endogenous pre-
sentation of the NP366 epitope contained
within the mature protein required TAP
function (Fig. 1, D and E).
To investigate whether antigen location
might influence T cell priming by cross-
presentation, we challenged naı̈ve mice
with RMA-S cells that contain the sNP366-
GFP-E749 gene construct. Efficient induc-
tion of T cell immunity against the E749
epitope located within the mature protein
was made evident by staining of peripheral
blood cells with MHC tetramers containing
E749 (Fig. 2A). In contrast, the NP366
epitope contained in the signal peptide of
the same fusion gene induced only low
numbers of antigen-specific T cells. To
determine whether this difference was a
direct result of the epitope location within
the protein or was due to other factors, such
as a difference in T cell precursor frequen-
cy, we challenged mice with RMA-S cells
containing the fusion gene with the two
epitopes in reverse order (sE749-GFP-
NP366). In this setting, mice developed a
pronounced NP366-specific T cell response,
whereas the E749 epitope located within the
signal peptide failed to induce efficient T
cell immunity, as judged by MHC tetramer
staining and by ex vivo interferon- (IFN-
) production (Fig. 2, A and B). In all mice
examined (n  40; P  0.0001), T cells
specific for the epitope located in the ma-
ture protein outnumbered those specific for
the signal peptide–encoded epitope. Antigen-
specific T cell responses to the C-terminal
antigens E749 and NP366 were stronger, on
Fig. 1. Endogenous antigen presentation of T cell epitopes from
signal peptides and mature protein segments. (A) Structure of the
sNP366-GFP-E749 and sE749-GFP-NP366 fusion gene products. The
arrowhead indicates the signal peptide cleavage site. (B) Secretion
of GFP variants. RMA sE7-GFP-NP cells (a), RMA sNP-GFP-E7 cells
(b), RMA cells (c), and RMA GFP-NP cells (cytosolic location; d)
were treated with brefeldin A for 5 hours (white area) or left
untreated (gray area). GFP expression was determined by flow
cytometry analysis; the y axis represents cell counts. (C) The
introduction of the NP366 or E749 epitope into signal peptides
does not affect signal peptide cleavage. Cellular GFP products (c)
were obtained by immunoprecipitation with polyclonal rabbit
antibody to GFP from RMA cells expressing cytosolic GFP-NP (cy),
sGFP-NP containing the wild-type signal peptide (s), sE7-GFP-NP (sE), or
sNP-GFP-E7 (sN). Cells were starved in Met/Cys-free Dulbecco’s modified
Eagle’s medium for 60 min before a 30-min pulse labeling with [35S]Met/
Cys in DMEM containing 5% fetal bovine serum. In vitro transcription/
translation (v) was performed with standard rabbit reticulocyte system
(Promega) according to the manufacturer’s protocol. Samples were ana-
lyzed by SDS–polyacrylamide gel electrophoresis. Compare lanes 6 and 7
(s), 9 and 10 (sE), and 11 and 12 (sN). (D and E) Analysis of NP366 antigen
presentation of RMA sNP-GFP-E7 (Œ), RMA sE7-GFP-NP (F), RMA (),
TAP-deficient RMA-S sNP-GFP-E7 (‚), and RMA-S sE7-GFP-NP (E)
cells. Percentages of IFN-–producing NP366-specific CD8
 T cells de-
rived from in vitro restimulated spleen cells of NP366-vaccinated mice (8)
were determined by intracellular cytokine staining (Pharmingen), either
upon incubation with the indicated cell transfectant (D) or upon peptide
stripping and subsequent loading of serial dilutions on D1 target cells (E) (8).
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Antigen bias in T cell cross-priming
average by factors of 30 and 16, respective-
ly, than T cell responses against the same
epitope when present in the signal peptide.
Collectively, these findings indicate that T
cell priming by cross-presentation is consid-
erably more efficient for epitopes derived
from mature proteins than for epitopes con-
tained within signal peptides.
We wanted to ascertain that the T cell
responses induced by tumor inoculation were
a result of cross-presentation and were not
due to a putative residual capacity of RMA-S
cells to present endogenous antigen in vivo.
Therefore, we sought to establish whether the
observed antigen bias would also be evident
in a system in which tumor cells lacked the
relevant MHC allele (2). Thus, we introduced
the two GFP fusion gene constructs into p815
cells (H-2d background and therefore lacking
the required H-2b–presenting allele) and used
them to challenge C57/Bl6  Balb/c F1 (H-
2b  H-2d) mice. Efficient antigen-specific T
cell induction to E749 occurred when this
epitope was located within the mature protein
but, again, not when located within the signal
sequence (Fig. 2C). Ex vivo T cell responses
to NP366 were undetectable in this setting
(14), potentially because of strain-dependent
differences in NP366-specific T cell precursor
frequency (16). However, when spleen cells
of the challenged mice were analyzed for
NP366-specific T cell responses upon in vitro
restimulation, a similar bias toward the NP366
epitope encoded within the mature protein
was apparent (Fig. 2D).
The selective priming of T cell respons-
es against epitopes contained within mature
antigens could potentially be a conse-
quence of immunoglobulin (Ig)–protein
complex formation. Specifically, Igs recog-
nizing the (secreted) mature protein might
form Ig-protein complexes that could be
taken up by dendritic cells via Fc receptor–
mediated endocytosis (17, 18). To deter-
mine whether Ig-protein complex forma-
tion is required for the observed bias in
antigen-specific T cell immunity, we chal-
lenged -deficient mice, which lack B cells
(19), with RMA-S cells containing either
GFP fusion gene construct. Again, T cell
responses to the mature antigens were effi-
ciently induced, whereas T cell immunity
induced by signal peptide– encoded
epitopes was marginal (Fig. 3A). Thus,
Ig-protein complex formation does not
measurably influence the antigen bias
observed in this system.
In an alternative scenario, the difference
in the capacity of the two protein fragments
to induce T cell immunity by cross-priming
might result from a difference in the ability
of APCs to extract and present the two
epitopes from cells or cellular remnants.
To test this idea, we incubated immature
murine D1 dendritic cells (20) with irradi-
ated RMA-S cells containing either GFP
fusion gene construct. Subsequent cross-
presentation of the NP366 epitope was more
efficient by a factor of 10 when derived
from the mature protein than when located
within the signal peptide (Fig. 3B). Thus,
the superior level of T cell induction ob-
served toward epitopes within mature pro-
teins can, at least in part, be attributed to
differences in the ability of APCs to cross-
present the two classes of antigens.
The observed antigen bias could be a con-
sequence of a specific inability to cross-
present T cell epitopes present in signal pep-
tides, or it could reflect a negative effect of
N-terminal location of the epitope. As a direct
test, we generated a fusion gene construct in
which the signal peptide was rendered dys-
functional by removal of the hydrophobic
segment that is bound by the signal recogni-
tion particle (s*E749-GFP-NP366, figs. S3 and
S4) (8). Mice that were challenged with
RMA-S cells transduced with the s*E749-
GFP-NP366 construct developed an E749-
specific T cell response whose magnitude
was equal to or greater than that of the NP366-
specific T cell response (Fig. 3C). These data
indicate that poor cross-priming is a direct
consequence of location of the epitope within
a functional signal peptide.
Prior experiments have sought to deter-
mine the contribution of direct priming and
cross-priming in the induction of tumor- and
virus-specific T cell responses by disrupting
either endogenous or exogenous antigen pre-
sentation (3–7). Our data show that epitopes
derived from signal peptides are efficiently
presented through the endogenous pathway
but not through the exogenous pathway.
Hence, we can analyze the contribution of
these two pathways in T cell induction in a
setting where both are operational. We chal-
lenged naı̈ve mice with RMA cells that con-
tained either GFP fusion gene construct. De-
spite the clear efficiency in endogenous pre-
sentation of both epitopes seen in in vitro
assays (Fig. 1, D and E), antigen-specific T
cell responses induced in vivo were skewed
Fig. 2. In vivo cross-priming is biased to-
ward epitopes located within the mature
protein. (A) Naı̈ve C57/Bl10 mice were
subcutaneously challenged with 2  106
cells of the indicated RMA-S transfectant.
Percentages of NP366-specific (top) and
E749-specific (bottom) CD8
 T cells in
peripheral blood were determined at the
indicated time points with the use of phy-
coerythrin-conjugated antibody to CD8
(Pharmingen) and APC-conjugated NP366- or
E749-containing MHC tetramers (27, 28).
Each dot represents an individual mouse;
bars denote average percentage. (B) Anti-
gen-specific T cells induced by cross-prim-
ing are functional. Twelve days after tumor inoculation, IFN- production of CD8 T cells was
determined directly ex vivo upon a 4-hour stimulation with 0.1 M NP366 or E749 peptide in the
presence of brefeldin A (top) and interleukin-2, and was compared with MHC tetramer staining
(bottom). (C and D) MHC tetramer staining of peripheral blood cells (C) or splenocytes (D) from
H-2d  H-2b F1 mice that were challenged with 10
7 cells of the indicated p815 transfectant,
measured directly ex vivo (C) or after 7 days in vitro restimulation with the appropriate peptide
(D). Identical results were obtained with H-2d–restricted mouse embryonic cells that contained
either construct (14).
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toward the epitopes contained in the mature
antigen, whether NP366 or E749 (Fig. 4).
Thus, exogenous antigen presentation proved
to be the dominant mechanism for T cell
induction, at least in this model system.
Our data show a marked divergence in
the efficiency of endogenous and exoge-
nous antigen presentation. The fact that
epitopes that are efficiently presented
through the endogenous pathway are not in
all cases efficiently presented upon exoge-
nous presentation may help to explain the
lack of cross-priming previously observed
in several model systems (6, 7). In this
regard, it is useful to note that the lympho-
cytic choriomeningitis virus (LCMV )–
derived GP33 epitope, which has been
shown to fail in inducing T cell immunity
via cross-priming, is derived from the
LCMV GP signal peptide (9). Another in-
teresting issue to address will be whether
these findings extend to the efficiency of
tolerance induction against peripheral anti-
gens that are not expressed within the thy-
mus. Thus, epitopes derived from peripher-
al antigens that fail to efficiently enter the
cross-presentation pathway may be less
likely to be exposed to naı̈ve T cells and
may therefore not induce peripheral toler-
ance (21, 22). Such “ignored” peripheral
antigens may prove particularly interesting
targets for the induction of tumor-specific
T cell immunity, as the T cell repertoire
against these antigens may not have been
affected by cross-tolerance (23).
How might the bias against signal peptide
epitopes be explained at the molecular level?
Potentially, signal peptides assemble with
cellular factors that reduce their accessibility
to the exogenous presentation pathway. Al-
ternatively, and perhaps more likely, if exog-
enous presentation involves transfer of un-
processed antigens (24), this is likely to be
inefficient for molecules that are degraded
rapidly after synthesis (25). In this latter mod-
el, exogenous presentation would depend on
the steady-state antigen levels in the donor
cell, as opposed to the protein synthesis rate
for endogenous antigen presentation (26).
The current data suggest a fundamental
difference between endogenous presentation
and exogenous presentation, a divergence
that is likely to influence immunogenicity
and immunodominance in virus- and tumor-
induced T cell responses. In addition, because
vaccine-induced T cell responses often rely
on cross-presentation, understanding the
rules that determine the efficiency of exoge-
nous presentation should be important in
helping to optimize vaccine design.
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Fig. 3. Differential exogenous presentation of
epitopes from signal peptides and mature proteins
by dendritic cells. (A) In vivo T cell induction
through cross-priming is independent of Igs. NP366-
specific (top) and E749-specific (bottom) CD8
 T
cell responses induced in -deficient mice upon
tumor inoculation with 2  106 RMA-S sNP366-
GFP-E749 cells (left) or with RMA-S sE749-GFP-
NP366 cells (right). (B) Epitopes derived from mature
antigens are more efficiently cross-presented than
epitopes located within a signal peptide. Irradiated RMA-S sNP-GFP-E7 cells (Œ), RMA-S sE7-GFP-
NP cells (F), and RMA-S cells () were fed to D1 cells, NP366-specific fluZ hybridoma cells were
added, and T cell activation was determined (8). (C) Antigen bias is dependent on signal peptide
location. C57/Bl6 mice were inoculated with 5 106 RMA-S sE749-GFP-NP366 cells (left) or RMA-S
s*E749-GFP-NP366 cells (right). Peripheral blood was analyzed at the indicated time points for
NP366-specific (top) and E749-specific (bottom) CD8
 T cells by MHC tetramer flow cytometry.
Fig. 4. T cell responses induced after challenge
with MHC-proficient RMA cells are biased to-
ward epitopes contained within mature anti-
gens. C57/Bl10 mice were subcutaneously
challenged with 5  105 RMA sNP366-GFP-
E749 cells (left) or RMA sE749-GFP-NP366 cells
(right). Peripheral blood was analyzed at the
indicated time points for NP366-specific (top)
and E749-specific (bottom) CD8
 T cells by
MHC tetramer flow cytometry.
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SUPPORTING MATERIAL
Materials and Methods
DNA constructs and cell lines
The gene construct sNP366–GFP–E749 
was generated by adding the amino acids 
MGVQIASNENMDAMVPCTLLLLLAAALAPTQ
TRAV to the NH2–terminus of the enhanced 
Green Fluorescent Protein (GFP). This 
sequence encodes the NP366 epitope (bold) 
preceded by four NH2–terminal influenza A 
NP derived amino acids and followed by the 
H–2Kb–derived signal peptide (italic). The 
amino acids GVQIRAHYNIVTF SELEKD were 
introduced at the COOH–terminus of GFP. This 
sequence encodes the E749 epitope (bold) 
preceded by four NH2–terminal influenza A 
NP–derived amino acids and followed by a 
short spacer sequence (underlined) to ensure 
that antigen presentation required cytosolic 
processing. In the gene construct sE749–
GFP–NP366, the two epitopes were introduced 
in reverse order, while the sequence of 
the flanking residues was maintained. The 
hydrophobic segment of the signal peptide 
was removed to generate a mutant signal 
peptide (s*) with the following sequence 
MGVQIRAHYNIVTFVPCTL. The NH2– and 
COOH–flanking amino acids were conserved 
to maintain comparable antigen processing 
conditions. The gene constructs were 
inserted into the plasmid pcDNA3.1 for in 
vitro transcription/translation, and into the 
retroviral vector pMX for introduction into the 
indicated cell lines as described previously 
(1). Single cell clones were selected on the 
basis of matched GFP expression by flow 
cytometry. 
In vitro direct antigen presentation 
assay
Spleen cells from mice that were 
immunized with NP366–containing RMA tumor 
cells were restimulated in vitro for 14 days in 
IMDM medium containing 10% fetal bovine 
serum, 5x10–4 µM NP366 peptide, and 10 
CU human recombinant  IL–2/ml (Chiron). 
NP366–specific T cells were incubated with the 
indicated number of tumor cells, and after 
4hr incubation in the presence of Brefeldin 
A (PharMingen) and IL–2, the percentage of 
IFNγ–producing CD8+ T cells was determined. 
For peptide elution, peptides were stripped 
from tumor cells by boiling in 10% acetic 
acid that contained 10µM of an irrelevant 
peptide, and passed through a 10 kDa cut–off 
filter. Serial dilutions were loaded on 5x104 
D1 cells, and activation of NP366–specific T 
cell cultures was determined by intracellular 
IFNγ–staining.
In vitro cross–presentation assay
The indicated RMA–S tumor cells were 
irradiated with 80 Gray and incubated at 37° 
C for 24 hrs. Subsequently, 1x105 D1 cells 
were incubated for 48 hrs with the indicated 
amount of tumor cells. 1x105 NP366–specific 
fluZ hybridoma cells were added for 16 hrs 
and T cell activation was determined by 
monitoring the conversion of chlorophenol 
red–galactopyranoside to chlorophenol red 
at 595 nm (2). In this assay, irradiation of 
tumor cells is required to avoid overgrowth 
of the cell cultures by the tumor cells but is 
not essential for antigen uptake by D1 cells. 
Addition of tumor cell supernatant did not 
induce detectable cross–presentation by D1 
cells, indicating that the source of the material 
that is cross–presented is cellassociated (3).
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The introduction of the NP366 or E749 epitope into signal peptides does not affect secretion 
of GFP variants. Indicated RMA cell transfectants were starved in Met/Cys–free DMEM 
medium for 60 min prior to a 30 min pulse labeling with 35Slabeled Met/Cys in DMEM 
medium containing 5% fetal bovine serum. Labeled cells were washed with cold medium, 
and samples of cells and supernatant were harvested at indicated time points. After cell 
lysis, GFP variants were immunoprecipitated with polyclonal rabbit anti–GFP. Samples were 
analyzed by SDS–PAGE. Approximately 50% of the sNP366–GFP–E749 migrates at a higher 
molecular weight at later chase time points. This material is also secreted and may represent 
a glycosylated form of this protein. 
Fig. S2
The introduction of the NP366 or E749 epitope into signal peptides does not affect targeting 
of nascent proteins to the ER, and does not prevent secretion. Indicated cell lines were 
starved in Met/Cys–free DMEM medium for 60 min prior to a 30 min pulse labeling with 
35S–labeled Met/Cys in DMEM medium containing 5% fetal bovine serum in the presence or 
absence of proteasome inhibitor lactacystin (Calbiochem) at a final concentration of 10µM. 
Labeled cells were washed with cold medium, and cultured in the continued presence or 
absence of lactacystin. Cells were harvested at the indicated time points. GFP variants 
were immunoprecipitated with polyclonal rabbit anti–GFP, and samples were analyzed by 
SDS–PAGE.
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and activation of NP366-specific T cell cultures was determined by intracellular IFN -
staining.
In vitro cross-presentation assay: The indicated RMA-S tumor cells were irradiated 
with 80 Gray and incubated at 37  C for 24 hrs. Subsequently, 1x105 D1 cells were 
incubated for 48 hrs with the indicated amount of tumor cells. 1x105 NP366-specific 
fluZ hybridoma cells were added for 16 hrs and T cell activation was determined by 
monitoring the conversion of chlorophenol red-galactopyranoside to chlorophenol red 
at 595 nm (2). In this assay, irradiation of tumor cells is required to avoid overgrowth 
of the cell cultures by the tumor cells but is not essential for antigen uptake by D1 
cells. Addition of tumor cell supernatant did not induce detectable cross-presentation 
by D1 cells, indicating that the source of the material that is cross-presented is cell-
associated (3).
Figures
Fig. S1: The introduction of the NP366 or E749 epitope into signal peptides does not 
affect secretion of GFP variants. Indicated RMA cell transfectants were starved in 
Met/Cys-free DMEM medium for 60 min prior to a 30 min pulse labeling with 35S-
labeled Met/Cys in DMEM medium containing 5% fetal bovine serum. Labeled cells 
were washed with cold medium, and samples of cells and supernatant were harvested 
at indicated time points. After cell lysis, GFP variants were immunoprecipitated with 
polyclonal rabbit anti-GFP. Samples were analyzed by SDS-PAGE. Approximately 
50% of the sNP366-GFP-E749 migrates at a higher molecular weight at later chase time 
points. This material is also secreted and may represent a glycosylated form of this 
protein.
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Fig. S2: The introduction of the NP366 or E749 epitope into signal peptides does not 
affect targeting of nascent proteins to the ER, and does not prevent secretion. 
Indicated cell lines were starved in Met/Cys-free DMEM medium for 60 min prior to 
a 30 min pulse labeling with 35S-labeled Met/Cys in DMEM medium containing 5% 
fetal bovine serum in the presence or absence of proteasome inhibitor lactacystin 
(Calbiochem) at a final concentration of 10 M. Labeled cells were washe with cold 
medium, and cultured in the continued presence or absence of lactacystin. Cells were 
harvested at the indicated time points. GFP variants were immunoprecipitated with 
polyclonal rabbit anti-GFP, and samples were analyzed by SDS-PAGE. 
Fig. S3: Deletion of the hydrophobic signal peptide segment yields a cell-associated 
GFP variant. RMA sE7-GFP-NP cells (a), RMA s*E7-GFP-NP cells (b), and RMA
cells (c), were treated with Brefeldin A for 5hrs (white area) or left untreated (gray 
area). GFP expression was determined by flow cytometry analysis.  
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Fig. S3
Deletion of the hydrophobic signal peptide segment yields a cell–associated GFP variant. 
RMA sE7–GFP–NP cells (a), RMA s*E7–GFP–NP cells (b), and RMA cells (c), were treated 
with Brefeldin A for 5hrs (white area) or left untreated (gray area). GFP expression was 
determined by flow cytometry analysis.
Fig. S4
Deletion of the hydrophobic signal peptide segment leads to loss of signal peptide cleavage. 
Cellular GFP products (c) were obtained by immunoprecipitation with polyclonal rabbit 
anti–GFP from RMA cells that expressed cytosolic GFP–NP (cy), sE7–GFP–NP containing a 
functional signal peptide (sE), or s*E7–GFP–NP containing a disrupted signal peptide (s*E). 
In vitro transcription/translation (v) was performed with standard rabbit reticulocyte system 
(Promega) according to the manufacturer’s protocol using pcDNA3.1 plasmids that encode 
the indicated GFP variant. Samples were analyzed by SDS–PAGE.
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Fig. S2: The introduction of the NP366 or E749 epitope into signal peptides does not 
affect targeting of nascent proteins to the ER, and does not prevent secretion. 
Indicated cell lines were starved in Met/Cys-free DMEM medium for 60 min prior to 
a 30 min pulse labeling with 35S-labeled Met/Cys in DMEM medium containing 5% 
fetal bovine serum in the presence or absence of proteasome inhibitor lactacystin 
(Calbiochem) at a final concentration of 10 M. Labeled cells were washed with cold 
medium, and cultured in the continued presence or absence of lactacystin. Cells were 
harvested at the indicated time points. GFP variants were immunoprecipitated with 
polyclonal rabbit anti-GFP, and samples were analyzed by SDS-PAGE. 
Fig. S3: Deletion of the hydrophobic signal peptide segment yields a cell-associated 
GFP variant. RMA sE7-GFP-NP cells (a), RMA s*E7-GFP-NP cells (b), and RMA
cells (c), were treated with Brefeldin A for 5hrs (white area) or left untreated (gray 
area). GFP expression was determined by flow cytometry analysis.  
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Fig. S4: Deletion of the hydrophobic signal peptide segment leads to loss of signal 
peptide cleavage. Cellular GFP products (c) were obtained by immunoprecipitation 
with polyclonal rabbit anti-GFP from RMA cells that expressed cytosolic GFP-NP 
(cy), sE7-GFP-NP containing a functional signal peptide (sE), or s*E7-GFP-NP 
co taining a disrupted signal peptide (s*E). In vitro t anscription/tran lation (v) w s 
performed with standard rabbit reticulocyte system (Promega) according to the 
manufacturer’s protocol using pcDNA3.1 plasmids that encode the indicated GFP 
variant. Samples were analyzed by SDS-PAGE. 
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The detection of antigen-specific T cell responses by MHC
multimer staining is rapidly becoming one of the core
immunological techniques, and the technology to produce
MHC multimers has been optimized substantially in recent
years. Furthermore, recent work demonstrates the potential of
high-throughput detection of T cell responses and suggests
that manipulation of T cell responses through the use of
multimeric MHC reagents is also feasible.
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Introduction
T cell receptors (TCRs) are capable of singling out
specific peptide–MHC (pMHC) complexes on target
cells amidst a wide variety of other pMHC complexes.
By exploiting the specificity of this interaction, multi-
meric forms of MHC molecules (MHC multimers) have
been designed with the aim of detecting antigen-specific
T cells amidst a multitude of unrelated T cells. The first
MHC multimer used for specific T cell analysis, a human
MHC class I tetramer, was described in 1996 by John
Altman [1]. Today, MHC multimers can range from
dimers to octamers, consisting of either MHC class I,
MHC class II or nonclassical MHC molecules, from
species including mouse, monkey and man.
In this review we discuss the value of currently available
MHC class I and class II multimer technologies in terms
of valency, expression system and peptide loading strat-
egy. In addition, we provide a roadmap for the future
development of multimeric MHC technology, and high-
throughput multimer systems in particular, as well as
potential clinical applications.
MHC multimer technologies
A great number of strategies has been developed for the
production of MHC multimers. As illustrated in Table 1,
themajor differences betweenMHCmultimers are found
in just three parameters: the valency of the multimeric
complex, the expression system through which the mole-
cules are produced, and the peptide-loading strategy used
to achieve occupancy of the peptide-binding groove with
the desired antigenic peptide.
Valency
TCRs have a low affinity for their cognate pMHC coun-
terparts, with an off-rate of only a few seconds [2].
Monomeric pMHC–TCR interactions are therefore too
unstable to be exploited as an effective labelling techni-
que, but — as for any multivalent interaction — combin-
ing multiple MHC molecules into one complex greatly
increases binding stability [3,4]. In their landmark paper,
Davis and colleagues [1] approached this need for multi-
valency by designing tetrameric forms of MHC mole-
cules. In this strategy, soluble MHC monomers are
biotinylated and converted to tetravalent structures by
binding to (fluorochrome-conjugated) streptavidin or avi-
din, which both have four biotin binding sites. The
resulting MHC tetramers remain by far the most popular
reagents for the detection of antigen-specific CD4+ and
CD8+ T cells by flow cytometry.
What’s in a name?
In spite of their name, however, it is quite unclear
whether binding of MHC tetramers to T cells occurs
in a tetravalent fashion. First, due to the rigid tetrahedral
configuration of these complexes only three out of the
four available MHC molecules are likely to bind simul-
taneously to the T cell surface [5]. Second, the conjugates
of (strept)avidin with the proteinaceous fluorochromes
phycoerythrin (PE) and allophycocyanin (APC) that are
used for MHC tetramer production are prepared by
chemical crosslinking and therefore also contain multi-
mers of (strept)avidin [6]. These higher order oligomers
appear to make an important contribution to T cell
binding, as evidenced by the fact that streptavidin–PE
‘tetramers’ show increased binding over Cy5-labeled
(true) tetramers, when tested for CD8-independent bind-
ing to human cytotoxic T lymphocytes (CTLs) [6]. These
data not only suggest that the valency of the standard PE
conjugates exceeds four, but also that — at least for
(strept)avidin-based multimers — a valency greater than
four might be preferred for optimal binding. Other and
arguably better defined multimers with valencies greater
than four exist, such as the commercially available MHC
pentamers, where five pMHC complexes face the same
direction through the use of a five-stranded coiled coil as
oligomerization domain. On the other side of the spec-
trum, MHC multimers with a valency of two (i.e. MHC
Current Opinion in Immunology 2005, 17:428–433 www.sciencedirect.com
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dimers) were designed in the laboratory of Jonathan
Schneck [7]. In these molecules, the extracellular domain
of MHC molecules is expressed as a genetic fusion with
an immunoglobulin scaffold, resulting in an MHC–Ig
dimer [7,8]. Although these MHC dimers were originally
used for T cell activation, these dimeric MHC molecules
are now also used as staining reagents in flow cytometry
[8]. Finally, several approaches have been developed for
the generation of MHC-coated artificial antigen-present-
ing cells (aAPCs). In these systems, multivalency is
achieved by coupling MHCmonomers to magnetic beads
[9,10], or by incorporating MHC monomers into liposo-
mal vesicles [11,12].
What’s your favourite number?
Faced with this multitude of multimers, which format
should one choose to detect antigen-specific T cells by
flow cytometry? The available data suggest that a valency
of four or possibly even greater is optimal for the detec-
tion of high-avidity CD8+ T cells with (strept)avidin-
based MHC multimers. It is noted, however, that the
scaffold used for multimerization is likely to influence the
valency that is required, by affecting the conformational
freedom of the attached MHC monomers. MHC dimers
are used infrequently in comparison to MHC tetramers,
although this could also be due to the more complicated
production process (see below). MHC pentamers have
the advantage of being more molecularly defined. At
present, not many peer-reviewed data on these new
molecules are available, but it seems likely that their
binding strength will not differ substantially from the
standard MHC tetramers.
A higher valency of the complex may become more
important when aiming to detect antigen-specific CD4+
T cells, as standardMHC class II tetramers appear to miss
lower avidity cells present in the antigen-specific CD4+ T
cell repertoire [12,13]. Low-avidity CD8+ T cells, such as
T cells specific for self-antigens, can be detected by
conventional MHC class I tetramers in at least some
cases [14,15] (and one should therefore be aware that
the detection of antigen-specific CD8+ T cells by MHC
tetramer staining is not necessarily indicative of a high-
avidity interaction). It seems plausible, however, that the
detection of low-avidity self-specific CD8+ T cells will
also be facilitated by the use of higher order MHC
oligomers.
Expression system
Recombinant MHCmolecules used for the production of
multimeric MHC reagents have been produced in either
bacterial cells or eukaryotic cells, such as insect cells and
mammalian cells. A clear advantage of the bacterial
expression systems is the ease with which large quantities
of proteins can be generated. MHC molecules that are
produced in Escherichia coli cells generally need to be
refolded in vitro. This process is straightforward for the
majority of MHC class I alleles and, with few exceptions
[8,10,16], bacterial expression has indeed been the pre-
ferred system for MHC class I multimer production. By
contrast, the efficiency with which MHC class II mole-
cules can be refolded in vitro is notoriously low, and the
majority of MHC class II production systems are there-
fore based on eukaryotic expression, such as baculovirus-
infected insect cells [17] or stable Drosophila cell
transfectants [18,19]. Although the yield of MHC class
II molecules obtained in such eukaryotic expression
systems can be optimized [20], the development of
E. coli expression strategies that provide higher yields
of refolded MHC class II molecules than the current
strategies [3,12,21] remains a laudable goal.
Peptide-loading strategy
The third — and rather important — parameter in the
generation ofMHCmultimers is themethod by which the
MHC molecules are loaded with peptide. Three funda-
mentally different approaches have been used to date:
1. Antigenic peptides can be included during the in vivo
process, through genetic linkage to one of the MHC
chains.
2. Peptides can be included during the in vitro produc-
tion process.
3. Peptides can be bound after MHC monomer, or even
MHC multimer, production.
Low-throughput strategies
From a structural point of view, genetic fusion of the
desired antigenic peptide with one of the MHC chains
makes sense for MHC class II molecules, but less so for
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Table 1
Distinct MHC multimer formats.
Peptide-binding strategy Dimera Tetramera Pentamera Octamera Polymer/aAPCa
Euk.b Bact.b Euk.b Bact.b Euk.b Bact.b Euk.b Bact.b Euk.b Bact.b
Exchange [8] [18 c,24] [10,11]
Bound during refolding [1c,4d,21] e [6] [9,43]
Linked peptide [16,44] [17 c,42] [12]
Only selected references are cited. MHC class I multimers are shown in bold; MHC class II multimers are shown in italics. aValency.
bExpression system. cMost widely used formats. dMonomers and tetramers have been produced, but higher order oligomers are also
possible. eLimited peer-reviewed data available at present. Euk., Eukaryotic; Bact., bacterial.
www.sciencedirect.com Current Opinion in Immunology 2005, 17:428–433
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MHC class I molecules. In the case of MHC class I
molecules, the terminal NH3+ and COO– groups are
normally buried in the MHC structure and contribute
to peptide binding [22,23]; genetic fusion of MHC to one
of the peptide termini is therefore bound to result in a
local change in the structure of the pMHC complex.
Genetic peptide fusions to MHC molecules have been
used fairly extensively to produce human and murine
MHC class II multimers [17,19]. High throughput synth-
esis of multimeric MHC molecules by this strategy,
however, is precluded by the fact that a different con-
struct and producer cell line is required for each peptide
antigen. Production of MHC multimers with several
different peptide antigens is more straightforward with
the commonly used strategy for MHC class I multimer
production, in which a synthetic peptide antigen is
included during the in vitro refolding process. Because
separate refolding and purification is still required for
each single MHC class I multimer, the production of
large collections of pMHC reagents remains a challen-
ging task.
High-throughput strategies
In cases in which a multitude of MHC multimers with
different antigens bound to the same MHC allele is
required, the preferred strategy is to bind peptide ligands
to preformed MHC monomers or multimers. For MHC
class II molecules, such ‘exchange’ strategies have been
developed, using either presumed peptide-free [18] or
class II-associated invariant chain peptide (CLIP)-bound
[24] MHC class II molecules as starting material.
Although the CLIP-based strategy is conceptually some-
what more appealing, as it mimics the in vivo binding of
ligands to MHC class II, no comparison between the two
strategies has been made.
Because of the greater number of identifiedMHC-class-I-
associated epitopes, a similar type of exchange strategy
would be of considerable use for the generation of MHC
class I multimers [8,10,25]. Because of the instability of
peptide-free MHC class I molecules [26,27], however,
the conditions that can be used to promote the release of
bound ligands, such as low pH, also affect the MHC
structure itself, and this type of exchange technology has
not gained widespread use for MHC class I. To circum-
vent this issue, we have recently developed so-called
‘conditional’ MHC class I ligands. These ligands can
be made to dissociate from MHC class I upon exposure
to defined triggers, such as ultraviolet light, that do not by
themselves destabilize MHC class I molecules (M
Toebes et al., personal communication). Using such con-
ditional ligands, a large array of MHC multimers can be
generated from preformedMHC complexes in one or two
hours, and the resulting complexes appear to bind to
antigen-specific T cells with comparable avidity and
specificity as conventional MHC class I tetramers. This
technique might prove to be of substantial use for the
generation of large collections of pMHC multimers, for
conventional MHC multimer flow cytometry, and for
high-throughput systems for T cell analysis (see below).
Future strategies and challenges
High throughput analysis with MHC multimers
At present, the detection of antigen-specific T cells by
MHC tetramer staining is a technology with a highly
limited throughput, as only a single T cell specificity
is analyzed per sample. For the definition of novel
pathogen- or tumour-associated epitopes, or for the
comprehensive screening of T cell responses in blood
samples, the simultaneous monitoring of a large number
of T cell specificities in a single sample would be highly
desirable.
Multiparameter flow cytometry
If MHC multimers with multiple specificities are to be
used in a single flow cytometric analysis, this requires that
MHC multimers of each separate specificity carry an
individual label [28]. The low diversity of fluorochromes
routinely used in conjunction with MHC multimers (i.e.
PE and APC) has severely limited the potential for multi-
parameter screening. Although the non-proteinaceous
fluorochromes have not worked well with the classical
MHC tetramer format, this problem can be overcome by
the use of octameric MHC reagents [6]. Perhaps more
important for the long-term development of multipara-
meter MHC multimer analysis is the recent interest in
fluorescent nanocrystals called quantum dots (qdots)
[29]. Qdots are more stable than organic fluorochromes,
and — importantly for their potential use with MHC
multimers — quantum dots are available in a wide
fluorescent spectrum and exhibit very narrow emission
spectra. On the basis of these properties, we consider it
plausible that MHC multimers, built on qdot-coupled
streptavidin, for example [30], will enable the simulta-
neous measurement of 10 or more T cell responses in a
single sample in the not-too-distant future. Furthermore,
if qdot-coupled MHC multimers can be made to contain
defined combinations of qdots, the combinatorial power
of the method could increase even further [31].
MHC-microarrays
As an alternative to flow cytometric analysis of multiple T
cell responses by MHC multimers, Soen and colleagues
[32] have developed anMHC-microarray-based approach
for T cell detection. In these arrays, each array spot
contains MHC molecules complexed with a specific
peptide, and T cell responses are measured by quantify-
ing either T cell binding or T cell activity in distinct spots.
Although only a modest number of pMHC specificities
were spotted in the first arrays, the use of peptide-
exchange systems for MHC class II [18,24] and MHC
class I molecules (M Toebes et al., personal communica-
tion), in which exchange reactions are performed on the
slide, has the promise to produce microarrays with a
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substantially larger number of specificities. In comparison
to multiparameter analysis of T cell responses by MHC
multimer flow cytometry, MHC microarrays are likely to
have a somewhat lower sensitivity, but such arrays should
be capable of visualizing T cell populations specific for a
vast number of (possible) antigens.
Manipulating T cell responses with MHC multimers
A series of studies has provided proof-of-principle for the
use of MHC multimers as reagents to boost desirable or
suppress unwanted T cell responses (Figure 1). MHC
multimers have been used for rapid and efficient ex vivo
isolation and expansion of specific T cells [11,33,34],
which should be of use for adoptive therapy following
allogeneic stem cell transplantation, for example [35].
MHC multimer–TCR interactions during such enrich-
ments could affect T cell viability, so to reduce the effects
of these interactions, Knabel and colleagues [36] have
devised a strategy for reversible multimer staining. This
technique forms an elegant addition to the standardMHC
multimer approach, but whether such reversible binding
improves the in vivo activity of adoptively transferred T
cells in human trials remains to be determined.
MHCmultimers could also conceivably be used for the ex
vivo removal of unwanted T cells, such as alloreactive T
cells contained in peripheral stem cell transplants.
Furthermore, several studies provide support for the
use of MHC dimers for the in vivo inactivation of auto-
reactive T cells, thereby preventing type I diabetes and
arthritis [37–39]. In addition to these non-conjugated
MHC multimers that rely on TCR signalling for their
biological effects, isotope-coupled MHC multimers have
been generated [40]. These 225Ac-labeled MHC tetra-
mers are promising reagents to induce killing of specific T
cell populations. Although the in vivo activity of this type
of ‘suicide tetramer’ remains to be established, the iso-
tope does not seem to be overly toxic in vivo [41].
Because the quantity of MHC multimers required for in
vitro enrichment or depletion is likely to be lower than the
amount required for in vivo use, these in vitro technologies
could perhaps be implementedmore readily. BeforeMHC
multimers can be used in any of these ex vivo or in vivo
clinical settings, however, it will obviously be essential to
develop procedures for the Good Manufacturing Practice
production of these reagents, which will prove a challenge
for translational researchers in the coming years.
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Potential clinical applications for MHC multimers. (a) MHC multimers can be used for the ex vivo selection and expansion of desired antigen-specific
T cells. These T cells can then be (re-)infused to enhance reactivity against defined tumour- or virus-associated antigens. (b) MHC multimers
can be used for the ex vivo depletion of undesired (e.g. graft-versus-host disease [GvHD]-associated) T cells from transplant material before
transfer to the recipient. (c) MHC multimers can be used for the in vivo inactivation of undesired (e.g. autoimmune-associated) T cells for the
prevention/treatment of autoimmune disease.




The dissection of T cell responses by MHC multimer
staining has become an established technique in precli-
nical research, and is becoming increasingly important for
clinical trial monitoring. The parallel development of a
variety of multimeric MHC strategies in the past decade
has been important to discovering which formats work
best and we expect that in the coming decade a small
number of these formats will become standard for MHC
multimer flow cytometry.More importantly, we speculate
that the near future will bring the arrival of technologies
that will enable high-throughput analysis of T cell
responses, either by flow cytometry or on solid surfaces.
In addition, MHC multimers might find increasing use as
therapeutic agents, be it either for the enrichment of
desired T cells, or the removal of rogue T cell popula-
tions.
Update
Elegant work has recently been published by the Stern
laboratory on the generation of MHC microarrays [45].
In this study, T cell responses against a number of pMHC
complexes are analyzed in parallel by cytokine capture.
Cebecauer and colleagues [46] have recently demon-
strated that the distance between individual pMHC
molecules of an MHC multimer affects the cytotoxic
effect of such multimers on antigen-specific T cells:
MHC molecules connected by short linkers induce rapid
cell death, whereas MHC molecules connected by long
linkers do not. This is valuable information for the
development of MHC multimers for clinical use.
Finally, the first papers have been published that make
use of the MHC class I pentamer technology to detect
antigen-specific T cells by flow cytometry [47,48].
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Major histocompatibility complex (MHC) class I multimer technol-
ogy has become an indispensable immunological assay system to
dissect antigen-specific cytotoxic CD8 T cell responses by flow
cytometry. However, the development of high-throughput assay
systems, in which T cell responses against a multitude of epitopes
are analyzed, has been precluded by the fact that for each T cell
epitope, a separate in vitro MHC refolding reaction is required. We
have recently demonstrated that conditional ligands that disinte-
grate upon exposure to long-wavelength UV light can be designed
for the human MHC molecule HLA-A2. To determine whether this
peptide-exchange technology can be developed into a generally
applicable approach for high throughput MHC based applications
we set out to design conditional ligands for the human MHC gene
products HLA-A1, -A3, -A11, and -B7. Here, we describe the devel-
opment and characterization of conditional ligands for this set of
human MHC molecules and apply the peptide-exchange technol-
ogy to identify melanoma-associated peptides that bind to HLA-A3
with high affinity. The conditional ligand technology developed
here will allow high-throughput MHC-based analysis of cytotoxic
T cell immunity in the vast majority of Western European individuals.
epitope  T cell  CD8
MHC Class I molecules are heterotrimeric complexes con-sisting of an invariant light chain called 2-microglobulin
(2m), a polymorphic heavy chain (HC) and an 8- to 11-aa
peptide ligand. These peptide–MHC (pMHC) complexes are
recognized by the T cell receptor (TCR) of CD8 T cells in a
peptide-specific fashion, and this interaction forms the molec-
ular basis of antigen recognition by CD8 T cells. In the past
decade, the mapping of pathogen-specific and autoimmune- or
cancer-associated T cell epitopes has been a major driving force
in the development of assay systems for immunomonitoring. In
addition, knowledge of such T cell epitopes forms a cornerstone
in the development of vaccine-based or adoptive T cell therapies.
As a first step in the mapping of disease-associated T cell
epitopes, peptide fragments of disease-associated proteomes
may be analyzed for binding to MHC molecules of interest, and
subsequent assays can then be used to determine whether T cell
reactivity against such pMHC complexes does occur. As dem-
onstrated in a landmark study by Altman and colleagues (1), such
antigen-specific T cell reactivity can efficiently be detected by the
staining of T cell populations with recombinant fluorescent
multimeric MHC molecules.
There is an increasing interest in the development of assay
systems, such as MHC-based microarrays, that can monitor a
multitude of T cell responses in parallel (2–4). Unfortunately,
current technology does not allow for the high-throughput
generation of different pMHC complexes, thereby limiting the
utility of these techniques. Specifically, because MHC class I
complexes that are devoid of peptide are markedly unstable (5,
6), current production processes for recombinant MHC com-
plexes require inclusion of a specific T cell epitope during the
initial refolding step (7), and this precludes the production of the
large collections of pMHC multimers that would be needed to
analyze antigen-specific T cell responses in a comprehensive
manner.
Based on these considerations, it seemed valuable to devise
technologies that allow the high-throughput parallel generation
of peptide-MHC class I complexes. As a step toward this goal,
we recently designed an HLA-A2-specific peptide that contains
a photocleavable moiety (8). When refolding reactions of
HLA-A2 heavy chain and 2m are performed with this ligand,
stable HLA-A2 complexes are formed. However, upon irradia-
tion with long-wavelength UV, the ligand is cleaved and disso-
ciates from the HLA-A2 complex. The resulting empty HLA-A2
complexes disintegrate rapidly, unless UV exposure is per-
formed in the presence of a ‘‘rescue peptide.’’ In this case, the
peptide-binding groove that has been vacated by UV exposure
will be occupied by the rescue peptide, resulting in the formation
of stable pMHC complexes with a distinct T cell specificity. The
utility of this approach has been demonstrated by the identifi-
cation of an HLA-A2-restricted CTL epitope from an H5N1
influenza strain isolated from a lethal case of avian influenza
infection in humans (8).
To determine whether this technology can be developed into
a broadly applicable high-throughput system for the dissection of
human CTL responses, we set out to design and test a panel of
UV-sensitive ligands for the human MHC gene products HLA-
A1, -A3, -A11, and -B7.
Results
Design of the Conditional Ligands. In an effort to test the feasibility
of developing a broadly applicable high-throughput platform for
MHC-based detection, we focused on a set of four gene products
(HLA-A1, -A3, -A11, and -B7) with a high prevalence in the
Western European population. By using the SYFPEITHI data-
base (9), a set of three to six high-affinity 9-mer peptides was
designed for each molecule, in which the UV-sensitive -amino
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acid (/)-3-amino-3-(2-nitro)phenyl-propionic acid was incor-
porated at different positions. Amino acid sequences were based
on known peptide motifs for each gene product and had a
predicted SYFPEITHI peptide-binding score of 25 (excluding
a potential detrimental effect of the -amino acid). In all
peptides, the photolabile building block was incorporated at
positions predicted to result in solvent exposure of the 2-nitro-
phenyl side chain, as based on structural data (10, 11), or the lack
of amino acid selectivity at this position (9). Although solvent
exposure of the 2-nitrophenyl side-chain is not required for the
UV-mediated cleavage step, this strategy was used to reduce the
likelihood that incorporation of the photolabile amino acid
would affect MHC binding capacity.
First, a series of small-scale refolding reactions was performed
with each of the 19 starting ligands [supporting information (SI)
Table 2]. The resulting pMHC complexes were subsequently
analyzed by gel-filtration HPLC and MHC ELISA to determine
three parameters: the efficiency of MHC refolding, the stability
of the pMHC complex in the absence of UV exposure, and the
UV-sensitivity of this complex. A description of the starting set
of conditional ligands and a summary of the outcome of these
assays in terms of stability and UV-sensitivity of the different
pMHC complexes is given in SI Table 2.
Of the 19 ligands tested, 3 either showed no or very poor
refolding with the corresponding MHC molecule or the pMHC
complex displayed a substantial instability upon storage or brief
37°C exposure. The remaining 16 pMHC complexes were ex-
posed to UV light and analyzed for unfolding of the pMHC
complex: 9 of these pMHC complexes displayed no or low
UV-induced unfolding, whereas the remaining 7 displayed ef-
ficient UV-induced degradation. From this set, the ligands that
yielded the highest efficiency of refolding were selected for
further optimization. Specifically, to facilitate rapid release of
the resulting peptide fragments upon UV exposure while max-
imizing complex stability under normal conditions, the anchor
residues of the selected ligands were altered while keeping the
UV-sensitive amino acid at the same position. After analyzing
this pool of second candidate ligands for the same three param-
eters, an optimal conditional ligand was selected for each HLA
gene product, termed p*[allele]: p*A1, STAPGJLEY; p*A3,
RIYRJGATR; p*A11, RVFAJSFIK; p*B7, AARGJTLAM;
where J is 3-amino-3-(2-nitro)phenyl-propionic acid.
Analysis of the Conditional pMHC Complexes. Large-scale refolding
reactions were performed to enable more detailed analysis of the
selected p* ligands for the four different molecules. In parallel,
refolding reactions were performed with a set of known epitopes
(termed pA1, pA3, pA11, and pB7) lacking a photolabile
residue, for use as controls in these experiments. For all four
HLA molecules, the efficiency of refolding of the different
p*MHC complexes was comparable to that of the corresponding
control pMHC (HLA-A1 p*A1, 21%; HLA-A3 p*A3, 20%;
HLA-A11 p*A11, 23%; HLA-B7 p*B7, 12%).
To set up a more rapid assay system for the measurement of
UV-induced MHC unfolding for the different complexes,
pMHC and p*MHC preparations were either exposed to UV or
left untreated, and the amount of remaining folded MHC was
then analyzed by ELISA (12, 13) of serial dilutions (shown for
HLA-A1 in SI Fig. 5). Having established a suitable pMHC
concentration to visualize the effect of UV exposure on p*MHC
stability via ELISA (between 10 and 20 nM, SI Fig. 5), a kinetic
analysis of UV-mediated degradation was performed for each
MHC product. UV exposure of control MHC complexes re-
folded with UV-insensitive peptides had no effect on their
stability, independent of the time of exposure. In contrast, each
of the p*MHC complexes showed substantial degradation after
a 1-min UV treatment, and the effect of UV exposure was close
to complete after a 5-min exposure (Fig. 1A).
To allow the use of conditional MHC complexes for various
high-throughput applications, it is essential that the unstable
MHC molecules that are formed upon UV exposure can bind a
newly added ligand and thereby be stabilized. To test whether
this is the case for the four HLA gene products under study,
exchange reactions were performed in the absence of peptide, in
the presence of an HLA-A2-restricted control peptide, or in the
presence of a known peptide ligand for each complex. For all
four HLA gene products, addition of the relevant ligand resulted
in a substantial rescue (71–108% of starting material, Fig. 1B),
whereas addition of the HLA-A2-restricted control peptide was
without effect. Combined, these experiments show that (i) all
four conditional ligands refold efficiently into stable MHC
complexes, (ii) the resulting complexes display a similar UV-
sensitivity, and (iii) the peptide-free MHC molecules generated
upon triggering can be charged with newly added allele-specific
ligands.
Peptide Cleavage and Exchange Kinetics. A caveat of the MHC
ELISA data in Fig. 1 is that the observed unfolding of MHC
upon UV exposure is an indirect measure of peptide dissociation
and may be influenced by the fact that the stability of the
peptide-free state can vary between different MHC molecules
Fig. 1. Characterization of conditional ligands for HLA-A1, -A3, -A11, and
-B7. (A) Control and p*-HLA complexes for each complex were exposed to UV
for the indicated times, and UV-induced MHC unfolding was measured by
ELISA. Control peptides: pA1 VTEHDTLLY, pA2 FLWGPRALV, pA3 RLRAEAQVK,
pA11 IVTDFSVIK, and pB7 RPHERNGFTVL. (B) The indicated p*-HLA complexes
were exposed to UV light for 0 or 60 min in the presence of no peptide, the
HLA-A2 restricted CMV-pp65 epitope NLVPMVATV (irrelevant peptide), or
their respective specific ligands, pA1, pA3, pA11, and pB7 (sequences under A)
and analyzed by MHC-ELISA. Values indicate means  SD of triplicates.
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(14). To allow a more direct measurement of the dissociation of
peptide fragments upon UV exposure, a fluorescently labeled
variant of p*A2 was produced: KILGC(Fl)VFJV (Flp*A2).
HLA-A2 complexes occupied with this f luorescent ligand were
then used in exchange reactions in the presence of an unlabeled
CMV pp65-derived HLA-A2 ligand. When aliquots of HLA–A2
Flp*A2 complexes are either left untreated or exposed to UV for
different time periods and analyzed by gel-filtration HPLC,
recovery of total MHC, as reflected by absorbance at 230 nm, is
identical for all samples. In contrast, when the amount of
remaining MHC-associated Flp* ligand is monitored by fluores-
cence analysis, a clear reduction is observed (Fig. 2A, 88%
reduction after 60-min UV exposure). Thus, the instability of
MHC upon UV exposure of p*MHC complexes is accompanied
by a parallel release of the fluorescent peptide fragment.
In the p*A2 ligand, the J residue is incorporated at p8 of the
nonameric peptide. Because the side chain of p9 is buried in the
F pocket of the peptide-binding groove, f luorescent labeling at
a COOH-terminal position relative to the cleavage site was
precluded for this peptide. To assess whether both peptide
fragments that are formed upon cleavage of a UV-sensitive
peptide dissociate with similar kinetics from the peptide binding
groove, subsequent analyses were performed with variants of the
p*B7 ligand, in which the photolabile residue is incorporated at
a more central position (p5). Two variants of the p*B7 ligand
were produced with a fluorescently labeled cysteine residue at
either an NH2- or COOH-terminal position relative to J
(AARC(Fl)JTLAM and AARGJTLC(Fl)M). HLA-B7 com-
plexes refolded with these peptides were then exposed to UV in
the presence of an unlabeled HLA-B7 ligand and analyzed by
gel-filtration HPLC. No substantial difference was observed
between the rate of dissociation of fluorescently NH2- and
COOH-terminal cleavage products (Fig. 2 B and C) and a 60-min
UV-exposure led to an 84% and 75% reduction of the fluores-
cent signal, respectively.
For both the fluorescently labeled NH2-terminal fragment of
p*A2 and the fluorescently labeled NH2- and COOH-terminal
fragments of p*B7 a small amount of fluorescent signal that
comigrated with the MHC complex was consistently observed
after UV exposure (Fig. 2 A–C). Because prolonged UV expo-
sure does not result in a substantial further decrease in this signal
(data not shown), it seemed unlikely that this signal reflected the
presence of uncleaved MHC-associated ligand. To test this
directly, peptides were extracted from UV-exposed or untreated
HLA-A2 Flp*A2 complexes by acid elution and analyzed by
reverse-phase HPLC. This analysis demonstrated that UV ex-
posure leads to a near-complete cleavage of the starting MHC-
associated material (Fig. 2D). Next, the fluorescent material that
remained MHC-associated upon UV exposure was isolated by
gel-filtration HPLC, followed by peptide elution. Subsequent
analysis of this material by reverse-phase HPLC demonstrates
that also the fluorescent material that remains MHC-associated
upon UV exposure does not contain substantial amounts of the
starting Flp *A2 ligand. The identity of the formed cleavage
products was not investigated (Fig. 2E).
To directly visualize the kinetics of binding of newly added
ligands to UV-exposed p*MHC complexes, HLA-A2 p*A2
complexes were exposed to UV light for 30 min in the presence
of the fluorescent A2 ligand FLPSDC(FI)FPSV (15) and then
incubated at room temperature for different periods. Subse-
quently, the amount of newly bound MHC ligand was deter-
mined by gel-filtration HPLC. A strong fluorescent signal was
seen when MHC complexes were analyzed directly after UV
exposure, and this signal did not increase measurably upon
further incubation. This indicates that binding of new ligands to
the MHC complex is essentially complete during the time of UV
exposure (Fig. 2F).
Detection of Antigen-Specific T Cell Responses with HLA-A1, -A3, -A11,
and -B7 Exchange Tetramers. As a stringent test of the value of
peptide-exchanged MHC complexes of the different gene prod-
ucts for the detection of antigen-specific T cell responses,
exchange reactions were performed with a series of pathogen-
derived epitopes and used for multimerization without further
purification. Subsequently, T cell staining of these MHC ex-
change tetramers was compared with that of MHC tetramers
generated in classical individual refolding reactions (1). In a first
set of experiments, the intensity of staining of epitope specific T
cell clones restricted by HLA-A1 and -A3 was analyzed, upon
incubation with different concentrations of classical MHC tet-
ramers or MHC exchange tetramers (SI Fig. 6). For both
HLA-A1 and -A3 complexes, MHC exchange tetramers and
classical MHC tetramers are indistinguishable in their capacity
to stain a relevant T cell clone (Fig. 3). Furthermore, in both
cases, background staining as revealed by incubation of an
irrelevant CTL clone with a high concentration of MHC tet-
ramer is negligible (0.05%, Fig. 3, SI Fig. 6). To extend this
Fig. 2. UV-induced peptide cleavage and exchange kinetics. (A) HLA-A2-
monomers refolded with the fluorescent UV-sensitive peptide Flp*A2 were
treated with UV in the presence of the HLA-A2 ligand NLVPMVATV for
different time periods and analyzed by gel-filtration HPLC. Absorption at 230
nm (Left) and fluorescence at 567 nm (Right) was measured. (B and C) HLA
B7-monomers refolded with either the fluorescent UV-sensitive peptides
AARC(Fl)JTLAM (B) and AARGJTLC(Fl)M (C) were treated with UV in the
presence of the HLA-B7 ligand TPRVTGGGAM for different time periods and
analyzed as in A. (D) HLA-A2-monomers refolded with the fluorescent UV-
sensitive peptide Flp*A2 were either left untreated or exposed to UV for 60
min. Extracted peptides were analyzed by reverse-phase HPLC. Black line,
untreated; red line, UV-treated. (E) As in D except that before peptide extra-
tion, elution material with the retention time of pMHC molecules was isolated
by gel-filtration HPLC. Black line, untreated; red line, UV-treated. (F) p*A2-
monomers were treated with UV for 30 min in the presence of 0.5 M
fluorescent FLPSDC(FL)FPSV and 49.5 M FLPSDCFPSV peptide and kept at
temperature for the indicated periods before analysis as in A.











analysis to clinically more relevant samples, MHC-exchange
tetramers and classical MHC tetramers were compared with
respect to the ability to detect low-frequency T cell responses in
peripheral blood samples. Tetrameric forms of p*MHC com-
plexes that had not been exposed to UV and that are therefore
uniformly occupied with the conditional ligand were included as
controls. In all cases tested, MHC exchange tetramers stained
the relevant T cell populations, and both the percentage and
fluorescence intensity were directly comparable to that observed
upon staining with MHC tetramers produced by individual
refolding reactions (Fig. 4).
Identification of Melanoma-Associated HLA-A3 Ligands. To test the
feasibility of the peptide-exchange technology to rapidly screen
large panels of peptides for MHC binding, we set out to identify
HLA-A3 ligands in melanoma-associated proteins. To date, only
four HLA-A3-restricted T cell epitopes have been identified in
melanoma-associated proteins, all of them derived from the
gp100 antigen (16–18). We designed a library of peptides derived
from the melanocyte differentiation antigens (gp100, mart-1,
tyrosinase, and tyrosine-related-protein-1 and -2), plus the mel-
anoma-associated protein Nodal (19) by using three binding
prediction algorithms for HLA-A3 (9, 20). The resulting 203
peptides (SI Table 3) were then analyzed for HLA-A3 binding
in a fluorescence polarization assay. Twenty-two peptides that
showed a high inhibition of binding of the tracer peptide were
selected for determination of IC50 values (SI Table 3). Impor-
tantly, this set of 22 identified HLA-A3 ligands included the four
known gp100 epitopes. Table 1 and SI Fig. 7 show that all 22
peptides form high-affinity ligands of HLA-A3, with IC50 values
ranging between 73 and 857 nM.
Discussion
The use of multimeric forms of pMHC complexes has become
a core immunological technique to visualize antigen-specific
CD8 T cell populations (7). Fluorescently labeled MHC mul-
timers are commonly used for the detection of antigen-specific
T cells by flow cytometry. In addition, there is an increasing
interest in the development of high-throughput assay systems,
such as MHC microarrays or combinatorial coding schemes, to
visualize pathogen-specific or other disease-associated immune
responses in a more comprehensive manner (2, 3, 21). A major
obstacle in the development of these high-throughput ap-
proaches for the dissection of antigen-specific CD8 T cell
immunity has been the fact that for each specific peptide-MHC
class I complex, a separate production run is required (1, 22),
limiting the practical use of MHC multimer-based T cell detec-
tion to a few T cell specificities.
We have set out to develop technologies that enable the rapid
generation of large collections of defined pMHC complexes in
parallel reactions. Here, we aimed to determine whether MHC-
based peptide-exchange technology can be developed into a
broadly applicable platform for the screening of human cytotoxic
T cell responses. To this purpose, we defined conditional ligands
for four different human MHC products: HLA-A1, -A3, -A11,
and -B7 (with the conditional ligands STAPGJLEY, RIYRJ-
GATR, RVFAJSFIK, and AARGJTLAM, respectively).
Refolding reactions with these conditional ligands are effi-
cient and result in thermostable p*HLA complexes that rapidly
degrade upon UV exposure. The presence of a cognate peptide
ligand during UV treatment leads to the replacement of the
cleaved conditional ligand in the peptide-binding groove of the
MHC molecule and thereby results in the generation of pMHC
complexes of a desired specificity. In line with this, f luorescently
labeled MHC tetramers generated in such exchange reactions
stain antigen-specific CD8 T cell populations with equal spec-
ificity and sensitivity as MHC tetramers prepared by individual
refolding reactions. Dissociation of cleaved peptide fragments
displays nonlinear kinetics, with release of 75–95% within 15 min
but only limited further release upon prolonged incubation.
Fig. 3. CD8 T cell clones specific for HLA-A1 CMV-pp65 (Left) and HLA-A3
EBV-EBNA-3a (Right) were stained with equal amounts of HLA-A1 CMV-pp65
or HLA-A3 EBV-EBNA-3a tetramers, generated via peptide exchange (Ex-
changed, Upper) or classical refolding (Traditional, Lower). Control cells rep-
resent staining with the matched MHC tetramer and cross-sample controls.
Fig. 4. Indicated pMHC complexes were prepared by classical refolding
reactions or by 1-h exchange reactions and converted to tetramers. As a
negative control, streptavidin-conjugated nonexchanged p*-MHC complexes
were used. HLA-typed peripheral blood mononuclear cells were stained with
the indicated pMHC tetramers and analyzed by flow cytometry: from top to
bottom: HLA-A1 CMV-pp50 (VTEHDTLLY); HLA-A3 EBV-EBNA-3a (RLRAE-
AQVK); HLA-A11 EBV-EBNA-3b (IVTDFSVIK); HLA-B7 CMV-pp65 (TPRVTGG-
GAM) tetramers, respectively. For all complexes, stainings were performed at
equal concentrations for all three columns. Numbers indicate the percentage
of MHC tetramer cells of CD8 cells.
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Based on reverse-phase analysis of f luorescent peptide that
remains MHC-associated upon UV exposure, it is apparent that
the residual MHC-bound product primarily consists of reaction
products, indicating that lack of dissociation is not due to
incomplete cleavage. Prior data have shown that the dissociation
of full-length peptides from MHC class I molecules also occurs
with biphasic kinetics (23) (although, as expected with half-lives
that are orders of magnitude greater). This has been interpreted
as evidence for the existence of a ‘‘closed’’ and ‘‘open’’ confor-
mational state of peptide-charged MHC molecules, and it is
possible that the same applies to MHC complexes analyzed here.
Of more importance for the practical use of MHC reagents,
the presence of a fragment of the conditional ligand in a fraction
of UV-exposed MHC molecules has no measurable effect on the
ability to detect antigen-specific CD8 T cell responses. Specif-
ically, the amount of MHC exchange multimer required to stain
HLA-A1 and -A3 restricted T cells does not substantially deviate
from that required when using conventional MHC tetramer
reagents (a factor of 0.8 and 1.5 for HLA-A1-CMV-pp65 and
HLA-A3-EBV-EBNA-3a). This may be explained by the fact
that of the four MHC complexes in a tetrameric MHC molecule
a maximum of three is likely to be simultaneously available for
binding and the identity of the fourth pMHC complex will in this
case be irrelevant (24). In addition, it is noted that also in
classical MHC refolding reactions, it is rather unclear to what
extent MHC occupancy is homogeneous.
To demonstrate the application of peptide exchange for
high-throughput screening of potential T cell epitopes, a screen
of melanoma-associated peptides was performed in the context
of HLA-A3. The time between obtaining the peptide library and
completing the final binding assay was a mere 3 weeks, including
quality controls and data analysis. Twenty-two peptides were
identified with high affinity for HLA-A3, and this included the
four previously described gp100-derived epitopes. These
epitopes could be used to monitor naturally occurring T cell
responses in melanoma patients. More intriguingly, this collec-
tion of epitopes may be used to isolate TCRs from vaccinated
HLA-transgenic mice (25, 26). For those epitopes that are
presented at the cell surface of melanoma cells, this would
provide a strategy for the targeting of melanomas by TCR gene
therapy with an expanding collection of TCRs (27).
With the collection of conditional ligands for five HLA gene
products that is now available, coverage of the Western Euro-
pean population has become substantial. Specifically, with this
set of molecules, high-throughput analysis is feasible for at least
one HLA-A or -B complex for 90% of individuals. However,
coverage of human populations in other areas is lower, with 58%,
65%, and 75% for populations in SubSaharan Africa, North
America, and Southeast Asia, respectively. Definition of condi-
tional ligands for the HLA-A24, -B15, and -B58 gene products
that are prevalent in these areas would be useful to increase
coverage in these areas to the same level.
MHC peptide exchange-based strategies may be used for both
large-scale T cell epitope discovery, as demonstrated here for
HLA-A3, and for T cell screening. The latter large-scale MHC-
based analyses of T cell responses will generally not be feasible
by standard MHC tetramer flow cytometry approaches, because
the amount of patient material that is required would be
prohibitive. Rather, it seems essential to develop robust plat-
forms that can be used to analyze large series of antigen-specific
cytotoxic T cell responses in parallel. Two conceptually different
approaches may possibly be used for this purpose. In a first
approach, parallel analysis of a large number of T cell specific-
ities is achieved by spatial encoding schemes, in which T cells
with a given specificity are selectively retained or active at
defined sites. The MHC microarray platforms as developed by
the Davis and Stern groups (2–4), have provided evidence for
the feasibility of this approach. As an alternative approach,
parallel analysis of antigen-specific T cell responses may poten-
tially be achieved by combinatorial coding schemes, in which T
cells specific for a given pMHC complex are defined by the
binding of combinations of differentially labeled MHC tetram-
ers. Dual T cell staining by using MHC tetramers conjugated to
PE and APC has proven feasible (28) and efforts to test the
feasibility of large scale combinatorial coding remain to be
completed (A.H.B., unpublished observations).
In addition to the use of peptide exchange strategies for
large-scale T cell monitoring, it seems likely that this technology
will also be valuable for the development of protocols for
antigen-specific adoptive T cell therapy. The infusion of antigen-
specific T cell populations is considered valuable to restore
antiviral immunity in transplant recipients and other immuno-
compromised patients (29), and a study in which the feasibility
of infusion of CMV-specific T cells obtained by MHC-tetramer-
assisted enrichment has been reported (30). In addition, selec-
tion of defined T cells may be used to enhance the antitumor
effect of allogeneic hematopoietic stem cell transplantation (31)
and TCR gene therapy protocols (27, 32, 33).
There is no conceptual difficulty in the production of MHC
tetramers or reversible MHC tetramers (34) under GMP con-
ditions. However, the production of the collection of GMP-grade
pMHC tetramers required for these various applications may be
cost-prohibitive, because for most of these applications, small
series of pMHC reagents rather than single pMHC products
would be preferred. For example, CMV-specific CD8 T cell
responses in healthy individuals are directed toward, on average,
eight different ORFs (35). Extrapolating this to the other human
Herpesviridae that are a cause of morbidity and mortality in
transplant recipients, a cell product intended to prevent activa-
tion of herpes simplex virus, varicella zoster virus, cytomegalo-
virus, and EBV would perhaps ideally include reactivity against
one or two dozen distinct CD8 T cell epitopes. Based on these
considerations, it seems attractive to develop GMP production
Table 1. IC50 values of selected peptides
Protein Peptide Position IC50, nM SEM
Gp100 IALNFPGSQK 86–95 127 7
LIYRRRLMK 614–622 159 18
GTATLRLVK 460–468 204 7
ALLAVGATK 17–25 212 5
ALNFPGSQK 87–95 247 12
GVSRQLRTK 34–42 343 23
QLVLHQILK 551–559 363 22
QLRALDGGNK 221–230 415 17
Nodal SLYRDPLPR 46–54 73 2
HAYIQSLLK 293–301 97 4
KTKPLSMLY 317–325 277 6
RVAGECWPR 175–183 735 5
Tyr YMVPFIPLYR 425–434 384 26
SLLCRHKRK 497–505 498 52
VSSKNLMEK 25–33 552 14
GLVSLLCRHK 494–503 857 42
Tyrp1 SLPYWNFATR 245–254 149 5
ASYLIRARR 497–505 169 18
Tyrp2 TLLGPGRPYR 196–205 120 1
GTYEGLLRR 301–309 194 14
RMYNMVPFF 461–469 310 19
VLLAFLQYR 521–529 578 50
Influenza NP ILRGSVAHK 265–273 181 7
CMVpp65 (HLA-A2) NLVPMVATV 495–503 50,000 ND
IC50 values of selected peptides determined in a competitive binding FP
assay after 45 h of incubation. Bold type indicates peptides previously de-
scribed as HLA-A3 epitopes. Values were determined in three independent
experiments. ND, not determined.











processes for p*HLA complexes, and the use of such GMP-grade
p*MHC complexes in simple exchange reactions may facilitate
the clinical development of oligoclonal adoptive T cell therapy.
Materials and Methods
Generation of Peptide–MHC Complexes. All peptides were synthesized by
standard Fmoc synthesis. (/)-3-amino-3-(2-nitro)phenyl-propionic acid was
generated as described (12). Fluorescent labeling of peptides was performed
as described in SI Text and confirmed by LC-MS. Labeled peptides were
purified by reverse-phase HPLC.
Recombinant HLA-A1, -A2, -A3, A11, and -B7 heavy chains were produced
in Escherichia coli. MHC Class I monomer refolding reactions with E. coli-
derived 2M were performed as described (22) and purified by gel-filtration
HPLC in PBS (pH 7.4). Biotinylation and MHC tetramer formation were per-
formed as described (12). pMHC complexes were stored at 20°C in PBS/16%
glycerol, MHC tetramers were stored at 20°C in PBS/16% glycerol/0.5% BSA.
Analysis of Peptide Exchange. Exchange reactions were performed by exposure
of pMHC complexes (25 g/ml in PBS) to long-wavelength UV, by using a
366-nm UV lamp (Camag) in the presence or absence of 50 M exchange
peptide. After UV-exposure, pMHC complexes intended for subsequent anal-
ysis by ELISA were incubated at 37°C for 60 min to promote unfolding of
peptide-free MHC molecules (6). For gel-filtration HPLC, incubations after UV
exposure were performed at room temperature. pMHC complexes intended
for use in flow cytometry were multimerized by the stepwise addition of
streptavidin-PE (Invitrogen). For gel-filtration HPLC, 300  21 and 300  7 mm
Biosep SEC S3000 columns (Phenomenex) were used for protein isolation and
analysis, respectively. Absorbance was monitored at 230 nm, and fluorescence
was monitored with excitation at 550 nm and emission at 567 nm. Peptide
elution and subsequent reverse-phase chromatography was performed as
described in SI Text. Sandwich ELISAs were performed as described (12).
Cells and Flow Cytometry. Frozen peripheral blood mononuclear cells from
individuals undergoing an HLA-matched allogeneic bone marrow transplan-
tation were obtained after informed consent and with approval from the
Leiden University Medical Center Institutional Review Board. For flow-
cytometric analysis, cells were stained with PE-labeled MHC tetramers for 5
min, followed by FITC-labeled anti-CD8 (BD Biosciences) staining for 15 min at
room temperature. Data acquisition was carried out on a FACSCalibur (Becton
Dickinson). Analysis was performed by using FlowJo (Tree Star).
Peptide Library and Binding Studies. Protein sequences for Nodal (NP060525),
Mart-1/Melan-a (NP005502) Tyrosinase (AAB60319), Tyrosinase-related pro-
tein 1 (CAG28611), Tyrosinase-related protein 2 (ABI73976), and GP100/
PMEL17 (NP008859) were analyzed for potential HLA-A3 ligands by using
SYFPEITHI (9), and the artificial neural network (ANN) and stabilized matrix
method (SMM) algorithms from IEDB (version prior to December 2007) (20).
Peptides were selected with a predicted binding value of either 21 for
SYFPEITHY (nona- and decamers), 6000 for ANN (nonamers only), or 600
for SMM (decamers only), resulting in 203 peptides. Synthesized peptides
(Pepscan Lelystad), were checked by LC-MS. HLA-A3 binding assays were
performed by using a fluorescence polarization (FP) assay. For this purpose, a
FP assay reported for HLA A2.1 (36) was modified for application with UV-
mediated peptide exchange, using fluorescently labeled A3-specific KVP-
CALINK (37) as tracer peptide (see SI Text). To determine the binding capacity
of peptides for HLA-A3, percentage inhibition relative to controls was deter-
mined at 5 M in an FP competition assay with conditional p*A3. For peptides
displaying 63% inhibition at 5 M, IC50 values were determined by gener-
ating dose–response curves of serial peptide dilutions from 50 M to 50 nM.
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Labeling of Peptides. 
Fluorescent labeling of peptides was 
performed as follows: 6 mg of peptide (50 
mg/ml in DMSO) was diluted in 1.5 ml 50 
mM Hepes buffer and low amounts of N,N–
dimethylformamide (DMF; Biosolve) were 
added whenever precipitates formed. 2.5 
mg of TMR–5–maleimide (Tebu–Bio) from 
a 50 mg/ml DMF stock solution was added, 
and the reaction mixture was incubated at 
room temperature for 36 h on an orbital 
shaker. Five microliters of the reaction 
was analyzed by LC–MS, and the reaction 
was terminated by the addition of DTT 
to a final concentration of 5 mM. Before 
purification, 1.5 ml of 10% trifluoroacetic 
acid (TFA; Biosolve)/5 mM DTT/50 mM 
Hepes was added. Labeled peptides were 
purified by reverse–phase HPLC (1525EF; 
Waters) with H2O/0.05%TFA as solvent A 
and acetonitrile/0.05% TFA as solvent B at 
a flow rate of 18 ml/min on a 10–µm 30 × 
250–mm dc18 Atlantis column (Waters). A 
linear gradient of 10–95% solvent B over 
14 min was used for a first elution. The 
fractions were then analyzed by LC–MS, and 
fractions containing fluorescently labeled 
peptide were further purified by using a 
similar protocol with a linear gradient of 
25–80% solvent B over 19 min for elution. 
Fractions were then lyophilized, dissolved 
in DMSO, and stored at –20°C.
Peptide Elution. 
HLA–A2 Flp*A2 complexes were either 
left untreated or exposed to UV light for 
60 min. For examination of the effect 
of UV treatment on the total pool of 
MHC associated plus released fluorescent 
ligand, peptides were extracted with 10 
µl of 10% TFA (Biosolve) for 60 min at 
room temperature. The material was then 
analyzed by reverse–phase chromatogra–
phy with H2O/0.05%TFA as solvent A and 
acetonitrile/0.05% TFA as solvent B at a flow 
rate of 1 ml/min on a 300 ×3.9 Delta Pak 
15µ C18 column (Waters). A linear gradient 
of 10–60% solvent B over 60 min was used 
for elution. To analyze the composition of 
material remaining MHC–associated after 
UV treatment, reactions were separated 
by gelfiltration chromatography after UV 
exposure and material eluting with the 
retention time of pMHC complexes was 
collected. Subsequently, samples were 
adjusted to contain an equal amount of 
fluorescent signal and concentrated to 100 
µl. Ten microliters of 10% TFA was added, 
and samples were incubated for 60 min at 
room temperature. Nine hundred microliters 
of H2O was added, and samples were 
analyzed by reverse–phase chromatography 
as described above.
Fluorescence Polarization Assay. 
For all fluorescence polarization binding 
assays peptides were diluted in bovine γ–
globulin in PBS (0.5 mg/ml; Sigma). The 
HLA–A3–binding peptide KVPCALINK was 
labeled with TMR–5–maleimide (Anaspec) 
and purified by reverse–phase HPLC as 
described above. This peptide (pTAMRA) 
was used as a tracer for fluorescence 
polarization (FP) experiments. Labeled 
peptide was standardized against a 
fluorescence intensity curve by using 
free TMR–5–maleimide as a standard. 
FP measurements were performed on a 
PerkinElmer Wallac EnVision 2101 Multilabel 
Reader. Samples were measured by using 
a 531–nm excitation filter, 579–nm S–
channel emission filter, a 579–nm P–channel 
emission filter, and a Bodipy–TMR FP Dual 
mirror (all filters and mirrors obtained from 
PerkinElmer). FP values are given as mP 




the following formula: polarization (mP) = 
1,000 × (S–GP)/(S+GP), where S and P 
are the fluorescence intensities measured 
in the S (parallel to polarization plane) 
and P (perpendicular to polarization plane) 
directions and G is the grating factor. The G 
factor is a correction factor for instrument 
(filters, mirror)–dependent variations in 
sensitivity for measurements in the S and 
P directions and is determined according to 
the instrument manufacturer’s instructions 
by measuring a 1 nM sample of free TAMRA. 
The G factor is then calculated using the 
following formula: G = (S/P) × (1–L/1,000)/
(1+L/1,000), where L is the theoretical 
or literature polarization value for the 
fluorophore, here TAMRA (L = 50 mP). 
Typically, G factors of 1–1.1 were obtained.
Epitope Screening. 
To determine the binding capacity 
of the predicted ligands for HLA–A3, 
percentage inhibition of binding of tracer 
peptide was determined at 5 µM in an FP 
competition assay with conditional p*A3. 
For this purpose, an FP assay was modified 
for application with UV–mediated peptide 
exchange for HLA–A3. In a 384 well black 
nonbinding surface assay plate (Corning) 
each well was loaded with 10 µl of a 
2.5× peptide solution (12.5 µM), 5 µl of a 
pTAMRA solution (5 nM) and 10 µl of a 2.5× 
HLA–A3 p*A3 solution (1.25 µM). For all 
preparations 0.25 mg/ml bovine γ–globulin 
in PBS was used as a buffer. The plate 
was spun for 1 min at 1,000 × g at room 
temperature. To start UV–mediated peptide 
exchange, the plate was placed 10 cm under 
a 365–nm UV lamp (2 × 15 W blacklight 
blue tubes, LxWxH 505 × 140 × 117 mm; 
Uvitec) located in a cold room (4°C). After 
30 min irradiation, the plate was sealed 
with thermowell sealing tape (Corning) 
and incubated at room temperature for 
45 h, when periodic readings showed no 
further increase in polarization, indicating 
the establishment of equilibrium. Controls 
included peptide free samples (1% DMSO) 
for 0% inhibition of tracer binding and 200 
µM ILRGSVAHK (A3–Flu epitope) samples 
for 100% inhibition of tracer binding. All 
data points were determined in triplicate. 
Competition Assay. 
For peptides displaying >63% inhibition 
at 5 µM IC50 values were determined by 
generating dose–response curves of serial 
peptide dilutions covering a range of 50 µM to 
50 nM using the UV–mediated FP competition 
assay described above. The binding affinity 
(IC50 value) of each competitor peptide 
was defined as the concentration that 
inhibits 50% binding of pTAMRA tracer 
peptide. Data were analyzed by using 
GraphPad Prism software (GraphPad). Fifty 
percent inhibitory concentrations were 
determined in at least three independent 
experiments for each peptide. Peptide 
concentrations used for determination of 
IC50 values were calculated by assuming 
maximum synthetic yield (2 µmol). For 13 
peptides containing tyrosine or tryptophan 
residues, concentrations were verified 
by measuring absorption at 280 nm (for 
calculations of extinction coefficients see: 
www.expasy.org/tools/protparam.html). 
Peptide concentrations as determined by 
absorption at 280 nm were in between 0.47 
and 1.05 of the predicted values. 
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Fig. 5. 
Establishment of an optimal MHC 
con–centration for ELISA analysis. 
HLA–A1 complexes containing a 
control HLA–A1 ligand pA1 or the 
UV–sensitive ligand p*A1 were 
exposed to 366 nm of UV for 0 or 
60 min, and serial dilutions were 
analyzed by ELISA. Vertical line 
indicates the MHC concentration 
used for subsequent analyses. MHC 
concentrations as established for 
the other MHC gene products were also in the 10–20 nM range.
Table 2. Conditional ligands tested
Overview of the peptides tested for each of the four HLA molecules. J indicated 3–amino–3–
(2–nitro)phenyl–propionic acid. Sequences in the top part of each panel reflect the peptides 
used in a first screen. Arrows indicate which peptides were chosen as leads for a second 
screen (bottom parts). For HLA–A11, a panel of high and low affinity binders was tested in 
a single screen with J at two different positions. The four conditional ligands selected for 
further analysis are depicted in bold. LR: low refolding efficiency, TI: thermo–instable, ND: 




Tetramer titration on T cell 
clones. CD8+ T cell clones 
specific for HLA–A1 CMV–
pp65 and HLA–A3 EBV–
EBNA–3a were stained with 
the indicated amounts of 
HLA–A1 CMV–pp65 (Top) 
and HLA–A3 EBV–EBNA–
3a (Bottom) tetramers. 
“Exchanged” indicates MHC 
tetramers generated via 
peptide exchange, whereas 
“Traditional’ indicates MHC 
tetramers generated via 
classical MHC refolding with the specific peptide. Images designated “Relevant Clone” and 
“Control” represent staining with the matched MHC tetramer and crosssample controls, 
respectively. Numbers indicate MFI of CD8+ cells.
Fig. 7. 
Dose–response curves of a competitive 
binding FP assay after 30–min UV 
irradiation and 45–h incubation using 
HLA–A3 p*A3 and the indicated peptides. 
IC50 values were determined from 
three independent experiments. A 
representative experiment is shown. mP 
indicates millipolarization.
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Table 3. Peptide library scanned for HLA-A3 binding
Two hundred three predicted HLA-A3 ligands from six melanoma-associated proteins were 
selected based on three binding prediction algorithms. In an initial screen, peptides were 
screened at 5 μM in a 45-hour FP competition assay format. Peptides in bold were chosen 
for further analysis to determine IC50 values. Underlined peptides represent previously 
described HLA-A3 ligands. Inhibition reflects the percentage reduction in polarization of the 
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Parallel detection of antigen-specific T-cell responses
by multidimensional encoding of MHC multimers
Sine Reker Hadrup1,4,5, Arnold H Bakker1,4,5, Chengyi J Shu1, Rikke S Andersen2, Jerre van Veluw1,
Pleun Hombrink3, Emilie Castermans1, Per thor Straten2, Christian Blank1, John B Haanen1,
Mirjam H Heemskerk3 & Ton N Schumacher1
The use of fluorescently labeled major histocompatibility
complex multimers has become an essential technique for
analyzing disease- and therapy-induced T-cell immunity.
Whereas classical major histocompatibility complex multimer
analyses are well-suited for the detection of immune responses
to a few epitopes, limitations on human-subject sample size
preclude a comprehensive analysis of T-cell immunity. To address
this issue, we developed a combinatorial encoding strategy that
allows the parallel detection of a multitude of different T-cell
populations in a single sample. Detection of T cells from
peripheral blood by combinatorial encoding is as efficient as
detection with conventionally labeled multimers but results
in a substantially increased sensitivity and, most notably, allows
comprehensive screens to be performed. We obtained proof of
principle for the feasibility of large-scale screening of human
material by analysis of human leukocyte antigen A3–restricted
T-cell responses to known and potential melanoma-associated
antigens in peripheral blood from individuals with melanoma.
T cells recognize virus-infected cells and tumor cells by detecting
the presence of disease-specific peptide–major histocompatibility
complexes (pMHC) with their clone-specific T-cell receptor. Both
for the monitoring of disease-specific immune responses and for
the development of new immunotherapeutics, it is essential to
specifically detect only those T cells that recognize a given pMHC
complex within the large pool of irrelevant T cells1. The use of
soluble multimeric pMHC complexes to detect such antigen-
specific T cells by flow cytometry was first described in 1996
(ref. 2) and has since then become a cornerstone of T-cell
monitoring3. However, a major limitation in the use of this
methodology is that at most, a few antigen specificities can be
monitored in a single biological sample because of limitations
on the number of available fluorochromes4.
Prior work has shown that it is feasible to detect antigen-specific
T cells by the binding of two different fluorochrome-coded major
histocompatibility complex (MHC) multimers containing the same
or a related peptide. This technology of double MHC multimer
staining has been used to reveal the fine specificity of T cells for
variants of single peptide epitopes5. If a large set of such dual-color–
encoded pMHCs could be combined in a single sample without
interfering with the ability of each single pMHC to detect specific
T cells, such a technology could conceivably be used to detect a
much larger number of T-cell specificities than is currently possible
with classical MHC multimer analysis.
Here we demonstrate that a large number of antigen-specific
T-cell responses (at least 25) can indeed be analyzed in parallel
through the use of pMHC multimers that are each coupled to a
unique combination of fluorochromes, with the same fluorescent
label being used many times, but in each case in a unique combina-
tion with one or more other labels. We exemplify the value of this
‘combinatorial encoding’ by dissecting melanoma-associated T-cell
responses in peripheral blood from individuals with melanoma.
RESULTS
The concept of combinatorial encoding
In this approach, a specific T-cell population is no longer defined
by a single fluorescent signal, as is the case in standard MHC
multimer stainings, but instead is visualized by the joint binding
of multiple fluorochromes. Conceptually, the approach can be
considered a self-assembling molecular coding scheme, in which
unique codes are only assembled at the moment of T-cell binding
(Fig. 1a). The power of such a scheme becomes evident with
an increasing number of available fluorochromes (Fig. 1b). In
this study, we explored two-dimensional combinatorial encoding
with eight fluorochromes, which deliver 28 unique codes (Sup-
plementary Table 1), and demonstrated the ability to expand to
three-dimensional combinatorial encoding using the five most
intense fluorochromes.
Feasibility of combinatorial encoding
We first determined the feasibility of using six different quantum
dots (Qdots) as fluorescent labels for pMHCmultimers, in addition
RECEIVED 6 FEBRUARY; ACCEPTED 28 MAY; PUBLISHED ONLINE 21 JUNE 2009; DOI:10.1038/NMETH.1345
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to allophycocyanin (APC) and phycoerythrin (PE) fluorescent
labels (Supplementary Table 1), which are more commonly used
for the detection of antigen-specific T-cell responses. By analyzing
peripheral blood samples for cytomegalovirus (CMV)-specific
CD8+ T-cell responses, we established that pMHC complexes that
were multimerized by coupling to streptavidin-conjugated Qdots,
APC or PE could all be used to detect antigen-specific T cells (Sup-
plementary Fig. 1). Subsequently we analyzed whether antigen-
specific T-cell populations could reliably be identified by the
binding of two pMHC multimers that contain the same antigenic
peptide but that are coupled to a different fluorochrome (Fig. 1a).
Testing of pMHC complexes conjugated to all 28 possible combi-
nations of two different fluorochromes demonstrated that such
dual encoding can in all cases reveal the appropriate T-cell popula-
tion, with only limited variation in detection efficiency between the
different color combinations (Fig. 2a). As expected, simultaneous
staining of T cells with two differentially labeled pMHC multimers
that contain the same antigenic peptide leads to a small reduction
in fluorescence intensity for each channel (an expected factor of 2 at
equimolarity). To limit this negative effect, we used the three Qdots
that yielded the lowest intensity signal on our flow cytometric
system (Qdots QD565, QD585 and QD800) in a 2:1 rather than 1:1
ratio relative to the other fluorochromes, and we did not use the
Qdot combinations QD565 and QD585; QD565 and QD800; and
QD585 and QD800 in subsequent experiments, thereby reducing
the number of combinations to 25.
Sensitivity of combinatorial encoding
Antigen-specific T-cell populations can be present at very low
frequencies, and pMHC multimers do show low-level background
staining. To test whether the detection of antigen-specific T cells
with combinatorial encoding affects background staining or the
frequency of antigen-specific T cells detected, we stained peripheral
bloodmononuclear cells (PBMCs) containing a low-frequency T-cell
response to the human leukocyte antigen (HLA)-A2–restricted
CMV epitope NLVPMVATV (CMV-NLV) with HLA-A2 CMV-
NLVmultimers or with irrelevant HLA-A2multimers and analyzed
them by flow cytometry. Specifically, we incubated PBMCs either
with the eight different single-color pMHC multimers in eight
separate stainings or with the 25 dual-color–encoded MHC multi-
mers in 25 separate stainings. We considered T cells positive for
MHCmultimer binding when detected above background either in
one channel (for single-color stainings) or
when detected in both relevant channels
(for dual-color encodings). Notably, the
frequency of false positive cells observed upon staining with
irrelevant HLA-A2 multimers was approximately tenfold lower
when using a dual encoding scheme as compared to the tradi-
tional single-staining approach (Fig. 2b). This is because most
background events are only positive in a single channel and are
therefore excluded by combinatorial encoding.
Having established the feasibility of dual-color encoding, we
examined whether multiple dual-color–encoded MHC multimer
stainings can be performed in parallel on a single sample. To ana-
lyze T cells reactive with any of the dual-color–encoded pMHC
multimers in a single sample, we developed a gating strategy. In
brief, we identified single live CD8+ T cells (Fig. 2c and Online
Methods) and analyzed T-cell populations reactive with any of
the dual-color–encoded pMHC multimers by gating on each of
the eight individual fluorochromes used to form the 25 different
unique combinations (Fig. 2c), as exemplified by gating PE and
QD705 double positive CD8+ T cells from both a relevant and
an irrelevant mix of pMHC multimers. This strategy identified
T cells with signal above background in a given combination of
two channels and that are negative in the remaining six channels,
thereby allowing the simultaneous analysis of 25 different combi-
nations in one flow cytometry experiment.
Single-sample visualization of up to 25 T-cell responses
We generated 25 different pMHCmultimers containing various viral
and cancer epitopes for the human MHC alleles HLA-A1, -A2, -A3
and -B7 (Supplementary Table 2) by MHC peptide exchange6–8.
Then, we coupled each of these pMHC multimers to two fluor-
ochromes, generating a set of unique codes (Supplementary Table
2). To compare the data obtained by combinatorial encoding with
conventional MHC-multimer analysis, we made PE-labeled pMHC
multimers in parallel using the same T-cell epitopes. To determine the
background of combinatorial encoding, we also prepared irrelevant
pMHC multimers in all two-color combinations.
We analyzed PBMCs from three healthy donors covering all four
HLA alleles (Fig. 3a–c) by (i) one single staining with the mix of
dual-color–encoded viral and cancer epitope pMHC multimers,
(ii) 25 separate stainings with all individual dual-color–encoded
pMHC multimers, (iii) one single staining with the mix of dual-
color–encoded irrelevant pMHC multimers or (iv) 25 separate
stainings with all 25 PE-labeled pMHC multimers. We performed









































Figure 1 | Overview of the combinatorial encoding
approach. (a) MHC molecules with different
peptide specificities (green, red and orange
peptides, top) are conjugated with different
fluorochrome color codes (red, green and blue
fluorochromes, second row) to generate
differentially encoded pMHC multimers (third row).
Combinatorial codes are then assembled on T-cell
surfaces (fourth row) and these T-cell samples are
analyzed by flow cytometry (bottom). (b) The
theoretical number of unique color combinations
that can be made using fluorochromes for the
indicated numbers of available channels in either
one-, two- or three-dimensional coding schemes.





























Multidimensional encoding of MHC multimers
and to prior analysis of antigen-specific T-cell responses in these
donors. Combinatorial encoding of pMHC multimers allowed the
simultaneous visualization of a large number of antigen-specific
T-cell populations in one single sample (Fig. 3 and Supplementary
Fig. 2). Notably, we found the same virus-specific T-cell popula-
tions in each donor when analyzed by individual PE-multimer
stainings. Furthermore, statistical comparison between staining
strategies i, ii and iv revealed a high interclass correlation (inter-
class correlation coefficient (r) ¼ 0.84 (95% confidence interval:
0.78–0.89)), describing an almost perfect agreement between the
outcomes of the three strategies9. Individual comparison between
the mix of 25 dual-color–encoded pMHCmultimers in one sample
(strategy i) with either the PE-tetramer stainings (strategy iv) or the
same set of dual-color–encoded pMHC multimers in 25 separate
stainings (strategy ii) reveal similarly high correlations (r ¼ 0.79
(95% confidence interval: 0.68–0.86) and r ¼ 0.83 (95% confi-
dence interval: 0.74–0.89), respectively) (Fig. 4). Thus, the simul-
taneous detection of multiple antigen specificities with sets of
pMHC multimers, in which each multimer is coupled to a distinct
combination of fluorochromes, is feasible. Finally, comparison of
the signals from the dual-color–encoded pMHC set containing
virus and tumor-associated epitopes (strategy i) with the signals
from the pMHC set containing 25 irrelevant MHC multimers
(strategy iii) indicates that the sensitivity of the approach is high
and that T-cell populations as infrequent as 0.02% of CD8+ cells
can be identified (Figs. 3a–c and 4a) (average background:
0.0012% of CD8+ T cells, s.d. ¼ 0.0035, n ¼ 100).
To validate the T-cell responses observed by MHC multimer
staining using a non–flow cytometry–based method, we performed
an INFg enzyme–linked immunosorbent spot (ELISPOT) assay
with these PBMCs using the same 25 peptides (Fig. 3a–c). All T-cell
responses detected by MHC multimer analysis were confirmed
by detection of INFg secretion. Note that the magnitude of T-cell
responses, as measured by INFg secretion, was in some cases
substantially lower than that measured by any of the MHC multi-
mer approaches, consistent with the observation that a variable
fraction of antigen-specific T cells acquires the capacity to secrete
effector cytokines.
To provide proof of principle for higher-dimension encoding
of antigen-specific T-cell responses, we generated eight different
combinations of five high-intensity fluorochromes (PE, APC,
QD605, QD655 and QD705), in which each antigen specificity
was encoded by a unique combination of three different fluoro-
chromes. Even though the frequency of antigen-specific T cells
detected was lower as compared to two-dimensional encoding
(0.29% versus 0.47% of CD8+ T cells), identification of CMV-
NLV–specific T cells in healthy donor PBMCs was feasible using
this three-dimensional encoding strategy (Supplementary Fig. 3).
a
b













    QD565            QD585              QD605     QD655              QD705             QD800
PE
1.02% (0.87) 1.03% (0.90) 1.12% (1.24) 1.39% (1.47) 0.92% (0.82) 1.29% (1.17)
APC
0.85% (1.02) 0.48% (1.14) 0.81% (1.02) 0.87% (0.89) 0.59% (1.13)
QD565
0.80% (0.85) 1.09% (1.15) 0.98% (1.18) 0.88% (0.83) 0.72% (0.64)
QD585
1.18% (0.98) 1.21% (0.94) 0.92% (0.74) 0.75% (0.61)
QD605
1.15% (1.19) 0.96% (1.14) 1.09% (0.94)
QD655

























































































































Figure 2 | Feasibility of T-cell staining with dual-color–encoded pMHC multimers. (a) Flow cytometry plots displaying fluorescence intensity for the fluorochromes
listed at the top and right side of the plot matrix. PBMCs stained using the 28 possible two-color combinations of HLA-A2 CMV-NLV MHC multimers in separate
stainings were analyzed, as indicated. Each plot is labeled with the percentage of HLA-A2 CMV-NLV–specific T cells out of total CD8+ cells and, in parentheses,
the number of detected HLA-A2 CMV-NLV–specific T cells divided by the average number of HLA-A2 CMV-NLV–specific cells found for all color combinations
(average of three experiments using three different donors). Dot plots were gated on approximately 10,000 CD8+ lymphocytes. Gray dots represent CD8+ T cells
with no MHC multimer binding, colored dots represent MHC multimer–reactive CD8+ T cells (b) Percentage of MHC multimer–positive T cells found with the
indicated techniques. Data are mean ± s.d., n ¼ 25 for gray bars and n ¼ 8 for black bars. (c) Schematic overview of the gating strategy used for identification
of pMHC-specific T cells after staining with dual-color–encoded MHC multimers. PBMCs were stained with relevant pMHC complexes to visualize antigen-specific
T cells (left) or with irrelevant pMHC complexes to indicate background staining (right). CD8+ and ‘dump’ (FITC) negative cells are selected (dark gray; top). Cells
positive in two different MHC multimer channels (PE, QD705) are indicated in purple, and cells positive in any of the other multimer channels indicated in black
(second row). Then one determines whether cells are double positive for the two selected colors (third row). Cells positive in three or more MHC multimer channels
are removed (bottom). In typical final data plots, an antigen-specific T-cell population is indicated by fluorescence in two defined channels (bottom, left).






























Finally, combinatorial encoding can be combined with single-
color antibody staining to determine the phenotype of pMHC-
specific T cells. To illustrate this, we analyzed the pheno-
type of three virus-specific T-cell populations, HLA-A2 Inf-GIL,
CMV-NLV and EBV-GLC. As described previously10,11, HLA-A2
CMV-NLV–specific T cells displayed a more differentiated pheno-
type (CD45RA+, CCR7–, CD62L– and CD57+ or CD57), as


































































































































































































































































































00.28% 0.18% 3.6% 0.06%



































































































































































00.03% 0.06% 0.07% 1.5%
A2 FLUGIL A2 EBVLMP2 CLG A2 EBVEBNA RPPA2 EBVLMP2 FLY
(1 specificity per sample) 
Dual-color pMHC multimers




(25 specificities per sample) 
Dual-color pMHC multimers
(1 specificity per sample) 
Dual-color pMHC multimers




(25 specificities per sample) 
Dual-color pMHC multimers
(1 specificity per sample) 
Dual-color pMHC multimers






















Figure 3 | Multiplex detection of virus-specific T-cell responses through combinatorial encoding. (a–e) Donor 1. (f–j) Donor 2. (k–o) Donor 3. Dot plots of
antigen-specific T-cell populations detected at a frequency 40.03% are shown by staining one sample with a mix of 25 different dual-color pMHC multimers
(a,f,k); by staining 25 individual samples with 1 of the 25 dual-color pMHC multimers (b,g,l); by staining one sample with a mix of 25 irrelevant dual-color
pMHC multimers (c,h,m); and by staining 25 individual samples with classical PE-labeled pMHC multimers each containing one of the 25 peptides (d,i,n).
All dot plots are shown with bi-exponential axes and display fluorescence intensity (a.u.) for the fluorochrome indicated on each axis. Graphical representation
of the frequency of antigen-specific CD8+ T cells directed against the 25 epitopes (Supplementary Table 2), when measured using the four different flow
cytometry–based strategies shown in a–d, f–l and k–n, and IFNg ELISPOT assay(e,j,o).





























Multidimensional encoding of MHC multimers
detected in the same sample (CD45RA+ or CD45RA, CCR7–,
CD62L– and CD57–) (Supplementary Fig. 4).
Identification of melanoma-associated T-cell epitopes
Having established the feasibility of combi-
natorial encoding for the parallel measure-
ment of a large number of antigen-specific
T-cell populations in a single sample, we
next determined the potential value of
combinatorial encoding in epitope identifi-
cation. In a recent screen8, we had identified
22 peptides from four different melanoma-
associated proteins that display a high affi-
nity for HLA-A3 (Supplementary Table 3).
This set included all four previously
described HLA-A3–associated epitopes as
well as 18 potential new epitopes. To
address the feasibility of screening small
patient samples for responses to sets of
potential epitopes, we generated MHC
reagents by UV-light–induced peptide-
exchange reactions6–8 for all 22 epitopes,
as well as for three HLA-A3–associated Epstein-Barr virus (EBV)-
derived and influenza A–derived epitopes, and we encoded these
reagents to form fluorescently labeled pMHC multimers as



















































































































25 different PE-tetramers in 25 individual samples
MHC multimer+ cells (% of total CD8+ cells)
25 different color codes in 25 individual samples






Figure 4 | Correlation between different T-cell
detection strategies. (a) Correlation between
antigen-specific T-cell frequencies as detected
by classical PE-labeled MHC multimer staining
and by dual-color–encoded MHC multimer staining
with 25 specificities per sample. (b) Correlation
between antigen-specific T-cell frequencies as
detected by dual-color–encoded MHC multimers
with one pMHC specificity per sample and by
dual-color–encoded MHC multimer staining with
25 specificities per sample. Donors are the same
as in Figure 3. r, interclass correlation coefficient.
For transforming to logarithmic scale all zero
values were converted to 0.0015. Dashed lines
represent the optimal linear correlation.
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Figure 5 | T-cell responses to melanoma-associated
peptides. (a) Dot plots show a representative
example of pMHC multimer–enriched PBMCs
from an individual with melanoma analyzed by
combinatorial encoding. Antigen-specific T-cell
populations were detected for gp100-LIY (PE and
QD565) (green) and Nodal-SLY (APC and QD585)
(pink). All dot plots are shown with bi-exponential
axes and display fluorescence intensity (a.u.)
for the indicated fluorochromes. (b) Summary of
antigen-specific T-cell responses of 28 individuals
to 22 melanoma-associated peptides (MEL),
20 HIV- and HCV-derived T-cell epitopes (HIV-HCV)
and three HLA-A3–restricted virus-derived T-cell
epitopes (EBV-FLU). The response of each individual
is shown for detection directly ex vivo (top) and
after enrichment and in vitro expansion (bottom).
(c) T-cell cultures (from different individuals)
that responded to the indicated peptide in an
intracellular IFNg staining assay. Assays were
performed on sorted pMHC multimer–reactive
T-cell populations incubated with T2-A3 cells pulsed
with or without the indicated peptide. Data from
representative cultures are shown for each epitope.






























PBMCs from 28 HLA-A3–positive individuals with melanoma for
T-cell responses to these potential antigens, either directly ex vivo
or after antigen-specific T-cell enrichment. In the latter case, we
only performed enrichments with pMHC multimers containing
melanoma-associated antigens, to avoid potential overgrowth of
virus-specific T cells during culture. As expected, we detected
EBV- and influenza A–specific responses in the majority (15 out
of 28) of the individuals with melanoma directly ex vivo.
Additionally, we detected a single melanoma-associated antigen-
specific response directly ex vivo. Notably, using parallel MHC
multimer staining, we detected many T-cell responses specific
for different potential melanoma-associated antigens after enrich-
ment (Fig. 5a). In total, we detected 24 responses targeting eight
distinct epitopes (Fig. 5b). Three of these epitopes consisted
of previously described gp100-derived peptides that have been
shown to be presented by tumor cells12–14. In addition, we observed
responses to five previously unknown T-cell epitopes from gp100
(QLRALDGGNK), Nodal (SLYRDPLPR and HAYIQSLLK) and
Tyrp2 (GTYEGLLRR and RMYNMVPFF). In all cases, we con-
firmed peptide specificity of the T cells with subsequent analysis by
conventional MHCmultimer staining followed by MHC tetramer–
based sorting. We assayed the functional activity of these T-cell
populations by measuring IFNg production upon incubation with
peptide-loaded T2-A3 target cells; we confirmed the functional
activity of 18 out of 22 cultures analyzed and for four out of the five
newly identified epitopes (Fig. 5c). We performed the same type
of combinatorial encoding analysis using HIV- and hepatitis C
virus (HCV)-derived peptides (Supplementary Table 4), antigens
to which the group of individuals we tested has presumably not
been exposed. In these analyses, a sample from only one individual
with melanoma showed reactivity against HCV-derived epitopes
(HCV-GVA and GCV-KVF) (Fig. 5b). Although we could not attri-
bute this single response to a known HCV exposure, the lack of
T-cell responses against any of the other viral antigens in these indi-
viduals with melanoma suggests that the frequent detection of T-cell
responses to the HLA-A3–restricted melanoma-associated antigens
in this cohort is a consequence of disease state. Although it remains to
be established whether T-cell responses against these antigens can
contribute to tumor control, these data make a strong case for the
value of combinatorial encoding in epitope identification.
DISCUSSION
With regard to the technical aspects of our approach, three points
are noteworthy. First, the use of differentially labeled pMHC
complexes carrying the same peptide led to a reduction in signal
in each individual channel owing to competition for available
binding sites, but such competition is apparently not a major
factor. In a setup that used eight channels for encoding, we detected
a signal that was clearly discernable above background for 25 out
of 28 possible two-dimensional combinations. Based on these data,
it seems plausible that with additional improvements in flow-
cytometric detection, multiplex analysis will be possible for most
or all potential combinations of fluorochromes even when moving
to higher-dimension encoding. Second, the sensitivity of detection
of antigen-specific T-cell responses by combinatorial encoding is
as high or higher than that of classical MHC multimer staining.
Background staining in MHC-based detection of T-cell responses
can generally be attributed to interaction of cells with a single
fluorescent marker or because of random interaction with all
fluorescent markers used. Thus, by restricting detection to those
T cells that interact with a defined combination of two and only two
of the fluorochromes used for encoding, such background events
are effectively removed. Finally, a potentially serious issue with the
use of combinatorial encoding is the fact that T cells are considered
highly cross-reactive. As an example, if CMV-specific T cells would
show a spurious cross-reactivity with any of the other pMHC
complexes used, such T cells would be detected in more than two
channels and thereby be excluded from analysis. Notably, for all
antigen-specific T-cell responses that we analyzed in parallel by
combinatorial encoding and classical MHC multimer staining,
there was a full match between the antigen-specific T-cell popula-
tions detected by the two assays and the correlation between the
assays was high. Thus, when using sets of dozens of unrelated
pMHC multimers, a possible cross-reactivity of T cells appears
not to be a measurable factor. We note that such cross-reactivity
can be expected to become a relevant issue in the case of high-
throughput analysis of T-cell responses with sets of pMHC multi-
mers with substantial structural homology, for instance, involving
peptide variants.
Prior work in animal models has demonstrated the value of
MHC-based detection of T-cell responses using large sets of pMHC
multimers by conventional single-channel analysis. Specifically,
for all four tested pathogens (H5N1 influenza A, Chlamydia
trachomatis, MHV-68 and Toxoplasma gondii6,15–17), new epitopes
had been identified in screens using 150–2,000 peptides. Notably,
if the same screens were to be performed on human PBMCs, this
would require approximately 300 ml to 4 l of peripheral blood.
However, with the ability to analyze at least 25 antigen specifi-
cities per sample, this is reduced to substantially more realistic
amounts. As a first demonstration of the potential value of large-
scale screening of human T-cell responses, we analyzed cytotoxic
T-cell responses to potential melanoma-associated antigens. Based
on these data, it seems likely that MHC-based detection of T-cell
responses will be of substantial value for large-scale screening
efforts aimed at the identification of pathogen-, cancer- or auto-
immune-associated epitopes. In addition, multiplexed measure-
ment of antigen-specific immune responses could form a useful
addition to current analyses of bulk T-cell frequencies in routine
human diagnostics.
METHODS
Methods and any associated references are available in the online
version of the paper at http://www.nature.com/naturemethods/.
Note: Supplementary information is available on the Nature Methods website.
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Generation of pMHC complexes. All peptides were synthesized
in-house using standard Fmoc chemistry or purchased from
Pepscan (Pepscan Presto BV). The UV light–sensitive building
block J was synthesized as described6–8. Recombinant HLA-A1,
-A2, -A3 and -B7 heavy chains and human b2m light chain were
produced in Escherichia coli. MHC class I refolding reactions
were performed as described18 and MHC class I complexes were
purified by gel-filtration high-performance liquid chromatography
in PBS (pH 7.4). Specific peptide-MHC complexes were generated
by MHC peptide exchange6–8. In brief, UV light–sensitive pMHC
complexes (100 mg ml–1) were subjected to 366 nm UV light
(Camag) for 1 h in presence of the various peptides (200 mM).
After exchange, samples were centrifuged at 16,000g for 5 min,
and supernatants were used for pMHC multimer formation.
Generation of pMHC multimers. pMHC multimers were gener-
ated using eight different fluorescent streptavidin (SA) conjugates
(Invitrogen): SA-QD565, SA-QD585, SA-QD605, SA-QD655,
SA-QD705, SA-QD800, SA-PE and SA-APC. For each 100 ml of
MHC monomer (concentration, 100 mg ml–1) 7.08 ml of SA-Qdot
conjugate (1 mM), 10.8 ml SA-PE (1 mg ml–1) or 6 ml SA-APC
(1 mg ml–1) was added, followed by incubation on ice for 20 min.
Assuming a 100% rescue after MHC peptide exchange, this would
result in an occupancy of 30 MHC monomers per SA-Qdot and
4 monomers per SA-PE or SA-APC. To block residual binding
sites, D-biotin (Sigma) was added to a final concentration of
26.4 mM, followed by incubation on ice for 20 min. PE- and
APC-labeled complexes were diluted twofold in PBS with 0.02%
(wt/vol) NaN3. For each pMHC complex, multimers were made
with two different fluorescent labels according to the schemes in
Supplementary Tables 2–4. For combinatorial T-cell staining,
multimer complexes of the same specificity were mixed 1:1 for
QD605-, QD655-, QD705-, PE- and APC-labeled complexes and
2:1 for QD565-, QD585- and QD800-labeled complexes in combi-
nation with any other color. Combinations of QD565, QD585 and
QD800 with each other were excluded. Combined pMHC mix-
tures for analysis of T-cell responses by combinatorial encoding
were generated by pooling and were stored with 0.02% NaN3
(Sigma) at 4 1C as 50-fold concentrated ready-to-use stocks for
T-cell staining (concentration was 100 mg ml–1 based on initial
monomer concentration). Before use, pMHC multimers were
centrifuged at 17,000g for 2 min, and the supernatant was used.
Although the stability of pMHC complexes can be expected to
differ between individual pMHC complexes, we have successfully
used pMHC mixtures stored in this manner for up to 2 months.
PBMC samples and T-cell staining. PBMCs were obtained from
healthy individuals and from individuals with stage IV melanoma
in accordance with local guidelines, with informed consent and
with approval from the local ethics committee (METC). All T-cell
staining was performed on cryopreserved material. For T-cell
staining of approximately 1  106 PBMCs or 2  105 cultured
T cells, 2 ml of single pMHC multimer, or 50 ml of dual-color–
encoded pMHC collections (final concentration: 2 mg ml–1 per
distinct pMHC based on initial monomer concentration) was
used. Final staining volume was 80 ml and cells were incubated for
10 min at 37 1C. Next, 20 ml of a fivefold concentrated antibody
mix consisting of CD8-Alexa700 (Caltag MHCD0829) (final
dilution 1/200), CD4-FITC (BD 345768) (final dilution 1/8),
CD14-FITC (BD 345784) (final dilution 1/32), CD19-FITC (BD
345776) (final dilution 1/16), CD40-FITC (Serotech MCA1590F)
(final dilution 1/40), CD16-FITC (BD 347523) (final dilution
1/64) was added, and cells were incubated for 20–30 min at
4 1C. Before flow cytometry analysis, cells were washed twice
and propidium iodide was added to allow dead-cell exclusion.
Flow cytometry. Data acquisition was performed on an LSR-II
flow cytometer (Becton Dickinson) with FacsDiva software using
the following 11-color instrument settings. For the 488-nm laser:
PI, 685LP, 695/40; PE, 550LP, 575/26; FITC, 505LP, 530/30; SSC,
488/10. For the 633-nm laser: Alexa700, 685LP, 730/45; APC,
660/20. For the 405-nm laser: QD800, 770LP, 800/30; QD705,
680LP, 710/50; QD655, 635LP, 660/40; QD605, 595LP, 650/12.
For the 355-nm laser: QD585, 575LP, 585/15; QD565, 545LP:
560/20. Approximately 200,000 lymphocytes were recorded for
each analysis. To identify antigen-specific T cells, the following
gating strategy was used. (i) Selection of live (PI-negative) single-
cell lymphocytes (FSC-W/H low, SSC-W/H low, FSC/SSC-A).
(ii) Selection of CD8+ and ‘dump’ (CD4, 14, 16, 19 and 40)
negative cells. FITC was used as a ‘dump channel’ to gate away all
irrelevant cells, as a means to reduce background19. (iii) Selection
of CD8+ T cells that were positive in two MHC multimer channels
and negative in the six other MHC multimer channels. Each cell
population positive in two and only two MHC multimer channels
received a unique color to facilitate analysis.
IFNc enzyme-linked immunosorbent spot assay. We coated
96-well nitrocellulose plates (Multiscreen MAIP N45; Millipore)
with 7.5 mg ml–1 mouse monoclonal antibody to IFNg (1-D1k;
Mabtech) in 75 ml PBS overnight at room temperature. After six
washes and blocking with 200 ml X-Vivo medium (Biowhittaker),
lymphocytes were added in three concentrations: 1  106, 5  105
and 2.5  105 cells per well, together with indicated peptide
(5 mg ml–1). After overnight incubation, plates were washed and
biotinylated secondary monoclonal antibody to IFNg was added
(7-B6-biotin; Mabtech). After a 2-h incubation, plates were
washed and avidin-enzyme conjugate (Life Technologies) was
added to each well. After 1 h of incubation at room temperature,
plates were washed and enzyme substrate (Dako) was added for
5–10 min. Reactions were terminated by addition of water, and
the number of spots was assessed using an ELISPOT counter
(Immunospot; CTL Inc.).
Enrichment of antigen-specific T cells. Antigen-specific T cells
were stained with PE multimers (1.25 ml of a 100 mg ml–1 stock
of each individual PE-multimer for 107 PBMCs) for 1 h at 4 1C.
Subsequently, cells were washed, and incubated with 20 ml
magnetic beads coated with antibody to PE (Miltenyi). Cells were
then isolated by MACS (Miltenyi), using an LS column, following
the manufacturer’s protocol. Eluted cells were washed and resus-
pended in 200 ml of T cell medium (IMDM (Gibco) with 10%
human serum (Invitrogen), 100 IU ml–1 IL-2 (Proleukin) and
20 ng ml–1 IL-15 (Peprotech)) with 5,000 anti-CD3/CD28–coated
Dynabeads (Invitrogen). Enriched cells were cultured in 96-well
plates and resuspended the next day. Cultures were split and
medium was refreshed at least twice a week. Note that residual
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within two days of culture (data not shown). After 2–3 weeks,
antigen-specific T-cell responses were measured by combinatorial
encoding-based MHC multimer flow cytometry.
T-cell sorting and culture. T cells were stained with the relevant
pMHC multimer and then sorted on a MoFlo (Dako) or FACSAria
(Becton Dickinson) into 105 irradiated feeder cells (JY plus
allogeneic PBMCs). Cells were spun and resuspended in IMDM
with 10% human serum, 100 IU ml–1 IL-2 and 0.5 mg ml–1 PHA
(Biochrom AG). Cultures were restimulated every second week.
Established cultures were tested for antigen-specificity by MHC
multimer staining.
Cytokine release assay. T2-A3 cells were loaded with the indicated
peptides for 1 h and washed once. Then, 1  105 T cells from
indicated cultures were incubated with 1  105 T2-A3 cells for 4 h
at 37 1C in IMDM with 10% human serum and protein transport
inhibitor (BD GolgiPlug). Cells were stained with PE-conjugated
antibodies to CD8 (clone SK1, BD) for 15 min at 25 1C, fixed
and permeabilized (BD Cytofix/Cytoperm kit), and stained with
APC-conjugated antibodies to IFNg (25723.11, BD) for 30 min at
4 1C. Samples were analyzed by flow cytometry (Cyan, Dako), data
analysis was performed using FlowJo.
Statistics. The three different staining approaches: (i) one single
staining with the mix of 25 dual-color–encoded viral and cancer
epitope pMHC multimers, (ii) 25 separate stainings with all 25
PE-labeled pMHC multimers or (iii) 25 separate stainings with all
individual dual-color–encoded pMHC multimers were compared
to determine the interclass correlation, using a two-way mixed
model (ICC3.1), calculated based on consistency. Interpretation of
the results is based on reference 9.
18. Garboczi, D.N., Hung, D.T. & Wiley, D.C. HLA-A2–peptide complexes: refolding and
crystallization of molecules expressed in Escherichia coli and complexed with
single antigenic peptides. Proc. Natl. Acad. Sci. USA 89, 3429–3433 (1992).
19. van Oijen, M. et al. On the role of melanoma-specific CD8+ T-cell immunity in
































Detection of antigen–specific T cells using MHC multimers coupled to different fluorochromes
Staining of a clonal HLA–A2 CMVNLV–specific T cell population mixed with an excess of HLA–
A2–negative PBMCs using MHC multimers conjugated to eight different fluorochromes: 












Staining of a clonal HLA-A2 CMVNLV-specific T cell population mixed with an excess of 
HLA-A2-negative PBMCs using MHC multimers conjugated to eight different
fluorochromes: PE, APC, QD565, QD585, QD605, QD655, QD705 and QD800. Dot plots 
are gated on live, single-cell lymphocytes.
Supplementary Figure 1
Detection of antigen-specific T cells using MHC multimers coupled to different fluorochromes
Nature Methods: doi:10.1038/nmeth.1345
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Supplementary Figure 2
Multiplex detection of virus–specific T cell responses through combinatorial encoding
(a–c) Dot plots showing all 28 different 2–D representations of gated CD8+ T cells of three 
healthy donors analyzed by dual–color encoded MHC multimer staining using the peptide set 
described in Supplementary Table 2 online. (a) Donor 1. (b) Donor 2. (c) Donor 3. (d) 
Representative example of staining of PBMCs from a healthy donor analyzed by dual–color 
encoded MHC multimer staining using irrelevant peptide–MHC multimers. (e) Dot plots for 










QD585 QD605 QD655 QD705
Supplementary Figure 2
Multiplex detection of virus-specific T cell responses through combinatorial encoding
a
(a-c) Dot plots showing all 28 different 2-D representations of gated CD8+ T cells of three 
healthy donors analyzed by dual-color encoded MHC multimer staining using the peptide 
set escribed in Supplementary Table 2 o line. (a) Donor  (b) Donor 2. (c) Donor 3. (d)
Representative example of staining of PBMCs from a healthy donor analyzed by dual-color 
encoded MHC multimer staining using irrelevant peptide-MHC multimers. (e) Dot plots for 
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Supplementary Figure 2
Multiplex detection of virus-specific T cell responses through combinatorial encoding
Nature Methods: doi:10.1038/nmeth.1345
89 
Multidimensional encoding of MHC multimers
Supplementary Figure 2
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Multiplex detection of virus–specific T cell responses through combinatorial encoding
Supplementary Figure 2
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Supplementary Figure 2
Multiplex detection of virus–specific T cell responses through combinatorial encoding
Supplementary Figure 2






Feasibility of 3D pMHC multimer staining
CMVNLV–specific T cells are stained with a combination of QD605, QD655 and QD705 labeled 
CMVNLV–MHC multimers. (a) The parameters QD605, QD655 and QD705, with the triple 
positive cells in white. (b) The parameters PE, APC and QD655 of the same sample. No triple 
















Feasibility of 3D pMHC multimer staining
CMVNLV-specific T cells are stained with a combination of QD605, QD655 and QD705 
labeled CMVNLV-MHC multimers. (a) The parameters QD605, QD655 and QD705, with 
the triple positive cells in white. (b) The parameters PE, APC and QD655 of the same 
sample. No triple positive cells were detected using this combination. 3D dot plots 
were made using FlowJo v7.5 (beta version).
Nature Methods: doi:10.1038/nmeth.1345
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Supplementary Figure 4
Phenotypic characterization of virus–specific T cells detected by combinatorial encoding
(a–c) dot plots from three healthy donors gated on approximately 200,000 CD8+ T cells after 
exclusion of ‘triple’ or ‘single’ pMHC multimer positive T cells. (top row) PBMCs were stained 
with pMHC–multimer complexes for HLA–A2 InfGIL (QD605 + QD655, blue), HLA–A2 CMVNLV 
(PE + QD655, green), and HLA–A2 EBVGLC (PE + QD605, red). (middle row) Phenotypic 
characteristics of virus–specific T cells based on CD45RA and CCR7 expression: a density 
plot gated on CD8+ T cells used to define quadrant gates (left), a dot plot showing all CD8+ 
T cells with pMHC positive T cells depicted in the indicated colors (middle), and a dot plot 
showing only pMHC positive T cells (right). (bottom row) Phenotypic characteristics of 
virus–specific T cells based on CD62L and CD57 expression: a density plot gated on CD8+ 
T cells used to define quadrant gates (left), a dot plot showing all CD8+ T cells with pMHC 
positive T cells depicted in the indicated colors (middle), and a dot plot showing only pMHC 
positive T cells (right).
Supplementary Figure 4






























(a-c) dot plots from three healthy donors gated on approximately 200,000 CD8+ T cells 
after exclusion of ‘triple’ or ‘single’ pMHC multimer positive T cells. (top row) PBMCs 
were stained with pMHC-multimer complexes for HLA-A2 InfGIL (QD605 + QD655, blue), 
HLA-A2 CMVNLV (PE + QD655, gr en), nd HLA-A2 EBVGLC (PE + QD605, red). 
(middle row) Phenotypic characteristics of virus-specific T cells based on CD45RA and 
CCR7 expression: a density plot gated on CD8+ T cells used to define quadrant gates 
(left), a dot plot showing all CD8+ T cells with pMHC positive T cells depicted in the 
indicated colors (middle), and a dot plot s owing only pMHC positive T cells (right). 
(bottom row) Phenotypic characteristics of virus-specific T cells b sed on CD62L and 
CD57 expression: a density plot gated on CD8+ T cells used to define quadrant gates 
(left), a dot plot showing all CD8+ T cells with pMHC positive T cells depicted in the 





Phenotypic characterization of virus–specific T cells detected by combinatorial encoding
Supplementary Figure 4



































































Multidimensional encoding of MHC multimers
Supplementary Table 1
The 28 unique color combinations that can be made using a two–dimensional matrix of eight 
fluorochromes
Supplementary Table 1
The 28 unique color combinations that can be made using a two-dimensional matrix of eight 
fluorochromes
PE APC QD565 QD585 QD605 QD655 QD705 QD800
PE x x x x x x x
APC x x x x x x
QD565 x x x x x
QD585 x x x x








Virus–derived and cancer–associated T cell epitopes
For each epitope MHC multimers were encoded by the indicated fluorochrome combination
Supplementary Table 2
Virus-derived and cancer-associated T cell epitopes
No. Protein HLA Restriction Peptide Coding
1 HPV E6 A2 TIHDIILECV PE & APC
2 CMV pp150 A3 TTVYPPSSTAK PE & Q565
3 Influenza A  M1 A2 GILGFVFTL PE & Q585
4 gp100 A2 IMDQVPFSV PE & Q605
5 EBV LMP2 A2 CLGGLLTMV PE & Q655
6 EBV BMF1 A2 GLCTLVAML PE & Q705
7 Tyrosinase A2 YMNGTMSQV PE & Q800
8 Survivin A2 LMLGEFLKL APC & Q565
9 CMV pp65 A1 YSEHPTFTSQY APC & Q585
10 EBV LMP2 A2 FLYALALLL APC & Q605
11 Influenza A NP A3 ILRGSVAHK APC & Q655
12 HA-2 A2 YIGEVLVSV APC & Q705
13 CMV pp65 A2 NLVPMVATV APC & Q800
14 CMV pp65 B7 TPRVTGGGAM Q565 & Q605
15 CMV pp50 A1 VTEHDTLLY Q565 & Q655
16 EBV BRLF1 A2 YVLDHLIVV Q565 & Q705
17 HPV E7 A2 YMLDLQPETT Q585 & Q605
18 EBV EBNA 3a A3 RLRAEAQVK Q585 & Q655
19 Influenza A  BP1 A1 VSDGGPNLY Q585 & Q705
20 CMV pp65 B7 RPHERNGFTV Q605 & Q655
21 EBV EBNA B7 RPPIFIRLL Q605 & Q705
22 HY A2 FIDSYICQV Q605 & Q800
23 CMV pp150 A3 TVYPPSSTAK Q655 & Q705
24 CMV IE1 A2 VLEETSVML Q655 & Q800
25 EBV BRLF1 A3 RVRAYTYSK Q705 & Q800
For each epito ultimers wer  encoded by the indicated fluorochr me combinati n
Nature Methods: doi:10.1038/nmeth.1345
97 
Multidimensional encoding of MHC multimers
Supplementary Table 3
Melanoma–associated HLA–A3 ligands
Three EBV– and influenza A–derived epitopes were included for direct ex–vivo stainings as a 
positive control. Sequences in bold are previously described T cell epitopes. Individual pMHC 
multimers were encoded by the indicated fluorochrome combination.
Supplementary Table 3
Melanoma-associated HLA-A3 ligands
Three EBV- and influenza A-derived epitopes were included for direct ex-vivo stainings as a 
positive control. Sequences in bold are previously described T cell epitopes. Individual pMHC 
multimers were encoded by the indicated fluorochrome combination.
Protein Peptide Position Coding
Gp100 IALNFPGSQK 86-95 PE & APC
LIYRRRLMK 614-622 PE & Q565
GTATLRLVK 460-468 PE & Q585
ALLAVGATK 17-25 PE & Q605
ALNFPGSQK 87-95 PE & Q655
GVSRQLRTK 34-42 PE & Q705
QLVLHQILK 551-559 PE & Q800
QLRALDGGNK 221-230 APC & Q565
Nodal SLYRDPLPR 46-54 APC & Q585
HAYIQSLLK 293-301 APC & Q605
KTKPLSMLY 317-325 APC & Q655
RVAGECWPR 175-183 APC & Q705
Tyr YMVPFIPLYR 425-434 APC & Q800
SLLCRHKRK 497-505 Q565 & Q605
VSSKNLMEK 25-33 Q565 & Q655
GLVSLLCRHK 494-503 Q565 & Q705
Tyrp1 SLPYWNFATR 245-254 Q585 & Q605
ASYLIRARR 497-505 Q585 & Q655
Tyrp2 TLLGPGRPYR 196-205 Q585 & Q705
GTYEGLLRR 301-309 Q605 & Q655
RMYNMVPFF 461-469 Q605 & Q705
VLLAFLQYR 521-529 Q605 & Q800
Influenza A NP ILRGSVAHK 265-273 Q655 & Q705
EBV EBNA 3a RLRAEAQVK 603-611 Q655 & Q800





HIV– and HCV–derived HLA–A3 restricted T cell epitopes
Three EBV– and influenza A–derived epitopes were included for direct ex–vivo stainings as 
a positive control. Individual pMHC multimers were encoded by the indicated fluorochrome 
combination.
Supplementary Table 4
HIV- and HCV-derived HLA-A3 restricted T cell epitopes
Three EBV- and influenza A-derived epitopes were included for direct ex-vivo stainings as a 
positive control. Individual pMHC multimers were encoded by the indicated fluorochrome
combination.
Virus Peptide Position Coding
HIV QVPLRPMTYK 86-95 PE & APC
HIV TVYYGVPVWK 614-622 PE & Q565
HIV RLRDLLLIVTR 460-468 PE & Q585
HIV RLRPGGKKK 17-25 PE & Q605
HIV KIRLRPGGK 87-95 PE & Q655
Hepatitis C virus RVCEKMALY 34-42 PE & Q705
Hepatitis C virus RLGVRATRK 551-559 PE & Q800
Hepatitis C virus KTSERSQPR 221-230 APC & Q565
Hepatitis C virus QLFTFSPRR 46-54 APC & Q585
Hepatitis C virus RMYVGGVEHR 293-301 APC & Q605
Hepatitis C virus LGFGAYMSK 317-325 APC & Q655
Hepatitis C virus GAYMSKAHGV 175-183 APC & Q705
Hepatitis C virus LIFCHSKKK 425-434 APC & Q800
Hepatitis C virus GVAGALVAFK 497-505 Q565 & Q605
Hepatitis C virus VAGALVAFK 25-33 Q565 & Q655
Hepatitis C virus SLTPPHSAK 494-503 Q565 & Q705
Hepatitis C virus CINGVCWTC 245-254 Q585 & Q605
Hepatitis C virus HDGAGKRVY 497-505 Q585 & Q655
Hepatitis C virus KVFPKALINK 196-205 Q605 & Q655
Hepatitis C virus LLFLLLADA 301-309 Q605 & Q800
Influenza A NP ILRGSVAHK 265-273 Q655 & Q705
EBV EBNA 3a RLRAEAQVK 603-611 Q655 & Q800







The generation of antigenic peptides and 
the interaction between pMHC complexes 
and T cell receptors are two important 
hallmarks of T cell–mediated immunity. 
This thesis describes our advances in the 
understanding of how MHC ligands are 
generated by APCs (chapters 2 and 3) as 
well as the development and use of pMHC 
based high–throughput techniques to 
analyze human T cell populations (chapters 
5 and 6). Here I will first discuss the 
progress that has been made in the last few 
years in the field of antigen presentation and 
how these results fit with the new insights 
that have been obtained by other groups. I 
will conclude with a description of the two 
techniques that we have developed and 
discuss the potential value of these methods 
for the analysis of T cell populations and 
identification of new T cell epitopes.
Generation of antigenic peptides 
from extracellular material in T cell–
mediated immunity 
In chapters 2 and 3 we investigate the 
mechanisms of various APC for generating 
antigenic peptides and describe new rules 
governing these mechanisms. Through the 
direct visualization of phagosomal protease 
activity in both macrophages and dendritic 
cells two new observations are made in 
chapter 2. First, the recruitment of cysteine 
proteases to a maturing phagosome after 
internalization of particulate material occurs 
sequentially in a time–dependent manner 
and not through bulk delivery. Additionally, 
there is a marked difference in protease 
recruitment between different APC types as 
well as between different cellular maturation 
states. These results indicate that there 
is distinct enzymatic regulation during 
phagosomal maturation with tight control 
on how extracellular material is processed. 
The observation that macrophages display 
more rapid recruitment of proteases than 
DCs fits with the notion that the two cell 
types play rather distinct roles in antigen 
processing and immunity; Macrophages act 
as scavengers against invading pathogens 
and therefore destroy internalized material 
rapidly, while DCs process material more 
slowly and in such a manner that T cells 
will be activated and recruited. Since our 
observations, several further studies have 
strengthened this notion by showing tightly 
regulated lysosomal activation during 
dendritic cell maturation, and more rapid 
antigenic destruction in macrophages than 
in DCs (3).
In chapter 3 the question was asked 
whether the parameters governing cross–
presentation and endogenous antigen 
presentation are equivalent. While antigens 
contained in different locations of a protein 
(signal peptide vs. carboxi–terminus) are 
presented comparably through endogenous 
presentation, this similarity is lost when 
the same protein is processed through 
the cross–presentation pathway. In that 
setting, only when antigens are contained 
in a portion of the mature protein with a 
relatively long half–life does cross–priming 
of T cells occur. These observations, 
together with those from the groups of Rock 
and Yewdell (4,5), were the first to show 
that long–lived cellular proteins rather than 
short–lived peptides are the major source 
of antigens through cross–presentation. In 
a later study our grouped also confirmed 
the relationship between protein half–life 
and the magnitude of a T cell response 
when comparing the effectiveness of DNA 
vaccines (6).
In this chapter we have presented 
evidence that the extracellular material 
internalized during cross–presented is 
proteinaceous, while chapter 2 describes 
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regulated delivery of proteases in the 
endocytic pathway (investigated in the 
context of MHC class II antigen presentation). 
Together these results suggest that there 
also is a similar method of regulation for the 
generation of antigenic peptides for cross–
priming. When also taking into account that 
free cytosolic peptides have a half–life of 
only seconds (7) a model emerges where 
degradation of extracellular material needs 
to be tightly controlled in dendritic cells 
to ensure initiation of T cell responses 
through   cross–priming. Furthermore, 
considering the above–mentioned notion 
that macrophages play a different role 
in immunity than DCs, this regulation 
on antigen generation should, at least in 
part, be DC specific and start right when 
material is internalized. We show in this 
thesis that part of this control is executed 
through organized delivery of proteases 
to the phagosome with clear differences 
between DCs and macrophages. Also, if 
mature proteins rather than peptides are 
the cross–presented material the processing 
should primarily take place inside the 
presenting APC. In the introduction I have 
discussed the different possible mechanisms 
of antigen transfer between cells during 
cross–presentation. Here, I will discuss 
the recent developments specifically in 
the field of phagosomal maturation and 
intracellular antigen processing after uptake 
of extracellular material by APCs, and in 
particular DCs.
A major factor in the processing 
of extracellular material is the gradual 
acidification of phagosomes. pH–sensitive 
propieces that occupy the enzymatic domain 
of many endocytic proteases ensure that 
these proteases only become active at the 
right acidic compartments, while there 
are also specific acidic ranges in which 
certain enzymes are functional (8). A new 
level of control in regards to phagosomal 
acidification was recently described in DCs 
by the groups of Mellman and Amigorena. 
Trombetta et al. were the first to show 
regulated acidification in DCs by showing 
in vitro that immature DCs lack a fully 
assembled V–ATPase (1). The laboratory 
of Amigorena then went on to describe in 
several publications that immature DCs 
also actively lower the pH of endocytic 
organelles through fusion with ‘inhibitory 
lysosome–related organelles’, thereby 
preventing rapid degradation of phagosomal 
content. This process is mediated by 
Rab27a–dependent recruitment of NOX2, 
which actively pumps out protons of the 
organelle (9–11). Although a reduction of 
lysosomal acidification after LPS treatment 
has been observed in macrophages (12), 
alkalinization through NOX2 does not 
occur in these cells (13). Thus, dendritic 
cells appear to be equipped with a unique 
active mechanism to control vesicular pH 
in order to regulate hydrolytic activity and 
thereby antigenic processing. This ensures 
that material is available long enough for 
binding to MHC molecules. Several studies 
have described the transfer of extracellular 
material to the cytosol from early endocytic 
vesicles, indeed well before low lysosomal 
pH is reached (14–16). The prolonged 
but transient period of low pH in early 
phagosomes of immature DCs followed 
by acidification of the vesicles to a level 
where proteases involved in the generation 
of peptides for MHC class II binding are 
active (8), therefore argues for a model 
where the processing of peptides involved 
in cross–priming CD8+ T cells occurs early 
in phagosomal maturation, followed by 
the generation of MHC class II associated 
peptides later on in the pathway (17,18).
As already mentioned in the introduction 
of this thesis, another recent development 
in the investigation on phagosomal antigen 
processing is the proposed contribution 
of the ER to the maturing phagosome. 
Although several publications have 
described the presence of ER–derived 
proteins in phagosomes, including the MHC 
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class I peptide loading machinery (15,19–
22) this issue remains controversial (23). 
Resolving the controversy surrounding the 
contribution of the ER to phagosomes as 
part of the antigenic processing machinery 
would be a significant advance in the field 
of cross–presentation. In light of this, two 
elegant studies of the group of Cresswell 
provide compelling evidence that ER 
components, such as the retrotranslocation 
machinery, indeed play a role in the transfer 
of at least soluble extracellular material 
to the cytosol (24,25) and Burgdorf et 
al. have recently provided evidence that 
soluble ovalbumin enters the cytosol rapidly 
after internalization and then re–enters the 
phagosome in a TAP–dependent manner 
(16).
This brings us to the question whether 
different modes of uptake, such as for 
example is the case for soluble vs. particulate 
material, play a role in how material is 
processed by the DC. Presentation of soluble 
antigens has generally been assumed to be 
regulated by similar mechanisms as those 
involved in the processing of particulate 
antigens. However, it is becoming more 
clear that extracellular material does 
not enter a common default vesicle after 
uptake by an APC (26). Rather, the mode 
of uptake,  cell–type and maturation state 
of the cell seem to be a determining factor 
as to how the material is processed. For 
example, material entering DCs through the 
DEC205 receptor primes T cells differently 
than the same antigens internalized via 
DCIR2 (27), where the first situation leads 
to both CD4+ and CD8+ T cell activation, 
while DCIR2–targetting only primes CD4+ T 
cells. Additionally, Burgdorf et al. recently 
showed that soluble material internalized 
via the mannose receptor is routed 
differently than material endocytosed via 
the scavenger receptor (28). This has 
led to renewed interest in the differential 
receptor expression between cell–types as 
well as altered receptor expression between 
maturation states (17). The insights from 
these and future studies should have a 
large impact in the field of antigen–uptake 
through receptor–targeting that has seen 
been growing steadily in the last decade 
(29). Specifically, control of the onset 
and magnitude of T cell responses might 
be influenced through specific receptor–
targeting of desired antigens. On the other 
hand, this extra level of cellular control 
might also make the unraveling of how 
extracellular antigens are processed inside 
a DC much more complicated.
Finally, receptors of the innate immune 
system might prove to also play a role 
in cross–presentation. It has been well 
established that TLR–triggering leads to 
DC maturation as well as the fact that TLR 
ligands increase protein immunogenicity. 
Recently Blander and Medzhitov have 
published several papers describing an 
important role for TLR–engagement in 
control of phagosome maturation (30–32). 
In those studies, internalization of bacteria 
leads to CD4+ T cell activation because TLRs 
are engaged, while apoptotic material does 
not lead to a T cell response. This latter 
could be reversed by addition of a TLR ligand 
to the apoptotic material. However, these 
findings remain controversial, since the lab 
of Russell failed to find a direct role for TLRs 
in phagosomal maturation and processing 
(33–35). It should be noted that all these 
studies have primarily examined CD4+ T 
cell activation. Given the various methods 
of control of phagosomal maturation and 
processing by DCs in generating MHC 
class I epitopes described above, it seems 
likely that there is also a role for TLRs in 
controlling how, when, and where MHC class 
I epitopes are generated after internalization 
of antigens, but further studies need to be 
performed to validate this.
Our research has given new insights on 
which extracellular material is processed 
for CD8+ T cell activation during cross–
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priming and which proteases are active 
during phagosome maturation. Especially 
these latter findings fit with the growing 
realizations that DCs are the primary 
cell type for generating both CD4+ and 
CD8+ T cell responses and that antigenic 
processing after uptake is tightly regulated. 
Macrophages seem to be optimized for the 
destruction of pathogenic particles. The 
phagocytic pathway of DCs, on the other 
hand, differs from that of macrophages in 
the ability to tightly control mechanisms 
such as phagosomal acidification, transport 
of proteins from the phagosome to the 
cytosol, recruitment of ER–resident proteins 
to the phagosome and, possibly, TLR 
engagement during phagosomal maturation 
(13).
pMHC multimers in high–throughput T 
cell analysis
Chapters 4 through 6 describe a 
different aspect of antigen presentation 
than the previous chapters: the use of 
MHC multimers in the analysis of T cell 
responses. The field of MHC multimers 
exists since the landmark publication of 
Altman et al. in 1996 describing for the first 
time the use of multimerized MHC molecules 
in flow cytometry for T cell analysis (36). 
Since then this ‘tetramer technology’ has 
become a core experimental tool in the field 
of T cell immunity. In chapter 4 we discuss 
the different available methods to generate 
MHC class I and MHC class II multimers 
and provide a roadmap for the future 
development of MHC multimer technology. 
One of the aspects that are covered 
in chapter 4 is the limitation of high–
throughput uses of MHC multimers in the 
analysis or selection of large sets of T cell 
populations. Due to the standard refolding 
and purification methods of generating 
peptide–specific MHC multimers, this 
technology is unsuited for the generation 
of large collections of different pMHC 
complexes, thereby precluding high–
throughput applications.
To overcome this limitation, our lab 
developed a peptide exchange technique 
using UV–sensitive conditional ligands for 
MHC multimers (37). These ligands allow for 
efficient UV–mediated disintegration in the 
MHC–bound state under conditions that do 
not affect the integrity of the MHC molecule, 
while at the same time conferring efficient 
pMHC refolding and long–term stability 
when no trigger is applied. Indeed, a large 
array of multimers can be generated in only 
several hours from one batch of conditional 
pMHC complexes (38).
The initial description of this technique 
was limited to HLA–A2 and it remained 
unclear whether this technique could 
be extended to other human HLA gene 
products. In chapter 5 we describe the 
development and characterization of 4 new 
conditional ligands for the gene products 
HLA–A1, –A3, –A11, and –B7. We thereby 
establish that peptide exchange technology 
is indeed a generally applicable approach 
for several HLA gene products and provide 
more insight in the biochemical kinetics 
of the exchange reaction. We show that 
dissociation of cleaved conditional ligands 
after UV–exposure is rapid and show that 
residual material is a reaction product rather 
than uncleaved material and ultimately 
does not interfere with detection of T 
cell responses. With this study, the HLA 
complexes for which conditional ligands are 
now available cover at least one allele of 
over 90% of Western European individuals.
With the establishment of the exchange 
technology it has become possible to 
rapidly generate batches of MHC complexes 
presenting a wide range of epitopes. This 
should allow for the development of different 
high–throughput screening methods of 
antigen–specific T cells. In chapter 6 we 
describe the development, testing and use 
of one such high–throughput screening 
approach, where we multidimensionally 
encode a large pool of different pMHC 
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complexes in order to simultaneously 
analyze multiple T cell populations with 
flow cytometry. Specifically, we coupled a 
unique combination of two fluorochromes 
to specific pMHC complexes while using the 
same fluorescent labels multiple times, but 
each time in a different combination of two 
labels. Using such an encoding approach 
to label MHC complexes with unique multi–
color tags allows to vastly increase the 
maximum available labeling combinations 
over the traditional use of single–color 
tags. For this, we use six of the recently 
developed quantum dots in combination 
with two traditional organic fluorochromes. 
Using  MHC multimers that are each 
uniquely encoded by 2 fluorochromes we 
are able to detect and analyze up to 25 T 
cell populations simultaneously out of the 
28 possible combinations. Combinatorial 
coding systems have been used in a number 
of settings to increase the number of 
analyses that can be performed on a single 
sample. For example combinatorial coding 
has been used to measure serum products 
such as cytokines using bead arrays in 
which encoding is performed by variation in 
bead size, fluorochrome and fluorochrome 
intensity (e.g. the cytometric bead arrays by 
BD (39)). In those cases, however, solutes 
are analyzed by binding to pre–encoded 
microbeads. Contrary to this, our technique 
differs through the involvement of de novo 
creation of a code during the assay.
In chapter 6 we validate combinatorial 
coding primarily using 2 dimensions. We 
also provide prove that an increase to 3 
dimensions is feasible, and we have by 
now tested up to 4 dimensions successfully 
(data not shown). With an increase in 
available fluorochromes and better detection 
capacities of flow cytometers, higher coding 
dimensions would allow for a vast increase 
of T cell populations that could be detected. 
Even with the current available technical 
limitations, the use of 17 fluorochromes (the 
maximal number of different fluorochromes 
that has to our knowledge been used in a 
single flow cytometric analysis (40), our 
2–dimensional coding system could already 
encompass up to 136 specific codes. The 
capacity to us higher dimensions would then 
allow for the encoding of many thousands 
of specificities.
The ability to use large sets of MHC 
multimers has been shown to be very 
instrumental in identifying novel epitopes 
by our lab and others (37,41–43), where 
epitopes were identified in screens in mouse 
models using sets of 150 to 2000 peptides. 
The development of the multidimensional 
encoding approach now also opens up this 
ability for analysis of human PBMCs, where 
sample size previously was the limiting factor. 
To demonstrate the value and possibility 
of large scale screening of human T cell 
responses directly, we analyzed cytotoxic T 
cell responses against a series of potential 
melanoma–associated antigens using both 
the techniques described in chapters 5 and 
6. In chapter 5 we screen a library of 203 
potential melanoma–associated peptides in 
the context of HLA–A3. The newly developed 
exchange technology allowed for rapid 
high–throughput binding assays, identifying 
22 peptides that display high binding affinity 
for HLA–A3. In chapter 6 we use the parallel 
detection technique to simultaneously 
analyze cytotoxic T cell responses against 
these 22 peptides in blood of melanoma 
patients. With this approach we could 
identify reactivity against 8 epitopes, of 
which 5 were not previously identified. This 
could have therapeutic implications, since 
MHC–based selection of antigen–specific T 
cells has been proposed as a strategy to 
boost melanoma–specific T–cell responses 
in individuals with melanoma (44). Our 
identification of potential novel associated 
epitopes should allow for a similar strategy 
in HLA–A3 positive patients.
This  melanoma–spec i f ic  screen 
shows the potential value of combining 
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both the exchange technology and the 
multidimensional encoding strategy to identify 
pathogen–, cancer–, and autoimmune–
associated epitopes.
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Dit  proefschr i f t  gaat  over  het 
afweersysteem. Tenminste, over een 
bepaald gedeelte van het afweersysteem, 
namelijk het ‘T–cel gemedieerde deel van 
het adaptieve immuunsysteem’. En dan 
ook nog eens over de vraag hoe binnen 
dat specifieke onderdeel bepaalde stukken 
eiwit door de cel gemaakt worden en hoe 
we deze zogenoemde epitopen zouden 
kunnen gebruiken in nieuwe technische 
toepassingen.
De voorgaande zinnen geven volgens mij 
gelijk aan dat het afweersysteem behoorlijk 
uitgebreid is en ingewikkeld in elkaar zit. Dat 
maakt het ook zo mooi om te onderzoeken. 
Maar het is daarom ook niet altijd makkelijk 
uit te leggen aan een niet–immunoloog hoe 
het afweersysteem precies werkt, laat staan 
welk onderdeel van het afweersysteem 
ik nou precies onderzoek. Toch wil ik een 
poging wagen in deze samenvatting, die 
daarom vooral gericht is op mensen buiten 
mijn vakgebied. Vakgenoten raad ik aan om 
(ook) het engelse gedeelte van dit boekje 
te lezen. Ik begin met een basisuitleg van 
het afweersysteem, en daarna leg ik uit 
wat mijn onderzoek dat in dit proefschrift 
beschreven wordt inhoudt.
Twee tactieken
He t  a fwee r s y s t e em ,  o ok  we l 
immuunsysteem genoemd, heeft als taak het 
lichaam tegen ziektemakers (‘pathogenen’) 
te beschermen. Om deze taak uit te voeren 
bestaan er vele verschillende types cellen 
die hierin samenwerken. De basis van alle 
verschillende afweermechanismen die deze 
cellen gebruiken ligt bij het vermogen om 
onderscheid te maken tussen ‘zelf’ en ‘niet–
zelf’. Lichaamseigen cellen moeten met rust 
gelaten worden terwijl lichaamsvreemd 
materiaal (inclusief eigen cellen met daarin 
een ziektemaker) zo snel mogelijk herkend 
en opgeruimd moet worden. In het lichaam 
wordt dus continue nagegaan of iets bij het 
lichaam hoort, of niet.
Er bestaan grofweg twee algemene 
tactieken om infectie door pathogenen 
zoals virussen, bacteriën en parasieten 
tegen te  gaan:  het  ‘aangeboren ’ 
afweersysteem bestaat uit cellen die weten 
wat lichaamsvreemd precies inhoudt en 
daar tegen optreden, terwijl het ‘adaptieve’ 
immuunsysteem juist opereert door na te 
gaan wat lichaamseigen is, en alles wat 
daar niet aan voldoet opruimt. Om dit 
wat concreter te maken: cellen van het 
aangeboren immuunsysteem herkennen 
onderdelen van ziektemakers die niet 
in ons eigen lichaam voorkomen. Als 
ze die bepaalde moleculaire structuren 
tegenkomen dan is het dus duidelijk dat er 
iets mis is en kan er opgetreden worden. 
Zo hebben veel bacteriën een celwand 
die uit andere materialen bestaat dan de 
celwand van zoogdieren. Het aangeboren 
afweersysteem kan deze bacteriële 
celwanden herkennen en zal dus specifiek 
op basis van de aanwezigheid van die 
structuur in het lichaam een afweerreactie 
starten. Het adaptieve systeem werkt 
eigenlijk precies andersom. Cellen van dit 
systeem hebben geen idee hoe pathogenen 
of onderdelen daarvan er uit zien, maar ze 
weten wel wat lichaamseigen is. Als ze iets 
tegenkomen wat daar niet onder valt, dan 
wordt dit aangevallen en opgeruimd.
Aangezien mijn proefschrift over het 
adaptieve afweersysteem gaat en hoe 
het mechanisme werkt dat tot activatie 
van T cellen leidt, zal ik wat meer over dit 
specifieke onderdeel uiteen wijden.
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T cellen, antigeen presentatie en APCs
T cellen zijn cellen die gespecialiseerd 
zijn in het vinden en opruimen van cellen 
die geïnfecteerd zijn met bacteriën en 
virussen. Er zijn twee types: helper T 
cellen die aan andere cellen signalen 
doorgeven dat er opgetreden moet worden 
en cytotoxische T cellen die zelf andere 
cellen kunnen doden. Beide types hebben 
een belangrijke receptor aan de buitenkant 
van de cel: de T cel receptor, of TCR. 
Elke T cel heeft een eigen, unieke TCR en 
omdat er vele miljoenen T cellen in het 
lichaam voorkomen, zijn er dus ook vele 
miljoenen verschillende T cel receptoren. 
Dit komt omdat tijdens het ontstaan van 
een T cel (wat in de thymus gebeurt) de 
TCR door mutaties en herschikkingen 
voor een gedeelte willekeurig in elkaar 
wordt gezet. Het is misschien interessant 
om te realiseren dat niet alle mutaties 
dus ‘slecht’ zijn. Sterker nog, deze (en 
andere) herschikkingen en mutaties in het 
lichaam zijn een cruciaal onderdeel van ons 
afweersysteem. Om te begrijpen waarom dit 
zo belangrijk is, moet ik eerst uitleggen wat 
deze receptoren precies herkennen.
Een belangrijke taak van T cellen is om 
na te gaan of een cel aan de binnenkant 
geïnfecteerd is met een pathogeen, maar 
een T cel kan natuurlijk niet letterlijk in 
een cel naar binnen kijken om te zien 
wat er aan de hand is. Het lichaam heeft 
hier een oplossing voor gevonden door 
een mechanisme te gebruiken dat aan 
de buitenkant een soort blauwdruk geeft 
van wat er binnenin een cel aan de hand 
is. Elke cel van het lichaam heeft hiervoor 
een eiwit complex op de buitenkant 
zitten, het MHC (Major Histocompatibility 
Complex) complex. Deze complexen kunnen 
kleine stukjes eiwit (liganden of epitopen 
genaamd) aan zich binden. Deze eiwit 
stukjes worden gevormd tijdens het proces 
van eiwitafbraak dat in de cel plaatsvindt. 
Vrijwel van elk eiwit dat in een cel wordt 
afgebroken komt een klein gedeelte op 
een MHC complex terecht. Dit complex 
van MHC met stukje eiwit wordt nadat het 
gevormd is naar de buitenkant van de cel 
getransporteerd. En omdat eiwit productie 
en afbraak non–stop in een cel plaatsvindt, 
zal er ook continue aan de buitenkant van de 
cel dus een overzicht zijn van wat er binnenin 
gebeurt. Het handige van dit systeem is dat 
virussen en bacteriën ook gebruik maken 
van het eiwit productie mechanisme van 
cellen, inclusief het onderdeel dat eiwitten 
afbreekt. Na een infectie zullen er dus ook 
stukjes eiwit van een virus of bacterie aan 
de buitenkant van een cel aanwezig zijn in 
het MHC complex. En T cellen zijn in staat 
om deze complexen te herkennen. De 
TCR van een T cel bindt namelijk aan MHC 
complexen en als er een geschikte binding 
plaatsvindt, dan wordt het afweersysteem 
aangezet om alle cellen die de combinatie 
van een MHC complex met juist dat stukje 
eiwit aan de buitenkant hebben zitten op te 
ruimen. Dit principe geeft ook de naam aan 
mijn onderzoeksveld: de eiwitten waarvan 
de stukjes op een MHC complex terecht 
komen, worden ‘antigenen’ genoemd. En de 
MHC complexen ‘presenteren’ deze stukjes 
feitelijk aan de T cellen via binding met hun 
TCR. Het veld wordt dan ook het vakgebied 
van ‘antigeen presentatie’ genoemd.
Eerder heb ik uitgelegd dat T cellen 
onderdeel van het adaptieve systeem zijn 
en dus weten wat eigen is, en tegen alles 
wat daar niet onder valt optreden. Nu het 
principe van antigeen presentatie bekend 
is, kan ik uitleggen hoe het afweersysteem 
er voor zorgt dat T cellen weten wat 
lichaamseigen is. De TCR komt, zoals 
eerder gezegd, gedeeltelijk met willekeur 
tot stand. Welke eiwit structuur binnen een 
MHC complex de TCR zal herkennen staat 
van te voren niet vast en elke TCR herkent 
een andere structuur. Als  de TCR van een 
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T cel gevormd is, bevindt de T cel zich 
nog in de thymus. In de thymus bevinden 
zich gespecialiseerde cellen met MHC 
complexen die ontzettend veel verschillende 
stukken eigen eiwit van het lichaam zelf 
presenteren. Van elke TCR wordt gekeken 
of hier op gereageerd wordt. Als dat zo is, 
dan wordt die specifieke T cel opgeruimd. 
Die TCR herkent immers een stukje van een 
lichaamseigen eiwit. Als er geen herkenning 
plaatsvindt, dan herkent de TCR dus ‘iets 
anders’. Wat dat precies is maakt niet uit: 
alles wat niet lichaamseigen is, is tenslotte 
lichaamsvreemd. In tegenstelling tot de 
cellen van het aangeboren afweersysteem 
hebben T cellen dus absoluut geen idee hoe 
een virus of bacterie er uitziet. Ze weten 
alleen wel hoe het eigen lichaam er uitziet 
en reageren met de rest.
 Naast T cellen spelen andere 
cellen ook een belangrijke rol in mijn 
onderzoek. Dit zijn cellen die in staat zijn 
om materiaal van buiten op te nemen en 
ook stukjes eiwit van dit materiaal aan hun 
MHC complexen te binden, naast de stukjes 
van hun eigen eiwitten. Deze cellen worden 
antigeen presenterende cellen, of kortweg 
APCs, genoemd. APCs kunnen bijvoorbeeld 
actief bacteriën opnemen en doden en 
tegelijkertijd via het MHC complex aan T 
cellen doorgeven dat andere cellen van het 
lichaam waarschijnlijk geïnfecteerd zijn. Ook 
kunnen ze helpen om bepaalde ontwijkings 
mechanismen van virussen te omzeilen, 
als een virus bijvoorbeeld actief de MHC 
complexen van een cel uitschakelt, door 
gedode lichaamscellen die nog virus eiwitten 
bevatten op te nemen en deze eiwitten aan 
het MHC complex te binden. Maar APCs zijn 
vooral erg belangrijk om aan de T cellen 
door te geven dat er ergens anders in het 
lichaam een infectie plaatsvindt en er door 
de T cellen opgetreden moet worden. De 
APCs die dit doen heten dendritische cellen 
(DCs).
Dit proefschrift
Ik heb dus onderzoek aan antigeen 
presentatie gedaan. Waar we specifiek 
naar gekeken hebben zijn twee vragen: 
1) hoe worden epitopen (dus de stukjes 
eiwit die aan het MHC complex binden) 
door een cel gemaakt, en welke regels en 
processen spelen hier een rol in? 2) Kunnen 
we epitopen en MHC complexen gebruiken 
om nieuwe technieken op te zetten om T 
cellen te analyseren? Het proefschrift is 
dan ook in twee onderdelen opgedeeld. 
Hoofdstukken 1 t/m 3 behandelen vraag 
1, en hoofdstukken 4 t/m 6 beschrijven de 
bevindingen op het gebied van vraag 2.
Eerste gedeelte
In hoofdstuk 2 bekijken we hoe APCs het 
materiaal dat ze van buiten de cel opnemen 
afbreken. We onderzoeken specifiek de 
activiteit van de enzymen die deze afbraak 
uitvoeren en kijken hoe en wanneer na 
het opnemen van materiaal deze enzymen 
actief zijn. Meer kennis op dit gebied kan 
er voor zorgen dat we beter in staat zijn te 
begrijpen hoe epitopen gemaakt worden 
en waarom na opname door de cel het ene 
materiaal wel, en het andere materiaal niet 
tot T cel activatie leidt. In dit onderzoek 
hebben we ook naar verschillende APC 
types gekeken en kunnen twee conclusies 
trekken: de activiteit van de enzymen die we 
bekeken hebben is meer gereguleerd dan 
eerder werd gedacht, en er is een verschil 
in enzym activiteit tussen verschillende 
cellen. Op basis van dit verschil stellen we 
voor dat een van de onderzochte celtypes, 
de macrofaag, gespecialiseerd is in het snel 
afbreken en uitschakelen van opgenomen 
pathogenen, terwijl het andere celtype, 
de DC, het opgenomen materiaal juist 
langzaam afbreekt zodat er genoeg tijd 
overblijft om epitopen te maken om aan 




Zoals hierboven beschreven is, kunnen 
epitopen gegenereerd worden uit eiwitten 
die in een cel zelf voorkomen, en uit eiwitten 
nadat deze door APCs zijn opgenomen. In 
hoofdstuk 3 stellen we de vraag of deze 
beide processen volgens dezelfde regels 
werken. Dit wordt gedaan door model 
epitopen op verschillende plekken binnen 
een eiwit te plaatsen en te bekijken of deze 
epitopen wel of niet op MHC complexen 
terecht komen en T cellen activeren. 
Voor de vorming van epitopen door cellen 
waarin het eiwit zelf tot expressie komt, 
maakt het niet uit waar in het eiwit we het 
epitoop geplaatst hebben. Echter, als de 
epitopen gevormd worden door een APC 
nadat deze zijn opgenomen, dan blijkt 
dat alleen epitopen die onderdeel zijn 
van een stabiel deel van het eiwit aan het 
MHC complex gebonden worden. Epitopen 
in instabiele delen van het eiwit die snel 
afgebroken worden zijn niet in staat T cellen 
te activeren. Dit onderzoek heeft tot twee 
belangrijke ontdekkingen geleid. Ten eerste 
werd het duidelijk dat de regels van het 
maken van epitopen verschilt tussen directe 
presentatie door een cel zelf en presentatie 
na opname door een APC. De belangrijkste 
conclusie is echter dat de stabiliteit van 
een eiwit een erg grote rol speelt in het 
activeren van T cellen via APCs, wat nog niet 
eerder was aangetoond. Op basis van deze 
resultaten adviseren we dan ook dat bij de 
ontwikkeling van vaccins er zeker aandacht 
besteed moet worden aan de stabiliteit en 
levensduur van eiwitten.
Tweede gedeelte
Het tweede deel van dit proefschrift 
beschr i j f t  en bouwt voort  op een 
veelgebruikte standaard techniek in 
de immunologie, de MHC multimeer 
technologie. Hoofdstuk 4 geeft een overzicht 
van deze techniek en onze mening over hoe 
deze in de toekomst verder ontwikkeld kan 
worden. De techniek maakt gebruik van het 
feit dat één specifieke TCR één specifieke 
combinatie van MHC complex met epitoop 
herkent. We zijn technisch in staat om MHC 
complexen met epitoop zelf in het lab te 
genereren. Als we meerdere van deze MHC 
complexen (elk met hetzelfde epitoop, en 
dus dezelfde specificiteit) samenvoegen 
en daar een fluorescerend molecuul aan 
koppelen ontstaat een zogenoemde ‘MHC 
multimeer’. Wanneer een voorraad van 
deze multimeren aan een mix van T cellen 
wordt toegevoegd, binden de multimeren 
zich uitsluitend aan de T cellen met de juiste 
TCR die reageert met het eiwit stuk dat aan 
de MHC complexen gebonden is. Omdat de 
multimeren fluorescent zijn kunnen we die 
T cellen zichtbaar maken. Deze techniek 
stelt ons dus in staat om binnen een heel 
grote poel van verschillende T cellen met 
verschillende TCRs juist die T cellen te 
identificeren waar we in geïnteresseerd 
zijn. Deze techniek bestaat inmiddels ruim 
10 jaar en is erg belangrijk geworden zowel 
in basaal onderzoek als bij verschillende 
klinische toepassingen.
Een erg groot nadeel van deze techniek 
is de tijdsduur. Het kost veel tijd en moeite 
om de MHC complexen te maken, en voor 
elke TCR die onderzocht wordt moet een 
aparte voorraad MHC complexen gemaakt 
worden. Het was dus lange tijd niet mogelijk 
om veel verschillende T cellen responsen 
tegelijk te analyseren. In hoofdstuk 5 
bouwen we voort op een recente techniek 
die ons lab heeft ontwikkeld om dit probleem 
te omzeilen. Eerder onderzoek van ons 
lab heeft laten zien dat we chemische 
epitopen kunnen maken die na bestraling 
met UV–licht uit elkaar vallen. Als we MHC 
complexen die deze epitopen bevatten 
bestralen in een vloeistof waar ook andere, 
niet UV–gevoelige, epitopen aanwezig zijn 
blijken we in staat om het UV–gevoelige 
epitoop na het uiteenvallen te vervangen 
door het epitoop dat in de vloeisof aanwezig 
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is. Door een grote hoeveelheid UV–MHC 
complexen te maken en deze in kleine 
hoeveelheden te bestralen in aanwezigheid 
van verschillende epitopen kunnen we nu 
in zeer korte tijd erg veel verschillende 
MHC complexen maken, iets wat voor deze 
techniek onmogelijk was. In hoofdstuk 
5 beschrijven we de ontwikkeling van 4 
nieuwe UV–gevoelige epitopen voor deze 
techniek voor verschillende type menselijke 
MHC complexen. Hiermee bewijzen we dat 
deze aanpak met UV–gevoelige epitopen 
algemeen toepasbaar is voor meerder 
MHC types. Daarnaast hebben we de 
biochemische reactie van het uiteenvallen 
van het UV–gevoelige epitoop in het 
MHC complex beter onderzocht en geven 
daarmee meer inzicht in o.a. de snelheid 
van de reactie.
Aangezien we nu in staat zijn om in korte 
tijd zeer veel verschillende MHC complexen 
te maken door middel van de UV–techniek 
uit hoofdstuk 5 hebben we onderzocht of 
we ook daadwerkelijk in korte tijd simultaan 
veel verschillende T cel populaties konden 
analyseren. Een probleem bij de analyse 
van menselijke T cellen, en zeker die van 
patiënten, is de gelimiteerde hoeveelheid 
materiaal dat doorgaans beschikbaar is. In 
hoofdstuk 6 onderzoeken we de mogelijkheid 
om door middel van combinaties van 
de fluorescente moleculen van de MHC 
multimeren meerdere T cel responsen 
tegelijkertijd te analyseren dan tot nu 
toe mogelijk was. Dit doen we door een 
voorraad van één specifieke MHC multimeer 
in tweeën te splitsen en elk deel een ander 
fluorescent molecuul te geven. T cellen 
met de juiste TCR zullen dus fluoresceren 
met twee kleuren, in tegenstelling tot de 
tot nu toe gangbare enkele kleur. Dit stelt 
ons dan in staat om met een beperkte 
hoeveelheid fluorescente moleculen erg veel 
verschillende combinaties te maken. Als 
we voorheen 4 kleuren gebruikten, konden 
we voorheen ook slechts 4 verschillede T 
cellen laten zien (bijvoorbeeld rood, groen, 
geel en blauw). Door MHC complexen met 
twee kleuren aan te duiden ben je in staat 
om kleuren te laten overlappen. Een T cel 
populatie die rood én groen kleurt is dan 
een andere populatie die rood én blauw 
kleurt. In dit voorbeeld van 4 kleuren zijn 
er bijvoorbeeld 6 combinaties mogelijk 
(rood–groen, rood–blauw, rood–geel, 
groen–blauw, groen–geel, blauw–geel), 
een winst van 2. In hoofdstuk 6 breiden 
we dit principe uit tot 8 kleuren en laten 
zien dat met deze ‘2–dimensionale code’ 
van 2 kleuren we in staat zijn om in één 
experiment 25 (van de maximaal haalbare 
28) verschillende T cel populaties aan 
te tonen. Deze techniek maakt het dus 
mogelijk om met het doorgaans weinige 
materiaal veel meer analyses uit te voeren.
Om aan te tonen dat beide technieken 
uit het laatste deel van dit proefschrift niet 
alleen correct werken maar ook toepasbaar 
zijn, hebben we ze toegepast in een screen 
om T cellen te ontdekken die reageren 
tegen tumor cellen van melanoom, een 
bepaalde vorm van huidkanker. Op basis 
van beschikbare computer modellen hebben 
we van 5 eiwitten die een rol spelen bij 
melanoom een lijst van 203 potentiële 
epitopen samengesteld. Vervolgens hebben 
we de UV–techniek van hoofdstuk 5 gebruikt 
om te bekijken welke van deze 203 epitopen 
daadwerkelijk aan het MHC complex kunnen 
binden, en met welke bindingssterkte. Dit 
leidde tot 22 mogelijke epitopen. Een test 
met deze aantallen was zonder de UV–
techniek praktisch niet mogelijk geweest. 
Vervolgens hebben we MHC complexen van 
deze 22 verschillende epitopen gemaakt 
en met de techniek van hoofdstuk 6 bij 
bloed van melanoom patiënten onderzocht 
of er ook T cellen aanwezig waren die 
met deze epitopen (in het MHC complex) 
reageren. Zonder deze techniek was dit 
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niet mogelijk geweest om alle 22 epitopen 
te testen vanwege de geringe hoeveelheid 
beschikbaar materiaal. Met deze test zijn 
we in staat gebleken om T cel populaties te 
identificeren tegen 8 van de 22 epitopen, 
waarvan er 5 niet eerder beschreven waren. 
Als deze T cel populaties inderdaad in staat 
zijn om tegen melanoom tumor cellen op te 
treden, wat momenteel wordt onderzocht, 
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